metoclopramide profile

Metoclopramide is a dopamine antagonist and prokinetic agent. It is primarily used to treat nausea and vomiting, often associated with gastroparesis or chemotherapy. The synthesis involves a multi-step process starting from 4-chloro-2-nitroaniline. Metoclopramide enhances gastric emptying by stimulating acetylcholine release, thus accelerating the passage of food through the stomach. It also blocks dopamine receptors in the chemoreceptor trigger zone of the brain, which is responsible for inducing nausea and vomiting. Metoclopramide is studied to investigate its potential in treating other conditions such as gastroesophageal reflux disease (GERD), migraines, and irritable bowel syndrome (IBS). The compound's effectiveness and potential for drug interactions are also subjects of ongoing research.'

Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	4168
CHEMBL ID	86
CHEBI ID	107736
SCHEMBL ID	18629
MeSH ID	M0013679

Synonym
metoclopramida [inn-spanish]
metoclol
metaclopramide
metoclopramidum [inn-latin]
plasil
plasil (pharmaceutical)
4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-methoxybenzamide
del 1267
reliveran
2-methoxy-4-amino-5-chloro-n,n-dimethylaminoethyl)benzamide
o-anisamide, 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-
einecs 206-662-9
methochlopramide
benzamide, 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-methoxy-
metoclopramide [inn:ban:jan]
moriperan
brn 1884366
metaclopromide
metochlopramide
5-chloro-2-methoxyprocainamide
n-(diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
primperan
BRD-K75641298-001-01-5
BRD-K75641298-003-05-2
maxeran
gastromax
metramid
parmid
metocobil
gimoti (metoclopramide nasal spray)
gtpl241
benzamide, 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxy-
o-anisamide, 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-
DIVK1C_000069
KBIO1_000069
NCI60_003185
SPECTRUM_001638
BIOMOL-NT_000082
NCGC00015643-01
cas-7232-21-5
lopac-m-0763
NCGC00015643-02
LOPAC0_000762
IDI1_000069
BSPBIO_002027
BSPBIO_000197
PRESTWICK3_000209
SPECTRUM5_001449
PRESTWICK2_000209
AB00053498
metoclopramide
C07868
364-62-5
4-amino-5-chloro-2-methoxy-n-(beta-diethylaminoethyl)benzamide
4-amino-5-chloro-n-(2-(diethylamino)ethyl)-o-anisamide
DB01233
2-methoxy-4-amino-5-chloro-n,n-(dimethylaminoethyl)benzamide
2-methoxy-5-chloroprocainamide
elieten (tn)
terperan (tn)
metoclopramide (jp17/inn)
D00726
BPBIO1_000217
BPBIO1_001100
NCGC00024440-04
clopra-yellow
KBIO2_007254
KBIOSS_002118
KBIO2_004686
KBIOGR_001307
KBIO3_001527
KBIO2_002118
SPECTRUM3_000504
SPBIO_002118
NINDS_000069
PRESTWICK1_000209
SPECTRUM2_001720
PRESTWICK0_000209
SPECTRUM4_000964
SPBIO_001740
NCGC00015643-03
NCGC00024440-03
CHEBI:107736 ,
metoclopramidum
4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxybenzamide
metoclopramida
elieten
HMS2089G16
NCGC00015643-08
AKOS000280832
L001078
terperan
methoxyclopramide
CHEMBL86
4-amino-5-chloro-n-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide)
BMSE000779
4-amino-5-chloro-n-(2-diethylamino-ethyl)-2-methoxy-benzamide (mcp)
4-amino-5-chloro-n-(2-diethylamino-ethyl)-2-methoxy-benzamide
(metaclopramide)4-amino-5-chloro-n-(2-diethylamino-ethyl)-2-methoxy-benzamide
(metoclopramide)4-amino-5-chloro-n-(2-diethylamino-ethyl)-2-methoxy-benzamide
4-amino-5-chloro-n-(2-diethylamino-ethyl)-2-methoxy-benzamide(metoclopramide)
4-amino-5-chloro-n-(2-diethylaminoethyl)-2-methoxybenzamide
NCGC00015643-07
hsdb 7841
megaldrate
gimoli
l4yeb44i46 ,
unii-l4yeb44i46
A823256
cas-364-62-5
dtxsid6045169 ,
tox21_110188
STL257058
dtxcid4025169
CCG-204847
NCGC00015643-06
NCGC00015643-09
NCGC00015643-05
NCGC00015643-04
metadrate
methoclopramide
HY-17382
CS-1064
FT-0628931
metoclopramide [hsdb]
metoclopramide [mi]
metoclopramide [jan]
metoclopramide [vandf]
metoclopramide [who-dd]
metoclopramide [mart.]
metoclopramide [inn]
metoclopramide [ep monograph]
S5862
SCHEMBL18629
tox21_110188_1
NCGC00015643-11
KS-5055
AB00053498-13
4-amino-5-chloro-n-[2-(diethylamino)-ethyl]-2-methoxybenzamide
n-(2-diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
metochloropramide
bdbm48320
cid_23659
us9132134, metoclopramide
4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxy-benzamide;hydrochloride
4-azanyl-5-chloranyl-n-[2-(diethylamino)ethyl]-2-methoxy-benzamide;hydrochloride
primperan (tablet) (salt/mix)
reglan (salt/mix)
regla
4-amino-5-chloro-2-methoxy-n-(.beta.-diethylaminoethyl)benzamide
maxolon (salt/mix)
2-methoxy-4-amino-5-chloro-n,n-dimethylaminoethylbenzamide
paspertin (salt/mix)
AB00053498_14
mfcd00211338
metoclopramide, vetranal(tm), analytical standard
metoclopramide, european pharmacopoeia (ep) reference standard
SBI-0050740.P004
NCGC00015643-13
Z2196779550
M2218
Q421095
BRD-K75641298-003-16-9
BCP30761
SDCCGSBI-0050740.P005
NCGC00015643-18
HMS3886P05
AMY8975
H11996
metoclopramide; 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxybenzamide
EN300-119507
AC-37197
benzamide, 4-amino-5-chloro-n-
a03fa01
metoclopramidum (inn-latin)
metoclopramida (inn-spanish)
metoclopramide (ep monograph)
metoclopramide (mart.)

Research Excerpts

Overview

Metoclopramide (MCP) is a drug that has been widely used in recent years due to its hyperprolactinaemia effect on mothers during breastfeeding. It has the potential to cause drug-induced movement disorders, including akathisia, which is characterised by an inner restlessness.

Excerpt	Reference	Relevance
"Metoclopramide is an antiemetic drug used widely during NVP, but the findings of studies evaluating its safety of use in pregnancy is inconsistent."	( Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis. Sun, L; Wen, X; Xi, Y; Zou, W, 2021)	1.8
"Metoclopramide (MCP) is a drug that has been widely used in recent years due to its hyperprolactinaemia effect on mothers during breastfeeding. "	( Investigation of the effect of metoclopramide on proliferation signal molecules in breast tissue. Gurgen, SG; İldan Çalım, S; Umur, N; Yazıcı, GN, 2022)	2.45
"Metoclopramide is a known substrate for P-gp, SULT2A1 and CYP2D6 and studies have revealed that caffeine- a major component of Cola nitida can induce P-glycoprotein (P-gp), SULT2A1 and SULT1A1, hence a possible drug interaction may occur on co-administration."	( The effects of oral administration of Cola nitida on the pharmacokinetic profile of metoclopramide in rabbits. Amadi, CN; Nwachukwu, WI, 2020)	1.5
"Metoclopramide is a commonly used medication in pediatric practice, and dystonia is a common adverse effect of it. "	( Metoclopramide-Induced Acute Dystonia: Data From a Pediatric Emergency Unit. Bal, C; Carman, KB; Kocak, O; Ozkan, S; Sahin, S; Yakut, A; Yarar, C, 2021)	3.51
"Metoclopramide (MCP) is a dopamine D"	( Proarrhythmic potential of metoclopramide in a sensitive whole-heart model. Burde, S; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Wolfes, J, 2021)	2.36
"Metoclopramide is a good and cost-effective therapeutic option for chemotherapy-induced nausea and vomiting."	( The anti-cancer effect of metoclopramide on triple-negative breast cancer cells. Chen, Y; Fan, R; Ji, X; Ji, Y; Liu, Y; Lu, P; Qin, S; Zhang, M; Zhao, J, 2021)	1.64
"As metoclopramide is a dopamine receptor antagonist, it has the potential to cause drug-induced movement disorders, including akathisia, which is characterised by an inner restlessness resulting in a need for constant movement."	( [Tardive akathisia after long-term metoclopramide treatment]. Andersen, CU; Hjelholt, AJ; Steffensen, C, 2021)	1.41
"Metoclopramide (MCP) is a commonly used anti-emetic in the emergency department (ED). "	( Metoclopramide induced pheochromocytoma crisis. Kim, HK; Leonard, JB; Munir, KM, 2018)	3.37
"As metoclopramide is an antiemetic and an analgesic, it was hypothesized that when added to reduce PONV, metoclopromide may enhance the multimodal feature of tramadol by the analgesic property of metoclopramide."	( Metoclopramide improves the quality of tramadol PCA indistinguishable to morphine PCA: a prospective, randomized, double blind clinical comparison. Chen, TX; Chois, JM; Liao, CC; Liu, YC; Maboudou, E; Pang, W; Wu, RS, 2013)	2.35
"Metoclopramide is a prokinetic drug used to treat GERD and it has been reported to be a most commonly prescribed medication in neonatal intensive care unit (NICU)."	( Is metoclopramide safe for the premature infant? Dilmen, U; Eras, Z; Oğuz, SS, 2013)	1.73
"1. Metoclopramide is a widely used clinical drug in a variety of medical settings with rare acute dystonic events reported. "	( Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Bolles, AK; Briggs, ED; Fujiwara, R; Furge, LL; Livezey, MR; Nagy, LD, 2014)	2.47
"Metoclopramide appears to be a promising candidate for the treatment of patients with intractable hiccups, with mild adverse events. "	( Metoclopramide for patients with intractable hiccups: a multicentre, randomised, controlled pilot study. Wang, D; Wang, T, 2014)	3.29
"Metoclopramide is a commonly used anti-emetic drug known to cause extrapyramidal symptoms as adverse effects, amongst which are dystonic reactions. "	( Metoclopramide induced acute dystonic reaction: a case report. Agbor, VN; Njim, T; Tianyi, FL, 2017)	3.34
"Metoclopramide is an effective and commonly used medication in acute migraine treatment but an experimental evidence base is lacking. "	( Metoclopramide inhibits trigeminovascular activation:evidence for effective acute attack treatment in migraine. Akçali, DT; Bolay, H; Doğanay Aydin, H; Vuralli, D, 2017)	3.34
"Metoclopramide is a useful medication in the anesthesia provider's armamentarium. "	( Metoclopramide and extrapyramidal symptoms: a case report. Hansen, DJ; Moos, DD, 2008)	3.23
"Metoclopramide is an anti-emetic drug which indication in migraine for vomiting and as an adjunctive drug to other analgesic has been reported elsewhere but the analgesic features of this drug in monotherapy has not been largely study in the medical literature."	( [Metoclopramide as a painkiller for intense migraine headache in emergency departments]. Huertas-Campistol, A; Lluch-López, J; Ramos-Brunet, A; Salazar-Tortolero, G; Vergez-Pinto, L, )	1.76
"Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. "	( Review article: metoclopramide and tardive dyskinesia. Camilleri, M; Rao, AS, 2010)	2.15
"Metoclopramide is a dopamine antagonist, which may enhance efficacy of ondansetron and dexamethasone."	( Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. Akewanlop, C; Ithimakin, S; Keerativitayanan, N; Laocharoenkeat, A; Nimmannit, A; Runglodvatana, K; Soparattanapaisarn, N; Srimuninnimit, V, 2012)	1.32
"Metoclopramide is a well-known anti-emetic drug with central and peripheral pharmacological effects. "	( Metoclopramide as an analgesic in severe migraine attacks: an open, single-blind, parallel control study. Cuello, D; Fragoso, M; Salazar, G; Sergio, P; Vergez, L, 2011)	3.25
"Metoclopramide is a prokinetic and antiemetic agent."	( Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. Alonso-Campero, R; Angeles-Uribe, J; Bernardo-Escudero, R; Cortés-Fuentes, M; de Jesús Francisco-Doce, MT; Villa-Vargas, M, 2011)	2.03
"Metoclopramide is an anti-emetic and gastrointestinal pro-motility agent associated with well-known neuropsychiatric adverse effects, such as dyskinesia, akathisia, and depression. "	( Metoclopramide and homicidal ideation: a case report and literature review. Quinn, DK; Surawski, RJ, )	3.02
"Metoclopramide is a prokinetic agent reported to be safe in parturients."	( Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. Habib, AS; Mishriky, BM, 2012)	2.54
"Metoclopramide is a centrally acting antiemetic and ketamine is a general anesthetic used with sedatives, tranquilizers and analgesics. "	( Antinociception by metoclopramide, ketamine and their combinations in mice. Al-Baggou, BKh; Mohammad, FK; Naser, AS, 2012)	2.15
"Metoclopramide seems to be a reasonable agent to prevent PONV."	( Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii's studies. Castro-Alves, LJ; Chang, R; De Oliveira, GS; McCarthy, RJ; Yaghmour, E, 2012)	1.52
"Metoclopramide is a dopamine receptor blocking drug that is commonly used to treat nausea and vomiting."	( Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Addis, A; Arnon, J; Berkovitch, M; Elbirt, D; Greenberg, R; Magee, L; Mazzota, P; Merlob, P; Moretti, M; Ornoy, A; Schuler-Faccini, L; Stahl, B, 2002)	2.48
"Metoclopramide (MCP) is a dopamine receptor antagonist and serotonine receptor agonist widely used as an antiemetic and gastric prokinetic drug. "	( In vitro protection of plasma cholinesterases by metoclopramide from inhibition by paraoxon. Ewald, V; Kühn, F; Missler, A; Petroianu, G; Thyes, C, )	1.83
"Metoclopramide (MCP) is a dopamine receptor antagonist and serotonin receptor agonist widely used as an antiemetic and gastric prokinetic drug. "	( In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox). Arafat, K; Camasamudram, V; Hasan, MY; Kosanovic, M; Petroianu, G; Saleh, A, )	1.81
"Metoclopramide (MCP) is a dopamine receptor antagonist and serotonin receptor agonist widely used as an antiemetic and gastric prokinetic drug. "	( In vitro protection of plasma cholinesterases by metoclopramide from inhibition by mipafox. Arafat, K; Kühn, F; Missler, A; Petroianu, G; Zuleger, K, )	1.83
"Metoclopramide is an effective treatment for migraine headache and may be effective when combined with other treatments. "	( Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. Brown, MD; Colman, I; Grafstein, E; Innes, GD; Roberts, TE; Rowe, BH, 2004)	2.16
"Metoclopramide is a D2-like receptor antagonist."	( Effect of saline load and metoclopramide on the renal dopaminergic system in patients with heart failure and healthy controls. Alvelos, M; Azevedo, A; Bettencourt, P; Ferreira, A; Pimenta, J; Rocha-Gonçalves, F; Serrão, P; Soares-da-Silva, P, 2005)	1.35
"Metoclopramide is an antiemetic drug which inhibits plasma cholinesterase activity. "	( Decreased mivacurium infusion rate and delayed neuromuscular recovery after metoclopramide: a randomized double blind placebo-controlled study. El Ayass, N; Hendrickx, P, 2005)	2
"Metoclopramide is a dopamine antagonist that is widely used in gastroesophageal disease and chemotherapy-induced emesis in the paediatric population. "	( Metoclopramide induced dystonia in children: two case reports. Duman, M; Ozdemir, D; Unal, N; Yis, U, 2005)	3.21
"Metoclopramide is a useful pharmacological agent for orthostatic hypotension."	( Recurrent syncope, hypotension, asthma, and migraine with aura: role of metoclopramide. Gupta, VK, )	1.09
"Metoclopramide is a commonly used drug to treat gastroesophageal reflux disease in infants. "	( Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Hibbs, AM; Lorch, SA, 2006)	3.22
"Metoclopramide (MCP) is a potent antiemetic, effective even for preventing emesis induced by cancer chemotherapy."	( Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part I. Influence of formulation variables on drug absorption in anesthetized rats. Abd ElHady, SS; Awad, GA; Mortada, ND; Zaki, NM, 2006)	1.33
"Metoclopramide is a dopamine receptor antagonist that is used to treat diabetic gastroparesis, chemotherapy-induced nausea, and migraines. "	( Acute chorea associated with metoclopramide use. Dubow, JS; Leikin, J; Rezak, M, )	1.87
"Metoclopramide is a dopamine receptor antagonist used in animals as both an antiemetic and a gastroprokinetic agent. "	( Sedative and hypnotic effects of combined administration of metoclopramide and ketamine in chickens. Al-Zubaidy, MH; Alias, AS; Mohammad, FK, 2007)	2.02
"Metoclopramide (MET) is a dopamine receptor agonist with antiemetic and prokinetic properties used for the treatment of nausea and facilitation of gastric emptying in patients with gastroparesis."	( Prevention of pain due to injection of propofol with IV administration of lidocaine 40 mg + metoclopramide 2.5, 5, or 10 mg or saline: a randomized, double-blind study in Japanese adult surgical patients. Fujii, Y; Nakayama, M, 2007)	1.28
"Metoclopramide appears to be an effective initial medical treatment for migraine headaches in the emergency department setting, but its pharmacologic mechanism remains incompletely understood. "	( Metoclopramide versus hydromorphone for the emergency department treatment of migraine headache. Griffith, JD; Kyriacou, DN; Mycyk, MB, 2008)	3.23
"Metoclopramide is a strong postsynaptic dopamine D(2) receptor blocker with no antipsychotic potency."	( Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Agovic, MS; Banerjee, SP; Lidsky, TI; Yablonsky-Alter, E, 2008)	1.42
"Metoclopramide is a widely used anti-emetic drug with potent dopamine-blocking effects on brain structures involved in emesis and prolactin secretion but it is apparently devoid of therapeutic effect in schizophrenia, thus calling into question the supposed role of dopamine blockade in the action of antischizophrenic drugs. "	( Selective permeation of the blood-brain barrier as a cause of the anomalous properties of 'atypical'neuroleptics. Herberg, LJ; Wishart, TB, 1980)	1.7
"Metoclopramide is a substituted benzamide derivative, structurally similar to procainamide and sulpiride. "	( Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models. Gershon, S; Kleinberg, D; Lautin, A; Rotrosen, J; Stanley, M, 1980)	3.15
"Metoclopramide is an effective agent for improving the upper gastrointestinal motor function in diabetic patients with gastroparesis."	( A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Behar, J; Deren, J; Falchuk, K; Ippoliti, A; McCallum, RW; Olsen, HW; Rakatansky, H; Rhodes, JB; Ricci, DA; Salen, G, )	1.1
"Metoclopramide is an effective non-phenothiazine antiemetic that acts, in part, by blockade of the dopamine receptors. "	( Prolonged metoclopramide-induced dyskinetic reaction. Leopold, NA, 1984)	2.11
"Metoclopramide is an effective antiemetic for cisplatin-induced vomiting when given in parenteral high-dose regimens but not oral low-dose regimens. "	( Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. Cariffe, P; Gala, KV; Grunberg, SM; Jamin, D; Johnson, K; Krailo, M; Lampenfeld, M; Strych, D, 1984)	1.95
"Metoclopramide is a good and reproducible stimulator of prolactin secretion."	( Dose-dependency and reproducibility of the prolactin response to metoclopramide. Kitaoka, M; Kobayashi, M; Kudo, M; Nakazono, M; Takebe, K, 1980)	1.22
"Metoclopramide is a useful adjunct to the palliative regimen extended to patients with upper gastrointestinal tumors."	( Tumor-associated gastroparesis: correction with metoclopramide. Bennett, RW; Haynie, TP; Shivshanker, K, 1983)	1.24
"Metoclopramide is a promising drug used not infrequently by practicing physicians. "	( Respiratory failure due to metoclopramide. Quinn, SF, 1983)	2.01
"Metoclopramide appears to be an effective drug in stimulating the mobility of the upper gastrointestinal tract without increasing gastric secretions."	( Review of a new gastrointestinal drug--metoclopramide. Nappi, JM; Ponte, CD, 1981)	1.25
"Metoclopramide is a drug that increases gastrointestinal motility, has few significant side effects, and may be of use in decreasing the ileus associated with acute spinal cord injuries."	( Prolonged ileus with acute spinal cord injury responding to metaclopramide. Fenzl, TC; Miller, F, 1981)	0.98
"Metoclopramide is an active antiemetic against cisplatin-induced acute emesis. "	( Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis. Kajita, M; Niimi, T; Saito, H; Shimokata, K; Yamori, S, 1994)	1.98
"Metoclopramide (MCA) is a structural analogue of procainamide used worldwide for preventing nausea and vomiting."	( Biochemical modulation of chemotherapy and radiotherapy in head and neck cancer. Kjellén, E; Lybak, S; Pero, R; Rydell, R; Wennerberg, J, )	0.85
"Metoclopramide is a dopamine receptor antagonist and, in large doses, has been shown to reverse the increase in renal blood flow, the diuresis and the natriuresis produced by a low-dose infusion of dopamine. "	( Effect of metoclopramide on renal vascular resistance index and renal function in patients receiving a low-dose infusion of dopamine. Bolsin, S; Hronek, I; Lowson, S; Munn, J; Tooley, M; Willcox, J, 1993)	2.13
"Metoclopramide is a drug which has experienced worldwide use in the clinic for over 30 years as an antiemetic. "	( Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide. Amiri, A; Andersen, I; Olsson, A; Pero, RW; Simanaitis, M, 1997)	1.95
"If metoclopramide were found to be an analgesic adjunct in these patients, it would offer an additional impetus for its routine use."	( Does metoclopramide supplement postoperative analgesia using patient-controlled analgesia with morphine in patients undergoing elective cesarean delivery? Birnbach, DJ; Danzer, BI; Kuroda, MM; Stein, DJ; Thys, DM, )	1.16
"Metoclopramide is a commonly used antiemetic."	( Local anesthetic effect of tramadol, metoclopramide, and lidocaine following intradermal injection. Chang, DP; Huang, MH; Mok, MS; Pang, WW, )	1.13
"Metoclopramide is a useful prokinetic drug in this patient population."	( Metoclopramide improves gastric motility in critically ill patients. Collee, G; Jooste, CA; Mustoe, J, 1999)	2.47
"Metoclopramide is an antiemetic drug used widely during pregnancy for nausea and vomiting. "	( Birth outcome following maternal use of metoclopramide. The Euromap study group. Baron, J; Christensen, K; Ekbom, A; Nielsen, GL; Sørensen, HT; Tage-Jensen, U, 2000)	2.02
"Metoclopramide is a dopamine-receptor antagonist which stimulates the upper gastrointestinal tract motility. "	( [Hypertensive crisis caused by metoclopramide]. Hursidić-Radulović, A, )	1.86
"S.c. metoclopramide appears to be a safe, effective treatment for hyperemesis gravidarum. "	( Home subcutaneous metoclopramide therapy for hyperemesis gravidarum. Bergauer, NK; Buttino, L; Coleman, SK; Gambon, C; Stanziano, GJ, 2000)	1.15
"Metoclopramide is an antidopaminergic drug that binds D2 receptor at the central nervous system and peripheral levels. "	( Effect of neonatal administration of an antidopaminergic drug (metoclopramide) on sexual behavior of male rats. Gonzales, GF; Ortega, JG; Salazar, M, )	1.81
"Metoclopramide is an antidopaminergic benzamide with mainly antiemetic effects, due to the interaction with dopamine receptors in the central trigger zone."	( [Current role of antidopaminergic drugs in pediatrics]. Bertamini, P; Bonetti, P; Cinquetti, M, 2000)	1.03
"Metoclopramide is a more cost-effective treatment."	( Metoclopramide versus ondansetron in prophylaxis of nausea and vomiting for laparoscopic cholecystectomy. Abrameit, W; Bass, CS; Roberson, R; Smith, RW; Wilson, EB, 2001)	2.47
"Metoclopramide is an antiemetic drug used frequently both in general practice and hospitals. "	( [Acute dystonia caused by metoclopramide (Afipran) therapy]. Bindoff, L; Farbu, E; Hagen, EM, 2001)	2.05
"Metoclopramide is a potent inhibitor of CYP2D6 at therapeutically relevant concentrations (K(i) = 4.7 +/- 1.3 microM), with negligible effect on other isoforms tested."	( The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Desta, Z; Flockhart, DA; Morocho, AM; Wu, GM, 2002)	1.3
"Metoclopramide is an anti-emetic medication that has been associated with movement disorders such as extra-pyramidal reactions and tardive dyskinesia (TD). "	( Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities. Bielecki, J; Eckholdt, CS; Matson, JL; Mayville, EA; Smalls, Y, )	1.85
"Metoclopramide is a useful agent during gastroscopic examination in cases of spasmodic pylorus."	( The effect of metoclopramide (Primperan) on the pyloric sphincter during gastroscopic examination. A double blind investigation versus placebo. Furugård, K; Hradsky, M, 1978)	1.34
"Metoclopramide is an effective agent in treating the symptom complex of delayed gastric emptying."	( Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Davidson, ED; Hersh, T; Moore, C; Perkel, MS, 1979)	2.42
"Metoclopramide is an antiemetic drug which occasionally produced acute dystonic reactions. "	( Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. Marsden, CD; Parkes, JD; Tarsy, D, 1975)	3.14
"Metoclopramide is an antiemetic drug; the effects on CNS (acute dystonic reaction, tardive dyskinesia, parkinsonism) occur in only 1 of 500 patients treated. "	( [Are metoclopramide dystonias familial?]. Ghini, T; Guala, A; Mittino, D; Quazza, G, )	2.09
"Thus metoclopramide seems to be an alternative to the traditional treatment of ureteral colic with morphia."	( Metoclopramide (Primperan) in the treatment of ureterolithiasis. A prospective double-blind study of metoclopramide compared with morphatropin on ureteral colic. Glyngdal, P; Jensen, A; Müller, TF; Naesh, O; Svare, E, 1990)	2.18
"Metoclopramide is a widely used product, which can accidentally cause acute dyskinesia, of which several forms may be observed, including dysarthria, tetany, spasmophilia, false cerebral vascular insult, trismus, hysteriform spell.... "	( [Metoclopramide intolerance and oral manifestations]. Andrejak, M; Devauchelle, B; Mizon, P; Nderagakura, F, 1991)	2.63
"As metoclopramide is a potent inhibitor of PCHE, interactions might be expected to occur between metoclopramide and drugs that require PCHE for biotransformation, such as suxamethonium and ester local anaesthetics."	( Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Kao, YJ; Tellez, J; Turner, DR, 1990)	1.1
"Metoclopramide is a useful adjunctive drug for intestinal intubation and radiologic examination."	( Metoclopramide: a dopamine receptor antagonist. DiPalma, JR, 1990)	2.44
"Metoclopramide (M.) is a neurolectic drug used with good results in digestive tracts disorders. "	( [Extrapyramidal type collateral effects of the administration of metoclopramide to children]. Bernardi, S; Bruni, L; Funaro, G; Grilli, MA; Tozzi, MC, )	1.81
"Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin."	( Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting. Schimke, J; Senn, HJ; Vergin, H; Wilder-Smith, C, 1989)	1.3
"Metoclopramide appears to be an alternative when inhibitors of prostaglandin synthesis or narcotics are contraindicated."	( Metoclopramide and ureteric colic. Hedenbro, JL; Olsson, AM, )	2.3
"Metoclopramide is a stimulant of upper gut motility and an anti-emetic. "	( From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists. King, FD; Sanger, GJ, 1988)	2.23
"Metoclopramide is an effective drug when used prophylactically in selected patients undergoing fluorescein angiography."	( Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein. Brown, RE; Drew, SJ; Sabates, R, 1987)	2.44
"Metoclopramide hydrochloride is an antiemetic and gastric motility stimulant with a wide variety of extrapyramidal side effects, including parkinsonism. "	( Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Diamond, BF; Kimmel, PL; Sirota, RA; Stein, HD; Trichtinger, MD; Yudis, M, 1986)	3.16
"As metoclopramide is a dopamine antagonist and dopamine-inadequate neurotransmission has been implicated in the pathogenesis of hepatic coma, this study was also designed to evaluate the effects of metoclopramide on mental state."	( Successful administration of metoclopramide for the treatment of nausea in patients with advanced liver disease. A double-blind controlled trial. Ballesteros, A; Briones, A; Garcia Ramos, G; Garza, J; Rosales, J; Strauss, R; Uribe, M; Villalobos, A, 1985)	1.07

Effects

Metoclopramide has an anti-dopaminergic effect similar to that of perphenazine and other inhibitors of dopaminergic neurones. It has a striking influence on arginine vasopressin (AVP) secretion.

Metoclopramide has been confirmed as an effective drug in treating and preventing various types of vomiting. It is also a useful agent in oesophageal reflux disease, gastroparesis, dyspepsia, and in a variety of functional gastrointestinal disorders.

Excerpt	Reference	Relevance
"Metoclopramide probably has a mechanism of action to prevent U46619-induced emesis via 5-HT(4) receptor activation and NK(1) tachykinin receptor antagonists could be useful to prevent emesis induced by TP receptor activation in man."	( Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret. Kan, KK; Ngan, MP; Rudd, JA; Wai, MK, 2008)	1.07
"Metoclopramide has a striking influence on arginine vasopressin (AVP) secretion."	( Recurrent syncope, hypotension, asthma, and migraine with aura: role of metoclopramide. Gupta, VK, )	1.09
"Metoclopramide thus has an anti-dopaminergic effect similar to that of perphenazine and other inhibitors of dopaminergic neurones."	( Metoclopramide potentiates the hypophyseal reactions to oestradiol. Dusková, J; Jahodová, J; Pribyl, T; Schreiber, V; Svobodová, V, 1984)	2.43
"Metoclopramide has a dual effect on intestinal smooth muscle. "	( The effects of metoclopramide in modifying the response of isolated guinea-pig ileum to various agonists. Bury, RW; Mashford, ML, 1976)	2.05
"The metoclopramide has a good effect to controlling excitation, hallucination, delusion and thinking disorder."	( [Curative effect observation and plasma level determination in treating schizophrenia with the higher dose metoclopramide]. Gu, SF, 1990)	0.97
"Metoclopramide also has an important place in the investigation of the role of dopamine in physiological and pathological processes."	( Metoclopramide--a review. Desmond, PV; Watson, KJ, 1986)	2.44
"Metoclopramide has been reported to have effects on intractable hiccup."	( Effectiveness and safety of metoclopramide in treatment of intractable hiccup: a protocol of systematic review and meta-analysis. Chen, T; Gao, Y; Wang, B; Wang, D; Wang, L; Zhang, B; Zi, C, 2022)	1.74
"Metoclopramide probably has a mechanism of action to prevent U46619-induced emesis via 5-HT(4) receptor activation and NK(1) tachykinin receptor antagonists could be useful to prevent emesis induced by TP receptor activation in man."	( Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret. Kan, KK; Ngan, MP; Rudd, JA; Wai, MK, 2008)	1.07
"Metoclopramide has the greatest evidence for efficacy followed by phenothiazines and tropisetron."	( Nausea and vomiting in advanced cancer. Ang, SK; Davis, MP; Shoemaker, LK, 2010)	1.08
"Metoclopramide has been shown to inhibit PCHE in vitro."	( Metoclopramide does not prolong duration of action of landiolol attenuating the hemodynamic response to induction of anesthesia and tracheal intubation. Abe, R; Furuya, H; Inoue, S; Kawaguchi, M; Kobayashi, H, 2010)	2.52
"Metoclopramide has analgesic effects and its combination with ketamine causes sedation and hypnosis."	( Antinociception by metoclopramide, ketamine and their combinations in mice. Al-Baggou, BKh; Mohammad, FK; Naser, AS, 2012)	1.43
"Metoclopramide has no significant prokinetic effect on gastric emptying in SHI patients when given in the early postinjury period."	( To determine the effect of metoclopramide on gastric emptying in severe head injuries: a prospective, randomized, controlled clinical trial. French, S; Kiratu, EM; Marino, LV; Nathoo, N, 2003)	1.34
"Metoclopramide (MCP) has been demonstrated to restore the depressed cellular immune function after hemorrhage by increasing the release of the immunomodulatory pituitary hormone prolactin. "	( Metoclopramide and cellular immune functions during polymicrobial sepsis. Exton, MS; Oberbeck, R; Pehle, B; Schedlowski, M; Schmitz, D; Schüler, M; Wilsenack, K, )	3.02
"Metoclopramide (MET) has long been used as a neuroleptic and antiemetic drug in clinical practice. "	( Metoclopramide attenuates iminodipropionitrile-induced oxidative stress and neurobehavioral toxicity in rats. Ahmad Khan, H; Al Deeb, S; Al Moutaery, K; Tariq, M, 2004)	3.21
"Metoclopramide has antinatriuretic effects only in HF patients."	( Effect of saline load and metoclopramide on the renal dopaminergic system in patients with heart failure and healthy controls. Alvelos, M; Azevedo, A; Bettencourt, P; Ferreira, A; Pimenta, J; Rocha-Gonçalves, F; Serrão, P; Soares-da-Silva, P, 2005)	1.35
"Metoclopramide has recently been used to treat DBA."	( Successful treatment of Diamond-Blackfan anemia with metoclopramide. Akiyama, M; Ariga, M; Eto, Y; Fujisawa, K; Hoshi, Y; Yanagisawa, T; Yokoi, K; Yuza, Y, 2005)	1.3
"Metoclopramide has a striking influence on arginine vasopressin (AVP) secretion."	( Recurrent syncope, hypotension, asthma, and migraine with aura: role of metoclopramide. Gupta, VK, )	1.09
"Metoclopramide has been suggested to relieve this, but two previous studies have shown conflicting results."	( Can administration of metoclopramide reduce artefacts related to abdominal activity in myocardial perfusion SPECT? Brogsitter, C; Burchert, W; Grüning, T; Jones, IW; Khonsari, M; Nevin, SM, 2006)	1.37
"2), metoclopramide has been confirmed as an effective drug in treating and preventing various types of vomiting and as a useful agent in oesophageal reflux disease, gastroparesis, dyspepsia, and in a variety of functional gastrointestinal disorders."	( Metoclopramide. An updated review of its pharmacological properties and clinical use. Brogden, RN; Hamilton, CW; Harrington, RA; Heel, RC; Linkewich, JA; Romankiewicz, JA, 1983)	2.19
"Metoclopramide thus has an anti-dopaminergic effect similar to that of perphenazine and other inhibitors of dopaminergic neurones."	( Metoclopramide potentiates the hypophyseal reactions to oestradiol. Dusková, J; Jahodová, J; Pribyl, T; Schreiber, V; Svobodová, V, 1984)	2.43
"Metoclopramide has been shown to increase the rate of absorption of several classes of drug, reflected by reduced time taken to achieve maximal plasma concentration (tmax) and increased maximal plasma concentration (Cmax)."	( Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Greiff, JM; Rowbotham, D, 1994)	1.01
"Metoclopramide has been reported to sensitize postjunctional muscarinic receptors, however, ML-1035 did not enhance acetylcholine-induced contractions."	( Analysis of neurogenic contractions induced by ML-1035 and other benzamides in the guinea-pig non-stimulated isolated ileum. Ahmed, NK; Butler, BT; Elsea, SH; Linnik, MD, 1994)	1.01
"Metoclopramide has only a mild influence on the contraction frequency."	( [Results of animal experiments with videodensitometry in the assessment of gastrointestinal motility]. Baehring, T; Raue, I; Weissbrodt, M; Werner, C, 1993)	1.01
"Metoclopramide has been shown to reduce the dose of thiopentone required for induction of anaesthesia. "	( Metoclopramide reduces the induction dose of propofol. Chhipa, JH; Page, VJ, 1997)	3.18
"Metoclopramide 0.15 mg/kg has no effect on the incidence of postoperative nausea and vomiting."	( Ondansetron dose response curve in high-risk pediatric patients. Kymer, PJ; Lawhorn, CD; Shirey, R; Stewart, FC; Stoner, JM; Volpe, P, 1997)	1.02
"Metoclopramide, especially, has been studied extensively in the past, but there are no studies that used the combination of both drugs for prevention of postoperative nausea and vomiting (PONV)."	( [Dimenhydrinate and metoclopramide for prevention of nausea and vomiting following septorhinoplasties in women]. Eberhart, LH; Georgieff, M; Morin, AM; Seeling, W; Ulrich, B, 1999)	1.35
"Metoclopramide has been shown to cause sulfhemoglobinemia, particularly when used in repeated high doses."	( An adolescent case of sulfhemoglobinemia associated with high-dose metoclopramide and N-acetylcysteine. Langford, JS; Sheikh, S, 1999)	1.26
"Metoclopramide has been used for almost 40 yr to prevent postoperative nausea and vomiting (PONV). "	( Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Henzi, I; Tramèr, MR; Walder, B, 1999)	3.19
"Metoclopramide, especially, has been studied extensively in the past, but there are no studies on the combination of both drugs for prevention of postoperative nausea and vomiting (PONV)."	( Dimenhydrinate and metoclopramide alone or in combination for prophylaxis of PONV. Eberhart, LH; Georgieff, M; Morin, AM; Seeling, W; Ulrich, B, 2000)	1.36
"Metoclopramide traditionally has been used as a prokinetic and antiemetic, but recently it also has been investigated as an agent to enhance analgesic efficacy. "	( The morphine-sparing effect of metoclopramide on postoperative laparoscopic tubal ligation patients. Gibbs, RD; Movinsky, BA; Pellegrini, J; Vacchiano, CA, 2002)	2.04
"Metoclopramide has a dual effect on intestinal smooth muscle. "	( The effects of metoclopramide in modifying the response of isolated guinea-pig ileum to various agonists. Bury, RW; Mashford, ML, 1976)	2.05
"Metoclopramide has been shown to stimulate motility of the gastrointestinal tract, including the esophagus. "	( Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS. Alarcon-Segovia, D; Ibañez, G; Ramirez-Mata, M, )	1.89
"Metoclopramide has been found to be beneficial in overcoming fescue toxicosis; increasing LH secretion stimulates return to ovulatory function after parturition."	( Effect of metoclopramide on luteinizing hormone secretion in postpartum anestrous cows. Jones, RD; Mizinga, KM; Smith, CK; Stuedemann, JA; Thompson, FN, 1992)	1.41
"The metoclopramide has a good effect to controlling excitation, hallucination, delusion and thinking disorder."	( [Curative effect observation and plasma level determination in treating schizophrenia with the higher dose metoclopramide]. Gu, SF, 1990)	0.97
"Metoclopramide has no intrinsic neuromuscular blocking activity, but its ability to inhibit plasma cholinesterase probably is the mechanism by which it prolongs succinylcholine block."	( Prolongation of succinylcholine block by metoclopramide. Kao, YJ; Turner, DR, 1989)	1.26
"Metoclopramide has previously been shown to inhibit the ketosis of starvation in rats and humans. "	( D2-dopaminergic blockade does not influence post-exercise ketosis in non-athletes. Koeslag, JH; Lochner, JV; Vahed, YA, 1989)	1.72
"Metoclopramide (Reglan) has been widely used as a motility agent because of its contractile effects on gastrointestinal smooth muscle. "	( Effects of metoclopramide on detrusor function. Mitchell, WC; Venable, DD, 1985)	2.1
"Metoclopramide has in previous studies been found to be synergic with acupuncture analgesia both in the laboratory and in the clinics. "	( No synergism between metoclopramide and acupuncture in chronic pain. Junnila, SY, 1986)	2.03
"Metoclopramide has wide applications in both clinical and experimental medicine. "	( Metoclopramide--a review. Desmond, PV; Watson, KJ, 1986)	3.16
"Metoclopramide has been shown to hasten gastric emptying; since cyclosporine is absorbed predominantly in the small intestine, coadministration of metoclopramide resulted in increased bioavailability of cyclosporine."	( The effect of oral metoclopramide on the absorption of cyclosporine. First, MR; Myre, SA; O'Flaherty, E; Pesce, AJ; Schroeder, TJ; Wadhwa, NK, 1987)	1.32
"Metoclopramide has been shown to hasten gastric emptying; since cyclosporine is absorbed predominantly in the small intestine, coadministration of metoclopramide resulted in increased bioavailability of cyclosporine."	( The effect of oral metoclopramide on the absorption of cyclosporine. First, MR; Myre, SA; O'Flaherty, E; Pesce, AJ; Schroeder, TJ; Wadhwa, NK, 1987)	1.32
"Metoclopramide treatment has been shown to augment milk production by stimulating prolactin secretion in women in whom lactational insufficiency develops after a full-term pregnancy. "	( Metoclopramide effect on faltering milk production by mothers of premature infants. Ackerman, BA; Ehrenkranz, RA, 1986)	3.16
"Metoclopramide tablets have been approved for use in the acute and chronic management of diabetic gastroparesis. "	( Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dugas, MC; Gavaler, JS; Lhotsky, DM; Schade, RR; Van Thiel, DH, 1985)	2.11
"Metoclopramide has gained acceptance as an effective drug for the control of nausea and vomiting in cancer patients receiving cisplatin chemotherapy. "	( Lack of effect of metoclopramide on cisplatin-induced nephrotoxicity in rats. Buyan, RD; Perkins, WE; Schroeder, RL, 1985)	2.05

Actions

Metoclopramide was found to increase the absorption rate constant (ka) of cimetidine by the duodenum and jejunum in both ligated and unligated rats. The drug improved lower esophageal sphincter pressure and reduced the gastric emptying delay.

Excerpt	Reference	Relevance
"Metoclopramide does not enhance lateralization of aldosterone excess in APA, but consistently increased the value of RASI in non-APA cases, thus unmasking potentially misleading suppression of aldosterone. "	( Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism. Barbiero, G; Battistel, M; Bisogni, V; Maiolino, G; Miotto, D; Rossi, GP; Rossitto, G; Sanga, V, 2016)	3.32
"Metoclopramide is shown to suppress trigeminovascular activation for the first time, providing an experimental basis for its role in migraine. "	( Metoclopramide inhibits trigeminovascular activation:evidence for effective acute attack treatment in migraine. Akçali, DT; Bolay, H; Doğanay Aydin, H; Vuralli, D, 2017)	3.34
"Metoclopramide does not cause a clinically significant change in IOP nor does it influence the changes in IOP during anesthesia and tracheal intubation. "	( Effect of intravenous metoclopramide on intraocular pressure: a prospective, randomized, double-blind, placebo-controlled study. Bhardwaj, N; Sudheera, KS; Yaddanapudi, S, )	1.89
"Metoclopramide caused an increase in resting tension of longitudinal muscle as well as an increase in resting output of either endogenous or labelled acetylcholine."	( The effects of metoclopramide on acetylcholine release and on smooth muscle response in the isolated guinea-pig ileum. Kilbinger, H; Kruel, R; Pfeuffer-Friederich, I; Wessler, I, 1982)	1.34
"Metoclopramide may enhance opioid analgesia, but it is not known if the drug is analgesic itself. "	( Evaluation of the analgesic effect of metoclopramide after opioid-free analgesia. Lisander, B, 1993)	2
"Metoclopramide may cause reversible nonthrombocytopenic vascular-type palpable purpura. "	( Reversible nonthrombocytopenic palpable purpura associated with metoclopramide. Goad, JA, 1999)	1.98
"Metoclopramide is known to enhance gastric emptying and stimulate duodenal and small-intestinal peristaltic activity. "	( The role of metoclopramide in peroral jejunal biopsy: a controlled randomized trial. Arvanitakis, C; Gonzalez, G; Rhodes, JB, 1976)	2.08
"Metoclopramide is known to produce three froms of extrapyramidal and motor side effects, namely: 1."	( [Extrapyramidal syndromes as side-effects of metoclopramide (Cerucal) medication]. Decke, D; Felber, W; Kunath, B; Papperitz, V, 1976)	1.24
"Metoclopramide may allow earlier tolerance of enteral liquids postoperatively."	( Outpatient cholecystectomy simulated in an inpatient population. Downes, TW; Hayes, DH; McKinnon, WM; Treen, DC, 1991)	1
"Metoclopramide was able to increase the plasma (2.6 +/- 0.2 ng/l in basal conditions and 6.1 +/- 0.6 ng/l at 30 min) but not the CSF AVP levels."	( Metoclopramide increases plasma but not cerebrospinal fluid vasopressin levels in man: study in hydrocephalic patients. Barreca, T; Cataldi, A; Francaviglia, N; Franceschini, R; Rolandi, E; Siani, C; Silvestro, C, 1991)	2.45
"Metoclopramide improved lower esophageal sphincter pressure and reduced the gastric emptying delay and gastroesophageal reflux in most patients but had a less consistent effect improving esophageal transit or esophageal body pressures."	( Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Benjamin, SB; Cattau, EL; Chobanian, SJ; Curran, J; Drane, WE; Johnson, DA; Karvelis, K, 1987)	2.44
"Metoclopramide was found to increase the absorption rate constant (ka) of cimetidine by the duodenum and jejunum in both ligated and unligated rats. "	( Effect of metoclopramide on the absorption of cimetidine in rats. Funaki, T; Furuta, S; Kaneniwa, N, 1986)	2.12

Treatment

Metoclopramide treatment reduces murine and human LSCs in vitro and prolongs survival of chronic myeloid leukemia (CML) mice through downregulation of pathways related to stemness and proliferation. Metoclopamide may have increased cephalexin absorption by affecting its delivery to the intestine.

Excerpt	Reference	Relevance
"Metoclopramide treatment reduces murine and human LSCs in vitro and prolongs survival of chronic myeloid leukemia (CML) mice through downregulation of pathways related to stemness and proliferation in LSCs."	( Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. Albers, CE; Arambasic, M; Bachmann, C; Baerlocher, GM; Bürgin, DT; Hoppe, S; Kallen, NM; Lüthi, U; Ochsenbein, AF; Radpour, R; Riether, C; Schürch, CM, 2021)	2.79
"Metoclopramide pretreatment provided protection against nausea and cramping associated with estrogen/progestin emergency contraception. "	( Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea. Buck, HW; Ragan, RE; Rock, RW, 2003)	3.2
"Metoclopramide pretreatment attenuates the nausea and cramping associated with Yuzpe emergency contraceptive treatment."	( Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea. Buck, HW; Ragan, RE; Rock, RW, 2003)	3.2
"Metoclopramide pretreatment may have increased cephalexin absorption by affecting its delivery to the intestine, and/or enhancing intestinal transporter PEPT1 function."	( Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. Albarellos, G; Kreil, V; Prados, AP; Rebuelto, M; Waxman, S, 2007)	2.5
"Metoclopramide pretreatment at 100 mg/kg, s.c."	( Metoclopramide protection of diazinon-induced toxicosis in chickens. Al-Zubaidy, MH; Mohammad, FK, 2007)	2.5
"Metoclopramide pretreatment in migraine attacks increased the serum concentration of tolfenamic acid at 1.5 h, but its peak concentration, time to peak concentration and the AUC0-5 h remained unchanged as compared with the values obtained with tolfenamic acid alone."	( Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Neuvonen, PJ; Tokola, RA, 1984)	1.27
"Metoclopramide-treated subjects and controls were seen by a rater who was "blind" to all diagnoses and treatments."	( The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Casey, DE; Ganzini, L; Hoffman, WF; McCall, AL, 1993)	1.34
"Metoclopramide-treated patients had significantly greater severity of tardive dyskinesia, drug-induced parkinsonism, and subjective akathisia than controls."	( The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Casey, DE; Ganzini, L; Hoffman, WF; McCall, AL, 1993)	1.34
"Metoclopramide treatment may not benefit dogs with GDV and delayed gastric emptying."	( Effect of metoclopramide on fed-state gastric myoelectric and motor activity in dogs. Hall, JA; Seim, HB; Solie, TN; Twedt, DC, 1996)	2.14
"Metoclopramide and placebo-treated patients were also 1.5 times (95% Cl 1.5-4.2) and 2.5 times (95% Cl 1.1-2.0) more likely, respectively, to experience nausea post-operatively."	( International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998)	1.24
"metoclopramide for treatment of hyperemesis gravidarum were identified from a national database."	( Home subcutaneous metoclopramide therapy for hyperemesis gravidarum. Bergauer, NK; Buttino, L; Coleman, SK; Gambon, C; Stanziano, GJ, 2000)	1.36
"5. Metoclopramide 60 mg pretreatment had no consistent effect upon plasma bromocriptine levels, the clinical or hormonal response."	( Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism. Debono, A; Marsden, CD; Parkes, JD; Price, P; Rosenthaler, J, 1978)	0.77
"Metoclopramide-treated patients experienced significantly earlier fetal and placental passage (P < 0.05)."	( Metoclopramide-enhanced analgesia for prostaglandin-induced termination of pregnancy. Cioffi, AM; Rosenblatt, WH; Silverman, DG; Sinatra, R, 1992)	2.45
"Metoclopramide-treated patients did not demonstrate a lower incidence of nausea or emesis but did tolerate oral liquids earlier after surgery than the placebo group (P less than 0.05)."	( Outpatient cholecystectomy simulated in an inpatient population. Downes, TW; Hayes, DH; McKinnon, WM; Treen, DC, 1991)	1
"Metoclopramide pretreatment, did not attenuate the dopamine induced rise in ERPF, GFR, urine flow, urinary dopamine excretion or supine systolic blood pressure but it did attenuate the rise in pulse rate, the fall in diastolic pressure, and the antikaliuretic effect of dopamine leading to a net kaliuresis when compared to placebo."	( Metoclopramide, domperidone and dopamine in man: actions and interactions. MacDonald, TM, 1991)	2.45
"Six metoclopramide-treated patients and one cisapride-treated patient dropped out of the study because of side effects."	( Cisapride and metoclopramide in the treatment of gastroesophageal reflux disease. Arabehety, JT; Fassler, S; Leitão, OR; Olarte, M; Serrano, C, 1988)	1.12
"The metoclopramide-treated group demonstrated a statistically significant decrease in the incidence of nausea and vomiting."	( Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein. Brown, RE; Drew, SJ; Sabates, R, 1987)	2.2
"Metoclopramide treatment has been shown to augment milk production by stimulating prolactin secretion in women in whom lactational insufficiency develops after a full-term pregnancy. "	( Metoclopramide effect on faltering milk production by mothers of premature infants. Ackerman, BA; Ehrenkranz, RA, 1986)	3.16
"Metoclopramide pretreatment in urethane-anesthetized rats prevented the decreases in MAP and heart rate induced by LY171555, whereas pretreatment with d(CH2)5Tyr(Me)AVP delayed the recovery phase of the depressor response."	( Mechanism of the depressor action of LY171555, a selective dopamine D2 receptor agonist, in the anesthetized rat. Chen, YF; Lindheimer, MD; Nagahama, S; Oparil, S, 1986)	0.99
"Treatment with metoclopramide induces the release of prolactin from the pituitary and stimulates erythropoiesis."	( Successful treatment of Diamond-Blackfan anemia with metoclopramide. Akiyama, M; Ariga, M; Eto, Y; Fujisawa, K; Hoshi, Y; Yanagisawa, T; Yokoi, K; Yuza, Y, 2005)	0.92
"Pretreatment with metoclopramide at a dose of 8 micrograms/kg prior to PBDA infusion partially blunted the blood pressure reduction produced by PBDA alone (-10% +/- 8% vs -20% +/- 4% compared to control values, p less than 0.1) but had no effect on PBDA -induced increases in renal plasma flow (+ 179% +/- 15% vs + 179% +/- 9% compared to control).(ABSTRACT TRUNCATED AT 250 WORDS)"	( Propylbutyldopamine. Mechanism of blood pressure lowering in hypertensive patients. Fennell, WH; Ginos, JZ; Mitchell, JR; Nelson, EB; Pool, JL; Ruud, CO; Taylor, AA, )	0.45
"Pretreatment with metoclopramide had no effect on AUC but caused significant increases in peak concentration and decreases in time to peak concentration in both groups."	( Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. Briant, RH; Dorrington, RE; Ferry, DG; Paxton, JW, 1983)	0.8
"Treatment with metoclopramide alone provoked a progressively greater release of prolactin as pregnancy advanced whereas in bromocriptine-treated animals an associated release of prolactin in response to metoclopramide was seen only between days 120 and 140 of pregnancy."	( Effects of metoclopramide and bromocriptine on prolactin secretion in the pregnant ewe. Cunningham, FJ; Fitzgerald, BP, 1982)	0.99
"Treatment with metoclopramide resulted in significantly lower mean gastric volume (15 vs."	( Gastric volume in early pregnancy: effect of metoclopramide. Cohen, SE; Wyner, J, 1982)	0.86
"Pretreatment with metoclopramide, 1 and 10 mg/kg i.v., resulted in dose-related inhibition (maximum inhibition 44% and 94%, respectively) of the renal vasodilator activity of dopamine without altering baseline parameters."	( Antagonism of the renal vasodilator activity of dopamine by metoclopramide. Hahn, RA; Wardell, JR, 1980)	0.83
"Pretreatment with metoclopramide (10.0 mg/kg; IP) or pimozide (1.0 mg/kg, IP), respectively, 30 min or 4 h before FCF (3.5 mg/kg; IP), which blocked the FCF-induced locomotor activity, failed to influence place conditioning produced by FCF."	( Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors. Aizenstein, ML; DeLucia, R; Planeta, Cda S, 1995)	0.61
"Pretreatment of metoclopramide (MCP) in this settings caused even higher and significant increases of natriuresis."	( Dopamine tonically modulates natriuresis in the saline-expanded dogs. Honda, K; Matsuzaki, K; Nagasaka, M; Nunokawa, T, 1995)	0.63
"pretreatment with metoclopramide (300 micrograms/kg), a dopamine D2 receptor antagonist that crosses the blood-brain barrier, or by combined pretreatment with i.v."	( Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors. Duarte, GP; Lahlou, S, 1998)	0.62
"Pretreatment with metoclopramide or with pimozide shifted the volume-pressure diagram of the stomach to the left; that is, at any given volume the pressure was greater after than before these drugs."	( Dopamine as a possible neurotransmitter in gastric relaxation. Valenzuela, JE, 1976)	0.58
"Pretreatment with metoclopramide prevented vomiting in all subjects, and votracon prevented vomiting in two."	( An apomorphine-induced vomiting model for antiemetic studies in man. Chremos, AN; Evans, EF; Proctor, JD; Wasserman, AJ, )	0.45
"Treatment with metoclopramide hydrochloride and bethanechol chloride resulted in improved attitude, appetite, Schirmer tear test response, and decrease in frequency of vomiting within 24 hours."	( A syndrome resembling feline dysautonomia (Key-Gaskell syndrome) in a dog. Lappin, MR; Wise, LA, 1991)	0.62
"Pretreatment with metoclopramide augmented the onset and peak response of dopamine."	( Characterization of dopamine receptors involved in central thermoregulation in rabbits. Gupta, PP; Srivastava, AK; Srivastava, YP; Verma, RB, 1991)	0.6
"Pre-treatment with metoclopramide appeared to reduce both of these effects of cholecystokinin, but only the decrease in cortisol was statistically significant."	( Hormonal effects of apomorphine and cholecystokinin in pigs: modification of the response to cholecystokinin by a dopamine antagonist (metoclopramide) and a kappa opioid agonist (PD117302). Baldwin, BA; Ebenezer, IS; Forsling, ML; Parrott, RF, 1991)	0.8
"Pretreatment with metoclopramide (20 mg/kg) or SCH 23390 (30 micrograms/kg), a new selective dopamine-1 antagonist, significantly attenuated the vasodilator responses to fenoldopam in all three vascular beds."	( Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. Lappe, RW; Todt, JA; Wendt, RL, 1986)	0.59
"Pretreatment with metoclopramide (5 mg/kg i.v.) abolished the pressor action of LY171555, whereas pretreatment with domperidone (2.5 mg/kg i.v.) and propranolol (10 mg/kg i.p.) did not affect the pressor action of LY171555."	( Mechanism of the pressor action of LY171555, a specific dopamine D2 receptor agonist, in the conscious rat. Chen, YF; Lindheimer, MD; Nagahama, S; Oparil, S, 1986)	0.59
"Treatment with metoclopramide reversed the MMC phase III inhibition at the antrum and pylorus, and partially reversed the inhibition at the duodenum and jejunum (p less than 0.05)."	( Metoclopramide reversal of decreased gastrointestinal myoelectric and contractile activity in a model of canine postoperative ileus. Becht, JL; Graves, GM; Rawlings, CA, )	1.91
"Pretreatment with metoclopramide (10 mg/kg, i.v.), a specific central and peripheral DA D2-receptor antagonist, completely blocked the suppressive effects of LY171555 on HVA and DOPAC levels.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Enhanced response to the inhibitory action of LY171555, a dopamine D2-agonist, on in vivo striatal dopamine release in DOCA/NaCl-hypertensive rats. Chen, YF; Oparil, S, 1987)	0.6
"Pretreatment with metoclopramide enhanced the CRH-induced cortisol increase from 30-120 min after CRH in normal men, but only at 15 and 30 min in 5 agromegalic patients."	( Pituitary-adrenocortical response to metoclopramide in patients with acromegaly and prolactinoma: a clinical evaluation of catecholamine-mediated adrenocorticotropin secretion. Adachi, N; Endoh, M; Horino, M; Ishii, R; Kikuoka, M; Matsuki, M; Nishida, S; Otsuka, R; Oyama, H; Yoneda, M, 1987)	0.87
"Pretreatment with metoclopramide or phentolamine did not block these effects, but pretreatment with propranolol significantly (P less than 0.05) blunted the increase in fasting glucose and insulin levels."	( Effect on the endocrine system of a new dopaminergic agent, ibopamine. Alexander, F; Allison, NL; Boden, G; Dubb, JW; Soreth, JT; Stote, RM, 1987)	0.6
"Pretreatment with metoclopramide antagonised acute morphine tolerance and suppressed the withdrawal signs (both in acute dependence type and abrupt withdrawal type)."	( Antagonism of morphine tolerance and dependence by metoclopramide. Bapna, JS; Ramaswamy, S, 1987)	0.85

Toxicity

Metoclopramide is commonly used to treat vomiting caused by seasickness and acute gastroenteritis on cruise ships. Serious adverse effects have not been reported from use at sea.

Excerpt	Reference	Relevance
"Metoclopramide administered before induction of spinal anesthesia for cesarean delivery appears to significantly reduce both pre- and postdelivery emetic symptoms without apparent adverse effects on mother or neonate."	( The antiemetic efficacy and safety of prophylactic metoclopramide for elective cesarean delivery during spinal anesthesia. Bader, AM; Datta, S; Lussos, SA; Thornhill, ML, )	1.83
" It is concluded that oral lorazepam is an effective and safe adjuvant to MCP for the control of vomiting during cancer chemotherapy."	( Low dose, oral lorazepam: a safe and effective adjuvant to antiemetic therapy. Advani, SH; Banavali, SD; Charak, BS; Gopal, R; Iyer, RS; Saikia, TK, 1991)	0.28
" Only one adverse event, headache, occurred in more than five patients in the granisetron group."	( Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Chevallier, B, 1990)	0.52
" The results justify further studies on the antineoplastic and adverse effects pertaining to interaction between anthracyclines and antiemetics."	( Epirubicin cytotoxicity but not oxygen radical formation is enhanced by four different antiemetics. Grankvist, K; Henriksson, R, 1989)	0.28
"Cisapride has not been found to have a significant frequency of adverse reactions, except for diarrhoea which occurs in about 4% of individuals taking the drug."	( How safe and acceptable is cisapride? Bennett, JR, 1989)	0.28
" Pyridoxine is considered safe for use during pregnancy, but its efficacy in treating nausea and vomiting has not been determined."	( Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. Leathem, AM, 1986)	0.27
" Before studying the efficacy of MCP as an antiemetic in children, we first had to establish the safe dose range."	( Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. Allen, JC; Gralla, R; Kellick, M; Reilly, L; Young, C, 1985)	1.71
" At the same time about 1/3 of these serious adverse drug reactions (ADR) was found to have been reported to the ADR-register."	( Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Westerholm, B; Wiholm, BE, 1984)	0.27
" At the same time, about 1/3 of these serious adverse drug reactions (ADRs) had been reported to the ADR register."	( Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Westerholm, B; Wiholm, BE, 1984)	0.27
"Controlled release metoclopramide is safe and effective in managing chronic nausea in patients with advanced cancer."	( Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Babul, N; Bruera, ED; Darke, AC; Harsanyi, Z; LeGatt, DF; MacDonald, RN; MacEachern, TJ; Spachynski, KA, 1994)	0.83
" Although adverse reactions are rare, a potential exists for extrapyramidal side effects to occur."	( Extrapyramidal side effects of metoclopramide in outpatient surgery patients. Dziura-Murauski, J; Holesha, W, 1994)	0.57
" The overall incidence of adverse experiences was significantly lower in the granisetron group (60."	( The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. , 1993)	0.52
" Thus, controlling the adverse side effects associated with radiation therapy is critical to optimal patient care."	( Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. Priestman, TJ, 1996)	0.29
" Ferristene distribution was assessed by 2 reviewers and adverse events were recorded."	( Ferristene as intestinal MR contrast agent. Distribution and safety of a fast ingestion procedure with oral metoclopramide. De Greef, D; Grandin, C; Lundby, B; Pringot, J; Van Beers, BE, 1996)	0.51
" Fewer patients from the OND group (13%) reported adverse events compared with the MET group (21%)."	( A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. Andersson, H; Capstick, V; du Bois, A; Kitchener, H; Lahousen, M; McKenna, CJ; Pinter, T; Wilkinson, JR, )	0.33
" The patient demonstrated toxic extrapyramidal effects."	( Metoclopramide toxicity in an infant. Batts, KF; Munter, DW, 1998)	1.74
"Those notified to the Spanish Drug watch system as possibly having suffered an adverse reaction to Metoclopramide (n = 98) or Clebopride (n = 123) between 1/1/1990 and 10/6/1997."	( [Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System]. Cuena Boy, R; Maciá Martínez, MA, 1998)	0.79
"3% of suspected adverse reactions to Clebopride and 51."	( [Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System]. Cuena Boy, R; Maciá Martínez, MA, 1998)	0.58
" The global incidence of adverse events was 45% higher with EC, though not significant (32 vs."	( Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. Geraud, G; Gómez, JP; Henry, P; Joffroy, A; Lainez, JM; Le Jeunne, C; Liaño, H; Pradalier, A; Titus i Albareda, F, 1999)	0.55
" The overall risk of adverse effects was not different among drug combinations."	( Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anderson, EA; Domino, KB; Polissar, NL; Posner, KL, 1999)	0.54
" The overall risk of adverse effects did not differ."	( Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anderson, EA; Domino, KB; Polissar, NL; Posner, KL, 1999)	0.54
"Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin."	( Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002)	0.31
" Measures to more effectively prevent nephrotoxicity should be developed for the safe use of heptaplatin."	( Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002)	0.31
" According to the Naranjo scale, this adverse drug event was probably the result of improved absorption of tacrolimus secondary to metoclopramide therapy."	( Tacrolimus toxicity associated with concomitant metoclopramide therapy. Callahan, BL; Park, JM; Prescott, WA, 2004)	0.78
" Five hundred thirty-five adverse effects were reported after the use of 22,697 sachets."	( Safety and efficacy of combined lysine acetylsalicylate and metoclopramide: repeated intakes in migraine attacks. Baudesson, G; Chabriat, H; Danchot, J; Joire, JE; Pradalier, A, 1999)	0.55
"The side effect of anticancer agents such as nausea and vomiting frequently interrupt chemotherapy."	( [Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"Tardive dyskinesia is a rare but possible drug-related adverse effect of MCP."	( [Therapy of postoperative nausea and vomiting in ENT--tardive dyskinesia as an adverse effect of metoclopramid--a case report]. Henckell, C; Metternich, FU; Tesche, S, 2006)	0.33
"34) and no adverse reactions in the study period."	( Intravenous administration of metoclopramide by 2 min bolus vs 15 min infusion: does it affect the improvement of headache while reducing the side effects? Ayrik, C; Erdur, B; Ergin, A; Ergin, N; Parlak, I; Parlak, M; Tomruk, O; Turkcuer, I, 2007)	0.63
" Secondary outcome variables were change of single symptoms, time till complete symptom relief, investigators' judgement of efficacy and tolerability, duration of inability to work and occurrence of adverse events."	( [Assessment of the efficacy and safety of the phytopharmacon STW 5 versus metoclopramide in functional dyspepsia--a retrolective cohort study]. Bock, P; Gundermann, KJ; Hanisch, J; Raedsch, R; Sibaev, A; Vinson, B, 2007)	0.57
" Adverse drug reactions were documented only under MCP."	( [Assessment of the efficacy and safety of the phytopharmacon STW 5 versus metoclopramide in functional dyspepsia--a retrolective cohort study]. Bock, P; Gundermann, KJ; Hanisch, J; Raedsch, R; Sibaev, A; Vinson, B, 2007)	0.57
" We assessed associations between the use of metoclopramide in pregnancy and adverse outcomes for the fetus, adjusting for parity, maternal age, ethnic group, presence or absence of maternal diabetes, smoking status, and presence or absence of peripartum fever."	( The safety of metoclopramide use in the first trimester of pregnancy. Gorodischer, R; Koren, G; Levy, A; Matok, I; Sheiner, E; Wiznitzer, A, 2009)	0.97
"In this large cohort of infants, exposure to metoclopramide in the first trimester was not associated with significantly increased risks of any of several adverse outcomes."	( The safety of metoclopramide use in the first trimester of pregnancy. Gorodischer, R; Koren, G; Levy, A; Matok, I; Sheiner, E; Wiznitzer, A, 2009)	0.97
" In retrospect, this adverse effect was not recognized for several weeks because the prescription had not been properly recorded in the chart, the patient initially denied using the drug, and extensive psychological adjustment difficulties were also present."	( Severe akathisia as a side effect of metoclopramide. Doorduijn, JK; Seynaeve, C; Van Gool, AR, 2010)	0.63
"Movement disorders as an adverse effect of metoclopramide have been described on a regular basis over the past decades."	( Severe akathisia as a side effect of metoclopramide. Doorduijn, JK; Seynaeve, C; Van Gool, AR, 2010)	0.9
"In this study, we aimed to investigate and compare the direct toxic and teratogenic effects of dimenhydrinate, metoclopramide and trimethobenzamide HCl, antiemetic drugs on embryonic growth and development in cultured rat embryos."	( Investigation of developmental toxicity and teratogenicity of antiemetics on rat embryos cultured in vitro. Acar, H; Fazliogullari, Z; Karabulut, AK; Unver Dogan, N; Uysal, II, 2013)	0.6
"The National Institutes of Health-appointed CRISIS Data and Safety Monitoring Board was charged with monitoring sample size adequacy and feasibility, safety with respect to adverse events and 28-day mortality, and efficacy with respect to the primary nosocomial infection/sepsis outcome."	( The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study. Anand, KJ; Berger, J; Casper, TC; Dean, JM; Harrison, R; Holubkov, R; Meert, KL; Newth, CJ; Nicholson, C; Willson, DF; Zimmerman, J, 2013)	0.39
"We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events."	( The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Deepak, P; Devi, R; Du, H; Ehrenpreis, ED; Leikin, JB; Sifuentes, H, 2013)	1.16
" The FDA Adverse Event Reporting System (FAERS) was analyzed for event reports, and for lawyer-initiated reports, with metoclopramide from 2004 to 2010."	( The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Deepak, P; Devi, R; Du, H; Ehrenpreis, ED; Leikin, JB; Sifuentes, H, 2013)	1.16
" Adverse event reporting increased after the warning."	( The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Deepak, P; Devi, R; Du, H; Ehrenpreis, ED; Leikin, JB; Sifuentes, H, 2013)	0.95
"The black box warning for metoclopramide has decreased its usage and increased its rate of adverse event reporting."	( The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Deepak, P; Devi, R; Du, H; Ehrenpreis, ED; Leikin, JB; Sifuentes, H, 2013)	1.25
"The observed adverse effects of metoclopramide in the preterm infant might be due to an excessive serum concentration of the drug as a result of its prolonged plasma clearance in this age group."	( Is metoclopramide safe for the premature infant? Dilmen, U; Eras, Z; Oğuz, SS, 2013)	1.29
"Metoclopramide is commonly used to treat vomiting caused by seasickness and acute gastroenteritis on cruise ships and serious adverse effects have not been reported from use at sea."	( Long-lasting adverse effects after short-term low-dose treatment with metoclopramide for vomiting. Dahl, E; Diskin, AL, 2014)	2.08
" We collected laboratory and clinical information while infants were exposed to erythromycin or metoclopramide and described the frequency of laboratory abnormalities and clinical adverse events (AEs)."	( Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants. Arnold, C; Benjamin, DK; Cheeseman, J; Cho, J; Chu, V; Clark, RH; Ericson, JE; Hornik, CP; Kaneko, S; Smith, PB; Wilson, E, 2015)	0.91
"The objective was to determine whether sex and age are associated with short-term headache relief, sustained headache freedom, or adverse medication effects in data collected during 3 emergency department (ED)-based acute migraine comparative efficacy trials."	( Age But Not Sex Is Associated With Efficacy and Adverse Events Following Administration of Intravenous Migraine Medication: An Analysis of a Clinical Trial Database. Bijur, PE; Cisewski, DH; Friedman, BW; Gallagher, EJ; Holden, L, )	0.13
" In each of these studies, (1) short-term efficacy (patient description of the headache as "mild" or "none" 1 hour after medication administration); (2) sustained efficacy (patient description of the headache as "none" within 2 hours of medication administration and no headache recurrence for 24 hours post ED discharge); and (3) the frequency of any adverse medication effects within 24 hours of medication administration was determined."	( Age But Not Sex Is Associated With Efficacy and Adverse Events Following Administration of Intravenous Migraine Medication: An Analysis of a Clinical Trial Database. Bijur, PE; Cisewski, DH; Friedman, BW; Gallagher, EJ; Holden, L, )	0.13
" Age was associated with both efficacy and adverse events."	( Age But Not Sex Is Associated With Efficacy and Adverse Events Following Administration of Intravenous Migraine Medication: An Analysis of a Clinical Trial Database. Bijur, PE; Cisewski, DH; Friedman, BW; Gallagher, EJ; Holden, L, )	0.13
" All studies in English reporting adverse effects associated with the use of metoclopramide in children (aged ≤18 years) were included."	( The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Dupuis, LL; Flank, J; Lau Moon Lin, M; Robinson, PD; Sung, L, 2016)	1.02
" The most common adverse effects reported in prospective studies of metoclopramide in children were extrapyramidal symptoms (EPS; 9 %, 95 % confidence interval [CI] 5-17), diarrhea (6 %, 95 % CI 4-9), and sedation (multiple-dose studies: 6 %, 95 % CI 3-12)."	( The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Dupuis, LL; Flank, J; Lau Moon Lin, M; Robinson, PD; Sung, L, 2016)	1.03
"The definitions of adverse effects reported in the included studies were heterogeneous, and the risk of bias in most studies was moderate."	( The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Dupuis, LL; Flank, J; Lau Moon Lin, M; Robinson, PD; Sung, L, 2016)	0.79
"The most commonly reported adverse effects associated with the use of metoclopramide in children-EPS, diarrhea, and sedation-were reversible and of no long-term significance."	( The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Dupuis, LL; Flank, J; Lau Moon Lin, M; Robinson, PD; Sung, L, 2016)	1.03
"We conducted a cross-sectional study using the Korea Adverse Event Reporting System database between July 1, 2010, and June 30, 2015."	( Current Status of Parkinsonism-Related Adverse Events and Associated Drugs in Korea. Kim, S; Suh, HS, 2019)	0.51
"There were 1402 adverse event reports associated with parkinsonism."	( Current Status of Parkinsonism-Related Adverse Events and Associated Drugs in Korea. Kim, S; Suh, HS, 2019)	0.51
"Metoclopramide and antipsychotics were reported in most adverse event reports associated with parkinsonism in Korea."	( Current Status of Parkinsonism-Related Adverse Events and Associated Drugs in Korea. Kim, S; Suh, HS, 2019)	1.96
" If treatment comes with only marginal improvements, concerns about adverse events become more relevant."	( From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis. Bielefeldt, K, 2017)	0.46
"We searched the Federal Adverse Event Reporting System for reports associated with the treatment of dyspepsia or gastroparesis."	( From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis. Bielefeldt, K, 2017)	0.46
"Despite biasing factors, such as pending legal action, the voluntary repository of adverse events provides insight into current medical practice and its associated risk."	( From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis. Bielefeldt, K, 2017)	0.46
" Adverse events (AEs) were recorded from the time of consent through to day 5; serious AEs were collected to day 30."	( Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5-Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding Intolerance. Almansa, C; Barnes, CN; Chapman, MJ; Deane, AM; Jones, KL; Nguyen, D, 2021)	0.62
" Other secondary outcomes were comparable, and the incidence of adverse events was not significantly different between the 2 groups."	( Efficacy and Safety of Enteral Erythromycin Estolate in Combination With Intravenous Metoclopramide vs Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients With Enteral Feeding Intolerance: A Randomized, Double-Blind, Controlled Pilo Bhurayanontachai, R; Boonpeng, A; Charoensareerat, T; Lerkiatbundit, S; Navasakulpong, A; Pattharachayakul, S; Sitaruno, S, 2021)	0.85
" Erythromycin is associated with adverse reactions, including corrected QT interval prolongation and cytochrome P450 3A4 isoenzyme inhibition."	( Safe Use of Erythromycin For Refractory Gastroparesis After Small Bowel Transplantation. Cruz, RJ; Humar, A; Poloyac, K; Roberts, M; Stein, W, 2022)	0.72
" The aim of this study was to conduct a systematic literature review (SLR) to evaluate the profile of adverse events (AEs) of dopamine antagonists used in the treatment of children and adults with gastroparesis."	( Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis. Bennett, D; Betts, M; Fahrbach, K; Huh, SY; Junqueira, DR; Neupane, B, 2023)	1.16

Pharmacokinetics

There were no statistically significant differences in the pharmacokinetic parameters, Cmax, tmax, AUC, and t1/2, for butorphanol with or without metoclopramide. Associating 8-MOP with metoclobramide does not alter the Pharmacokinetic values of 8- MOP. The means and variances of the pharmacokeretic parameters of the cis and trans isomers of cefprozil were similar in fasting subjects and were affected in a parallel manner.

Excerpt	Reference	Relevance
"1 Pharmacokinetic and concentration-effect studies have been carried out following intravenous injection of 10 mg metoclopramide hydrochloride to seven normal male volunteers."	( Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. Bateman, DN; Davies, DS; Kahn, C; Mashiter, K, 1978)	0.71
"The indications, contraindications and usefulness of pharmacodynamic tests in current radiological diagnosis of diseases of the digestive tract are reviewed and iscussed."	( [The employment of pharmacodynamic tests in the radiological examination of the digestive tract (author's transl)]. Basilico, L; Bonomo, L; Lupini, A; Renda, F, 1978)	0.26
" The means and variances of the pharmacokinetic parameters of the cis and trans isomers of cefprozil were similar in fasting subjects and were affected in a parallel manner by food, metoclopramide, propantheline, and probenecid."	( Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. Barbhaiya, RH; Pittman, KA; Shukla, UA, 1992)	0.71
"Metoclopramide was administered by continuous infusion to two groups each of 14 patients on chemotherapy, randomized to receive either doses adjusted to individual pharmacokinetic parameters or doses adjusted as usual to body weight."	( Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. Brechot, JM; Chastang, C; Delattre, C; Dupeyron, JP; Laaban, JP; Rochemaure, J, 1991)	2.01
"09 l h-1 kg-1, plasma drug concentrations and the half-life of metoclopramide were greater in patients following both routes of drug administration."	( Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Attali, P; Etienne, JP; Hagege, H; Magueur, E; Singlas, E; Taburet, AM, 1991)	0.84
" Pharmacokinetic analysis showed mean peak metoclopramide concentration at 30 min of 99."	( Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. McCallum, RW; Polepalle, S; Spyker, D; Valenzuela, G, 1991)	0.91
" The mean peak plasma concentration, mean area under plasma concentration time curve and mean half-life of cefpodoxime proxetil were similar in all groups as compared to control."	( Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil. Batts, DH; Euler, AR; Heald, DL; Hughes, GS; Patel, R; Spillers, CR, 1990)	0.28
" Thus, with respect to the pharmacokinetic target parameters, little difference can be found between the two suppository forms each containing 20 mg metoclopramide-base and under trial in this study."	( Bioavailability and pharmacokinetics of rectally administered metoclopramide. Krammer, R; Miczka, M; Nitsche, V; Schimmel, H; Strobel, K; Vergin, H, 1990)	0.72
"19 mg/l with doses which varied considerably owing to marked scattering of pharmacokinetic parameters."	( [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. Brechot, JM; Delattre, C; Delfour, C; Dupeyron, JP; Guyon, F; Lebeau, B; Rochemaure, J, 1988)	0.59
" There were no significant differences between the first versus tenth dose values for Tmax (2."	( Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. Butler, HL; Carchman, SH; Kearns, GL; Lane, JK; Wright, GJ, )	1.57
" A single dose pharmacokinetic comparison of Gastrobid Continus and Maxolon was carried out perioperatively in two groups of 12 gynaecological patients; each group comprised six patients for major surgery and six patients for minor surgery."	( A single dose pharmacokinetic study of Gastrobid Continus and Maxolon in the perioperative period. Ellis, FR; Madej, TH; Tring, I, 1988)	0.27
" Pharmacokinetic and demographic data of 83 treatments were analysed by the NONMEM program using a linear 2-compartment model."	( Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients. Bateman, DN; Grevel, J; Kelman, AW; Taylor, WB; Whiting, B, 1988)	0.51
"8 min, respectively, with fetal half-life being significantly longer."	( Metoclopramide pharmacokinetics in pregnant and nonpregnant sheep. Axelson, JE; Gruber, NC; McErlane, BA; McMorland, GH; Riggs, KW; Rurak, DW, 1988)	1.72
" The pharmacokinetic parameters of high-dose metoclopramide were found to be similar to those reported for standard promotility doses, and no dose dependency was demonstrated over the range of doses studied."	( Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. Cohen, JL; Joseph, C; McDermed, JE; Strum, SB, 1985)	0.8
" Alizapride's main pharmacodynamic effects are on the central nervous system."	( [Pharmacodynamics of alizapride (author's transl)]. Laville, C; Margarit, J, 1982)	0.26
" The elimination half-life of metoclopramide is dose-dependent after both intravenous and oral administration of single doses between 5 and 20mg."	( Clinical pharmacokinetics of metoclopramide. Bateman, DN, )	0.71
" A 2-compartment open model was taken as a basis for the calculation of the plasma concentration curves and the pharmacokinetic parameters."	( [Pharmacokinetics and bioequivalence of various oral formulations of metoclopramide]. Bishop-Freudling, GB; Reeves, DS; Strobel, K; Vergin, H, 1983)	0.5
"A method for determination of metoclopramide in serum, urine, and saliva is described that can be applied to both pharmacokinetic and clinical studies."	( High-pressure liquid chromatographic method for determination of metoclopramide in serum, urine, and saliva, with a pharmacokinetic study in patients. Popović, J, 1984)	0.79
"Simultaneous oral administration of digoxin and three benzamides (Metoclopramide, Alizapride, Bromopride) to the rat, modify digoxin's pharmacokinetic parameters: peak plasma concentration, elimination phase half life and bioavailability (Bromopride, Alizapride in function with dose-level)."	( Pharmacokinetic study of digoxin-benzamide interaction in the rat. Jacquot, C; Metivier, B; Renault, H; Servin, A, 1984)	0.5
" The mean terminal half-life was 13."	( The pharmacokinetics of single doses of metoclopramide in renal failure. Bateman, DN; Blain, PG; Dodd, TR; Gokal, R, 1981)	0.53
" 2 The mean plasma beta half-life was 156."	( The pharmacokinetics of metoclopramide in man with observations in the dog. Bateman, DN; Davies, DS; Kahn, C, 1980)	0.57
"The short elimination half-life of metoclopramide necessitates frequent administration for optimal relief of nausea."	( Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Babul, N; Bruera, ED; Darke, AC; Harsanyi, Z; LeGatt, DF; MacDonald, RN; MacEachern, TJ; Spachynski, KA, 1994)	0.78
" Additional pharmacokinetic parameters for metoclopramide were determined following intravenous administration to seven cows."	( Bioavailability and pharmacokinetics of metoclopramide in cattle. Bowen, JM; Jones, RD; Mizinga, KM; Stuedemann, JA; Thompson, FN, 1994)	0.82
" Pharmacokinetic parameter values were calculated using noncompartmental methods."	( Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. Barbhaiya, RH; Knupp, CA; Milbrath, RL, 1993)	0.69
" Blood and urine were collected for measurement of pharmacokinetic parameters."	( The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Bateman, DN; Boddy, A; Cope, LH; Woodhouse, KW; Wynne, HA; Yelland, C, 1993)	0.51
" No significant differences were observed in the pharmacokinetic profiles of the three formulations of metoclopramide."	( Comparative central nervous system effects and pharmacokinetics of neu-metoclopramide and metoclopramide in healthy volunteers. Kilminster, S; Moller, C; Mould, GP; Pero, RW; Rotmensch, HH; Sutton, JA, 1997)	0.74
" The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs."	( Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Berstad, A; Hatlebakk, JG, 1996)	0.29
" Concomitant intake of 8-MOP with metoclopramide did not significantly influence these 3 pharmacokinetic values."	( Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997)	0.95
" Associating 8-MOP with metoclopramide does not alter the pharmacokinetic values of 8-MOP and should not require any change in PUVA treatment."	( Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997)	0.97
" There were no statistically significant differences in the pharmacokinetic parameters, Cmax, tmax, AUC, and t1/2, for butorphanol with or without metoclopramide."	( Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women. Barbhaiya, RH; Shyu, WC; Vachharajani, NN, 1997)	0.73
" A single-dose pharmacokinetic study of oral metoclopramide (0."	( Pharmacokinetics of metoclopramide in neonates. Blumer, JL; Kearns, GL; Reed, MD; van den Anker, JN, 1998)	0.88
" The analytical method was successfully applied for the determination of pharmacokinetic parameters after ingestion of 10 mg dose of metoclopramide."	( RP-HPLC method with electrochemical detection for the determination of metoclopramide in serum and its use in pharmacokinetic studies. Chmielewska, A; Konieczna, L; Lamparczyk, H; Plenis, A; Zarzycki, PK, 2001)	0.75
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" Pharmacokinetic parameters were calculated with compartmental and non-compartmental analysis."	( Pharmacokinetic interaction study between ranitidine and metoclopramide. Farcău, D; Leucuţa, A; Nanulescu, M; Vlase, L, 2004)	0.57
"The pharmacokinetic interaction of fluoxetine with metoclopramide in healthy volunteers was evaluated."	( Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Farcau, D; Leucuta, A; Nanulescu, M; Vlase, L, 2006)	0.84
" No differences between treatments were found for other pharmacokinetic parameters."	( Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. Albarellos, G; Kreil, V; Prados, AP; Rebuelto, M; Waxman, S, 2007)	1.78
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"To develop a semi-mechanistic population pharmacokinetic model based on gastric emptying function for acetaminophen plasma concentration in critically ill patients tolerant and intolerant to enteral nutrition before and after prokinetic therapy."	( A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. Aarons, L; Dukes, G; Maclaren, R; Ogungbenro, K; Vasist, L; Young, M, 2011)	0.37
" Population pharmacokinetic modelling was carried out in a nonlinear mixed effects analysis software, NONMEM."	( A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. Aarons, L; Dukes, G; Maclaren, R; Ogungbenro, K; Vasist, L; Young, M, 2011)	0.37
"The four-compartment semi-mechanistic population pharmacokinetic model adequately described the data."	( A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. Aarons, L; Dukes, G; Maclaren, R; Ogungbenro, K; Vasist, L; Young, M, 2011)	0.37
" Sixty days later, 6 of the 8 dogs were given 10 g of PWG followed by cyclosporine, and pharmacokinetic parameters were compared with those previously obtained after administration of cyclosporine alone."	( Effects of powdered whole grapefruit and metoclopramide on the pharmacokinetics of cyclosporine in dogs. Cerundolo, R; Court, MH; Hanley, MJ; Radwanski, NE; Shofer, FS, 2011)	0.64
"Although metoclopramide or coadministration of metoclopramide and 2 g of PWG had no effect on the pharmacokinetic parameters of cyclosporine, compared with results for cyclosporine alone, the higher (10-g) dose of PWG resulted in 29% faster mean time to maximal plasma cyclosporine concentration, 54% larger area under the curve, and 38% lower apparent oral clearance."	( Effects of powdered whole grapefruit and metoclopramide on the pharmacokinetics of cyclosporine in dogs. Cerundolo, R; Court, MH; Hanley, MJ; Radwanski, NE; Shofer, FS, 2011)	1.05
"This was a single-center, randomized, open-label, parallel-group, single- and multiple-dose, pharmacokinetic study."	( Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. Alonso-Campero, R; Angeles-Uribe, J; Bernardo-Escudero, R; Cortés-Fuentes, M; de Jesús Francisco-Doce, MT; Villa-Vargas, M, 2011)	0.59
" A single and multiple-dose, randomized, open-label, parallel, pharmacokinetic study was conducted."	( Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy mal Alonso-Campero, R; Angeles-Uribe, J; Bernardo-Escudero, R; Cortés-Fuentes, M; Francisco-Doce, MT; Villa-Vargas, M, 2012)	0.6
" This study aimed to characterize the pharmacokinetics of posaconazole in adults and investigate factors that influence posaconazole pharmacokinetics byusing a population pharmacokinetic approach."	( Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Brüggemann, RJ; Burger, DM; Dolton, MJ; McLachlan, AJ, 2014)	0.4
" Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was performed to measure dog plasma MCP, and pharmacokinetic parameters were calculated."	( Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs. Fan, X; Li, W; Li, Y; Sun, J; Tang, D; Yang, P; Yin, X; Zhang, H; Zheng, A, 2018)	1.92
"This was a randomized, two-phase cross-over pharmacokinetic study separated by a 4-week wash-out time period, 12 healthy non-smoking volunteers received metoclopramide 20 mg as a single oral dose and after 4 weeks, cilostazol 100 mg twice daily for 4 days then with metoclopramide 20 mg on test day."	( Evaluation of Pharmacokinetic Interaction of Cilostazol with Metoclopramide after Oral Administration in Human. Ahmad, S; Hussain Shah, SN; Kaukab, I; Kharaba, Z; Murtaza, G; Saad, AA, 2019)	0.95
"The results showed delayed Tmax of metoclopramide by cilostazol, which could lead to the conclusion that cilostazol affects the absorption of metoclopramide."	( Evaluation of Pharmacokinetic Interaction of Cilostazol with Metoclopramide after Oral Administration in Human. Ahmad, S; Hussain Shah, SN; Kaukab, I; Kharaba, Z; Murtaza, G; Saad, AA, 2019)	1.03
" The aim of this study was to investigate the pharmacokinetic interactions of Cola nitida and metoclopramide in rabbits."	( The effects of oral administration of Cola nitida on the pharmacokinetic profile of metoclopramide in rabbits. Amadi, CN; Nwachukwu, WI, 2020)	1
" The following pharmacokinetic parameters were also decreased: area under the curve (51%), peak plasma concentration (39%), half-life (51%); while an increase in elimination rate constant (113%) and clearance rate (98%) were noted indicating rapid elimination of the drug."	( The effects of oral administration of Cola nitida on the pharmacokinetic profile of metoclopramide in rabbits. Amadi, CN; Nwachukwu, WI, 2020)	0.78
"This study was aimed at the evaluation of rifampicin's enzyme induction effect on the pharmacokinetic parameters of orally administered metoclopramide."	( Influence of Rifampicin Pre-treatment on the In vivo Pharmacokinetics of Metoclopramide in Pakistani Healthy Volunteers Following Concurrent Oral Administration. Abrar, MA; Anwer, N; Kaukab, I; Murtaza, G; Shah, SNH, 2020)	0.99
"This randomized, single-blind, two-phase cross-over pharmacokinetic study separated by a 4-week washout period was conducted at a single center in Pakistan."	( Influence of Rifampicin Pre-treatment on the In vivo Pharmacokinetics of Metoclopramide in Pakistani Healthy Volunteers Following Concurrent Oral Administration. Abrar, MA; Anwer, N; Kaukab, I; Murtaza, G; Shah, SNH, 2020)	0.79
"The objective of this study was to assess the influence of enzyme suppression on the values of various pharmacokinetic factors of orally administered metoclopramide."	( Effect of clarithromycin pre-treatment on the pharmacokinetics of metoclopramide after their simultaneous oral intake. Alfoteih, YA; Buabeid, MA; Kaukab, I; Kharaba, ZJ; Murtaza, G; Shah, SNH, 2020)	0.99

Compound-Compound Interactions

Intravenous administration of dexamethasone combined with metoclopramide had significant effects in prophylaxis of nausea and vomiting after LC.

Excerpt	Reference	Relevance
" We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B)."	( Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research Basurto, C; Bracarda, S; Di Costanzo, F; Donati, D; Malacarne, P; Monici, L; Patoia, L; Picciafuoco, M; Roila, F; Tonato, M, 1989)	0.72
"This study was designed to compare the antiemetic effect of betamethasone alone with that of betamethasone combined with metoclopramide."	( [Antiemetic efficacy of betamethasone versus betamethasone combined with metoclopramide in cisplatin-treated cancer patients]. Kagami, Y; Narimatsu, N; Nishio, M; Sakurai, T; Tomita, M, 1989)	0.72
"Nausea and vomiting are reported in approximately 60% of neoplastic patients treated with doxorubicin used alone at doses greater than or equal to 50 mg/m2 or in combination with other noncisplatin antiblastic agents."	( A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. Ballatori, E; Basurto, C; Bracarda, S; Del Favero, A; Roila, F; Tonato, M, 1988)	0.51
"We designed a multicenter, double-blind randomized study to determine the safety and antiemetic effectiveness of intravenous (IV) methylprednisolone (P) combined with high-dose IV metoclopramide (MTC) v MTC alone in 200 untreated cancer patients receiving cisplatin chemotherapy."	( Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Ballatori, E; Basurto, C; Bella, M; DiCostanzo, F; Donati, D; Morsia, D; Passalacqua, R; Roila, F; Tognoni, G; Tonato, M, 1987)	0.74
"Two patients with orthostatic hypotension, complicating diabetes mellitus, were treated with dopaminergic antagonist metoclopramide alone or combined with the nonsteroidal anti-inflammatory agent flurbiprofen."	( Metoclopramide alone or combined with flurbiprofen in the treatment of orthostatic hypotension associated with diabetes mellitus. Beretta-Piccoli, C; Weidmann, P, 1982)	1.92
" Oral granisetron in combination with a corticosteroid provides superior anti-emetic control to the met/dex regimen in patients undergoing highly emetogenic chemotherapy."	( Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Cedar, E; Cunningham, J; Goedhals, L; Heron, JF; Jordaan, JP, 1994)	0.5
"The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma."	( Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Jørgensen, M; Victor, MA, 1996)	0.78
" We compared ondansetron and metoclopramide, both combined with dexamethasone, in cisplatin-treated patients."	( Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. , 1997)	0.92
" Tropisetron in combination with dexamethasone produced the best control of both acute and delayed emesis."	( Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gosse, H; Imhoff, W; Ukena, D, 1994)	0.29
"From 1994 to 1996, 27 prospective cystectomy patients received intravenous metoclopramide (metoclopramide group) combined with early nasogastric tube removal (less than 24 hours)."	( Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion. Donat, SM; Pisters, LL; Slaton, JW; Swanson, DA, 1999)	0.79
"We have studied the antiemetic efficacy of droperidol alone, and in combination with metoclopramide in first trimester termination of pregnancy in day surgery."	( A comparison of antiemetic efficacy of droperidol alone and in combination with metoclopramide in day surgery anaesthesia. Loo, CC; Sia, TH; Tan, HM; Thomas, E, 1997)	0.75
"Early NGT removal combined with metoclopramide after postchemotherapy RPLND allowed earlier diet tolerance and shortened hospital stays without increased complications."	( Early nasogastric tube removal combined with metoclopramide after postchemotherapy retroperitoneal lymph node dissection for metastatic testicular nonseminomatous germ cell tumor. Davis, JW; Donat, SM; Doviak, MJ; Pisters, LL, 2002)	0.86
" We designed a study to evaluate the efficacy of a setron (granisetron) in the delayed phase, compared with metoclopramide, each combined with a corticosteroid."	( A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Aapro, MS; Bernhard, J; De Pree, C; Maibach, R; Sessa, C; Thuerlimann, B, 2003)	0.76
"To determine whether 10 mg, 25 mg, or 50 mg metoclopramide combined with 8 mg dexamethasone, given intraoperatively, is more effective in preventing postoperative nausea and vomiting than 8 mg dexamethasone alone, and to assess benefit in relation to adverse drug reactions."	( Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. Behrends, K; Bulst, D; Gelbrich, G; Krause, U; Kühnast, T; Olthoff, D; Rohrbach, A; Wallenborn, H; Wallenborn, J; Wiegel, M, 2006)	0.85
"We conclude that theophylline overdose combined with metoclopramide may provoke new-onset seizures, especially in young patients following heart transplantation."	( Seizures after heart transplantation--two cases of non-immunosuppressant drug interactions in young patients. Baszyńska-Wachowiak, H; Buczkowski, P; Jemielity, M; Pawłowska, M; Perek, B; Straburzyńska-Migaj, E; Urbanowicz, T, 2014)	0.65
"Compare the prophylactic use of metoclopramide and its combination with dexamethasone in the prevention of PONV in patients undergoing laparoscopic cholecystectomy (LC)."	( Metoclopramide, versus its combination with dexamethasone in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a double-blind randomized controlled trial. Chandacham, K; Chotirosniramit, A; Chotirosniramit, N; Jirapongcharoenlap, T; Junrungsee, S; Ko-Iam, W; Paiboonworachat, S; Pongchairerks, P; Sandhu, T, 2015)	2.14
"Intravenous administration of dexamethasone combined with metoclopramide had significant effects in prophylaxis of nausea and vomiting after LC and shorten the hospital stay."	( Metoclopramide, versus its combination with dexamethasone in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a double-blind randomized controlled trial. Chandacham, K; Chotirosniramit, A; Chotirosniramit, N; Jirapongcharoenlap, T; Junrungsee, S; Ko-Iam, W; Paiboonworachat, S; Pongchairerks, P; Sandhu, T, 2015)	2.1
"A systematic review and meta-analysis of published randomized controlled trials was performed to update the present evidence about the safety and efficacy of dexamethasone combined with other antiemetics versus single antiemetics for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy."	( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis. Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016)	0.43
"Pooled data from 14 RCTs (1542 patients) favored dexamethasone combined with other antiemetics over single antiemetics as a prophylaxis against postoperative nausea and vomiting after laparoscopic cholecystectomy in the early postoperative period (OR = 0."	( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis. Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016)	0.43
"Dexamethasone combined with other antiemetics provided better prophylaxis than single antiemetics against postoperative nausea and vomiting after laparoscopic cholecystectomy."	( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis. Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016)	0.43
" In this study, we aimed to detect, document, and descriptively analyze the potential drug-drug interactions in hospitalized solid tumor's patients in a Middle Eastern referral oncology-hematology University-affiliated hospital."	( Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East. Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021)	0.62
" The potential drug-drug interactions between chemotherapy and nonchemotherapy drugs were evaluated with Lexi-Interact ver."	( Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East. Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021)	0.62
" We detected 227 drug-drug interactions with moderate or major severity out of included patients in which 96, 71, 32, and 28 interactions were in the category of C, D, B, and X, respectively."	( Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East. Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021)	0.62
"Potentially moderate or major drug-drug interactions frequently occur among solid tumor's cancer patients necessitate the establishment of a clinical pharmacy service for providing relevant pharmacotherapy consultations to prevent this potentially serious concern."	( Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East. Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021)	0.62
"In this pilot study, we aimed to determine the efficacy and safety of enteral erythromycin estolate in combination with intravenous metoclopramide compared to intravenous metoclopramide monotherapy in mechanically ventilated patients with enteral feeding intolerance."	( Efficacy and Safety of Enteral Erythromycin Estolate in Combination With Intravenous Metoclopramide vs Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients With Enteral Feeding Intolerance: A Randomized, Double-Blind, Controlled Pilo Bhurayanontachai, R; Boonpeng, A; Charoensareerat, T; Lerkiatbundit, S; Navasakulpong, A; Pattharachayakul, S; Sitaruno, S, 2021)	1.05
"This randomized, double-blind, controlled pilot study included 35 mechanically ventilated patients with feeding intolerance who were randomly assigned to receive 10-mg metoclopramide intravenously every 6-8 hours in combination with 250-mg enteral erythromycin estolate (study group) or placebo every 6 hours for 7 days."	( Efficacy and Safety of Enteral Erythromycin Estolate in Combination With Intravenous Metoclopramide vs Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients With Enteral Feeding Intolerance: A Randomized, Double-Blind, Controlled Pilo Bhurayanontachai, R; Boonpeng, A; Charoensareerat, T; Lerkiatbundit, S; Navasakulpong, A; Pattharachayakul, S; Sitaruno, S, 2021)	1.04
"To investigated the effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine for patient-controlled intravenous analgesia (PCIA) on patients after open gastrointestinal tumor surgery, and compared this combination with traditional PCIA with pure opioids or epidural analgesia (PCEA)."	( Analgesic effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine after open gastrointestinal tumor surgery: a retrospective study. Chen, YJ; Huang, J; Li, TT; Liu, F; Wang, TH; Xiong, LL; Yin, L, 2022)	0.72
"The analgesic effects of PCIA with sufentanil in combination with flurbiprofen axetil and dexmedetomidine on postoperative analgesia was better than that of traditional pure opioids PCIA, and similar with that of PCEA."	( Analgesic effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine after open gastrointestinal tumor surgery: a retrospective study. Chen, YJ; Huang, J; Li, TT; Liu, F; Wang, TH; Xiong, LL; Yin, L, 2022)	0.72

Bioavailability

The bioavailability of metoclopramide monochloride hydrate after single dose oral administration of a controlled-release capsule (Gastro-Timelets) in four normal volunteers was compared with that of oral metoclo-hydrate solution. Bioavailability of the drug was not significantly reduced by food nor by metoclobramide pre-treatment. The rate of absorption of metClo was delayed after Administration of a slow release tablet.

Excerpt	Reference	Relevance
" The rate of absorption of metoclopramide was delayed after administration of a slow release tablet and the maximum plasma concentration was about 50% lower than after a solution."	( Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Graffner, C; Lagerström, PO; Lundborg, P; Rönn, O, 1979)	0.88
" Thus factors influencing the rate of gastric emptying may alter the rate of absorption of most if not all orally administered drugs."	( Drugs, diseases and altered gastric emptying. Nimmo, WS, 1976)	0.26
" By adding metoclopramide simultanously to the oral D-xylose doses it could be demonstrated that the slower motility of the gastrointestinal tract in newborns and young infants is not exclusively responsible for the slower rate of absorption of D-xylose."	( The age-dependence of intestinal absorption using d-xylose as an example. Gladtke, E; Heimann, G; Roth, B, 1977)	0.65
"The bioavailability of a new enteric-coated tablet of aspirin (Ecotrin, Smith, Kline and French) was evaluated after single doses to eight volunteers."	( Single-dose evaluation of a new enteric-coated aspirin preparation. Champion, D; Day, R; Graham, G; Paull, P, 1976)	0.26
" The addition of metoclopramide increased the rate of diazepam absorption and peak concentrations were reached by 30 min, while morphine, pethidine and atropine reduced the rate of absorption with no apparent peak being reached by 90 min."	( Some pharmacological factors influencing the absorption of diazepam following oral administration. Dundee, JW; Gamble, JA; Gaston, JH; Nair, SG, 1976)	0.6
" However, absorption during labour, as reflected by maternal blood levels at delivery and cord blood levels, suggests that amoxycillin is poorly absorbed and may not reach adequate therapeutic levels in the fetus."	( Gastro-intestinal absorption and transplacental transfer of amoxycillin during labour and the influence of metoclopramide. Buckingham, M; Elstein, M; Miller, JF; Welply, G, 1975)	0.47
" The well known bioavailability parameters of absorption and the area under the curve of the fractional absorbed time profiles up to 30 min were used as an index of gastric emptying."	( Influence of cisapride, metoclopramide and loperamide on gastric emptying of normal volunteers as measured by means of the area under the curve of the cumulative fraction absorbed-time profiles of paracetamol. Moncrieff, J; Sommers, DK; van Wyk, M, 1992)	0.59
"An open trial was carried out in eight healthy male and female volunteers to examine the bioavailability as well as the main kinetic parameters of Migränerton (metoclopramide and paracetamol; CAS 364-64-5 and CAS 103-90-2, resp)."	( [Pharmacokinetic aspects of a combination of metoclopramide and paracetamol. Results of a human kinetic study and consequences for migraine patients]. Becker, A; Berner, G; Leuschner, F; Vögtle-Junkert, U, 1992)	0.74
" Bioavailability of the drug was not significantly reduced by food nor by metoclopramide pre-treatment."	( The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine. Francetić, I; Kopitar, Z; Plavsić, F; Povsic, L; Urbancic, J; Vrhovac, B, )	0.67
"2 l kg-1) and absolute bioavailability (79 +/- 19 vs 84 +/- 15%) were similar in the two groups."	( Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Attali, P; Etienne, JP; Hagege, H; Magueur, E; Singlas, E; Taburet, AM, 1991)	0.6
" atropine and pirenzepine) and the results were compared with the bioavailability (i."	( The mean cumulative fraction absorbed-time profiles of paracetamol as an index of gastric emptying. Meyer, EC; Moncrieff, J; Sommers, DK; van Wyk, M, 1990)	0.28
" The method provides high sensitivity and selectivity and has been used successfully in bioavailability studies."	( Determination of opiates and other basic drugs by high-performance liquid chromatography with electrochemical detection. Band, C; Besner, JG; Caillé, G; Rondeau, JJ; Stewart, J; Varin, F; Yamlahi, L, 1989)	0.28
" Absolute bioavailability was 50."	( Bioavailability of intranasal metoclopramide. Buss, DC; Ellershaw, J; Nash, A; Routledge, PA; Ward, MJ, 1989)	0.57
" The bioavailability of cimetidine was not significantly affected by metoclopramide and it was marginally reduced by the antacid."	( Effects on cimetidine bioavailability of metoclopramide and antacids given two hours apart. Barzaghi, N; Crema, F; Mescoli, G; Perucca, E, 1989)	0.78
" These results indicate that absorption rate of droxicam has been modified but bioavailability does not suffer modification in conditions of altered gastric emptying."	( The influence of gastric emptying on droxicam pharmacokinetics. Bartlett, A; García-Barbal, J; Martínez, L; Roser, R; Sagarra, R; Sánchez, J, 1989)	0.28
" Gastric emptying after each premedication was assessed indirectly from the rate of absorption of oral paracetamol."	( Comparison of the effect of cisapride and metoclopramide on morphine-induced delay in gastric emptying. Bamber, PA; Nimmo, WS; Rowbotham, DJ, 1988)	0.54
" The linearity of kinetic parameters and absolute bioavailability of metoclopramide were examined."	( Linearity of metoclopramide kinetics at doses of 5-20 mg. Axelson, JE; McErlane, B; McMorland, GH; Ongley, RC; Price, JD; Rurak, DW; Tam, YK; Wright, MR, 1988)	0.88
"Intravenous metoclopramide is known to increase the rate of absorption of oral diazepam if administered at the same time."	( Co-administered oral metoclopramide does not enhance the rate of absorption of oral diazepam. Atkinson, HC; Begg, EJ; Chapman, MH; Sharman, JR; Woolner, DF, 1988)	0.97
" Metoclopramide has been shown to hasten gastric emptying; since cyclosporine is absorbed predominantly in the small intestine, coadministration of metoclopramide resulted in increased bioavailability of cyclosporine."	( The effect of oral metoclopramide on the absorption of cyclosporine. First, MR; Myre, SA; O'Flaherty, E; Pesce, AJ; Schroeder, TJ; Wadhwa, NK, 1987)	1.51
" Metoclopramide has been shown to hasten gastric emptying; since cyclosporine is absorbed predominantly in the small intestine, coadministration of metoclopramide resulted in increased bioavailability of cyclosporine."	( The effect of oral metoclopramide on the absorption of cyclosporine. First, MR; Myre, SA; O'Flaherty, E; Pesce, AJ; Schroeder, TJ; Wadhwa, NK, 1987)	1.51
"The bioavailability of metoclopramide monochloride hydrate after single dose oral administration of a controlled-release capsule (Gastro-Timelets) was compared with that of oral metoclopramide monochloride hydrate solution in four normal volunteers."	( Bioavailability of controlled-release metoclopramide. 1st communication: single dose study. Beckett, AH; Behrendt, WA; Hadzija, BW, 1987)	0.85
"The bioavailability of metoclopramide monochloride hydrate after oral multidose administration of controlled-release metoclopramide capsules (Gastro-Timelets) was compared with that of oral metoclopramide monochloride hydrate solution in 10 healthy men."	( Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. Beckett, AH; Behrendt, WA; Hadzija, BW, 1987)	0.85
" The initial bioavailability was 67."	( Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. Awni, WM; Cass, O; Goodman, M; Matzke, GR; Melikian, AP; O'Connell, ME; Wright, GJ, 1987)	0.55
" In contrast, the median oral bioavailability was considerably higher in patients with cirrhosis of the liver (82%) than in patients with normal liver function (60%)."	( Absolute bioavailability of metoclopramide given orally or by enema in patients with normal liver function or with cirrhosis of the liver. Achtert, G; Brockmann, P; Gatzen, M; Hausleiter, HJ; Hellenbrecht, D; Hellstern, A; Leuschner, U; Manus, B; Saller, R, 1987)	0.57
"The oral bioavailability of high-dose metoclopramide was studied in 12 patients, who received oral or intravenous (i."	( Oral bioavailability of high-dose metoclopramide. Bateman, DN; Taylor, WB, 1986)	0.82
"This was a randomized, crossover study of the bioavailability and pharmacokinetics of metoclopramide given by intranasal (IN), oral (PO), and intramuscular (IM) routes."	( Pharmacokinetic comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers. Citron, ML; Jaffe, ND; Kalra, J; Kay, BG; Miller, FR; Nathan, KA; Reynolds, JR, 1987)	0.73
"Metoclopramide was found to increase the absorption rate constant (ka) of cimetidine by the duodenum and jejunum in both ligated and unligated rats."	( Effect of metoclopramide on the absorption of cimetidine in rats. Funaki, T; Furuta, S; Kaneniwa, N, 1986)	2.12
" Taken as a whole, these data suggest that the effect of meals to increase bioavailability of CGZ could be mediated at least in part, through an increase in GI residence time."	( Bioavailability studies with ciglitazone in beagles. II. Effect of propantheline bromide and metoclopramide HCL on bioavailability of a tablet. Capponi, VJ; Cox, SR; Harrington, EL, )	0.35
" These mechanisms include: (1) impaired hepatic drug metabolism due to inhibition of hepatic microsomal enzymes, (2) reduced hepatic blood flow, resulting in decreased clearance of drugs that are highly extracted by the liver, (3) increased potential for myelosuppression when administered concurrently with other drugs capable of causing myelosuppression, and (4) altered bioavailability of acid-labile drugs."	( Review of cimetidine drug interactions. Darvey, DL; Sorkin, EM, 1983)	0.27
"Metoclopramide is rapidly and well absorbed from the gastrointestinal tract, and in man undergoes variable first-pass metabolism (oral bioavailability 32 to 100%)."	( Clinical pharmacokinetics of metoclopramide. Bateman, DN, )	1.87
" Intravenous administration of sulfinpyrazone demonstrated that the tablets had a high bioavailability (about 90%), and the time to peak plasma concentration of the sulfide and the amount formed were similar to those seen after oral administration."	( Role of the gut flora in the reduction of sulfinpyrazone in humans. George, CF; Oates, J; Renwick, AG; Sembi, J; Strong, HA, 1984)	0.27
" No significant difference was found in the bioavailability of either the aspirin or metoclopramide from the combination as compared to the individual components."	( The pharmacokinetics of the individual constituents of an aspirin-metoclopramide combination ('Migravess'). Dinneen, LC; Langemark, M; Manniche, PM, 1984)	0.73
" An approximate value of 71% was obtained for the bioavailability of metoclopramide of Gastronerton retard capsules."	( [Bioavailability of metoclopramide in a sustained-release preparation]. Becker, A; Berner, G; Leuschner, F; Wagener, HH, 1984)	0.83
"The bioavailability of metoprolol was studied in eight healthy young and seven healthy elderly volunteers."	( Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. Briant, RH; Dorrington, RE; Ferry, DG; Paxton, JW, 1983)	0.48
"Pharmacokinetics and absolute bioavailability of 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide (bromopride, Viaben), in various preparations (bromopride injection solution, bromopride suppositories for adults, drops and capsules, respectively) in various dosages were calculated."	( [Pharmacokinetics and absolute bioavailability of bromopride from various pharmaceutical formulations]. Brodbeck, R; Lücker, PW; Tinhof, W; Wetzelsberger, N; Weyers, W, 1983)	0.27
"Simultaneous oral administration of digoxin and three benzamides (Metoclopramide, Alizapride, Bromopride) to the rat, modify digoxin's pharmacokinetic parameters: peak plasma concentration, elimination phase half life and bioavailability (Bromopride, Alizapride in function with dose-level)."	( Pharmacokinetic study of digoxin-benzamide interaction in the rat. Jacquot, C; Metivier, B; Renault, H; Servin, A, 1984)	0.5
"6 mg), both separately and combined, on the absorption rate and relative oral bioavailability of the antiarrhythmic drug, mexiletinee (400 mg) was studied in eight fasting healthy males using a Latin Square design for order of pretreatment administration."	( The effect of metoclopramide and atropine on the absorption of orally administered mexiletine. Birkett, DJ; Grygiel, JJ; Meffin, PJ; Smith, KJ; Wing, LM, 1980)	0.62
" The bioavailability of tolfenamic acid, measured as the area under the serum tolfenamic acid concentration-time curve (AUC0-5 h) and the peak concentration, was not influenced by metoclopramide."	( The effect of metoclopramide on the absorption of tolfenamic acid. Anttila, VJ; Neuvonen, PJ; Tokola, RA, 1982)	0.82
" The bioavailability results were as follows: metoclopramide of Gastronerton tablets 80."	( [Bioavailability of metoclopramide with special reference to relevant literature data]. Berner, G; Emschermann, B; Gladtke, E; Haase, W; Leuschner, F; Vögtle-Junkert, U; Wagener, HH, 1982)	0.85
" It is concluded that the negative effect of the antacid on the bioavailability of atenolol is caused by a reduction in the in vivo dissolution rate due to increased gastric pH."	( The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. Lundborg, P; Persson, BA; Regårdh, CG, )	0.44
" Oral bioavailability was 71."	( The pharmacokinetics of single doses of metoclopramide in renal failure. Bateman, DN; Blain, PG; Dodd, TR; Gokal, R, 1981)	0.53
"01) reduced the bioavailability (area under the plasma level-time curve) of cimetidine, on average by one third."	( Impaired cimetidine absorption due to antacids and metoclopramide. Brand, M; Gugler, R; Somogyi, A, 1981)	0.51
" 4 Bioavailability of a 10 mg oral dose of metoclopramide varied between 32 and 97%."	( The pharmacokinetics of metoclopramide in man with observations in the dog. Bateman, DN; Davies, DS; Kahn, C, 1980)	0.83
"Etoposide demonstrates incomplete and variable bioavailability after oral dosing, which may be due to its concentration and pH-dependent stability in artificial gastric and intestinal fluids."	( Pharmacological attempts to improve the bioavailability of oral etoposide. Clark, PI; Craft, H; Heap, L; Joel, SP; Robbins, S; Slevin, ML; Webster, L, 1995)	0.29
"This investigation was carried out to evaluate the bioavailability of a new tablet formulation of metoclopramide hydrochloride (10 mg), Metosil relative to a recognized product, Plasil BP."	( Comparative bioavailability of two tablet formulations of metoclopramide hydrochloride. al-Rayes, S; el-Sayed, YM; Gouda, MW; Ismail, AO; Niazy, EM, 1995)	0.75
"An investigation on the bioavailability of a tablet with 10 mg metoclopramide-HCl (CAS 363-62-5) Cerucal was performed in a two-way cross-over study with 12 volunteers."	( [The bioequivalence of metoclopramide in two tablet formulations]. Berndt, A; Dobrev, D; Gramatté, T; Oertel, R; Richter, K; Terhaag, B, 1995)	0.84
" These effects would be expected to increase the initial rate of absorption of orally administered drugs, but reduce total bioavailability of the agents."	( Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Greiff, JM; Rowbotham, D, 1994)	0.29
"The bioavailability of metoclopramide was investigated in three steers following administration of 8 mg/kg by the oral, abomasal (cannula), and intravenous routes, using a Latin square design."	( Bioavailability and pharmacokinetics of metoclopramide in cattle. Bowen, JM; Jones, RD; Mizinga, KM; Stuedemann, JA; Thompson, FN, 1994)	0.87
"Methods are discussed which permit the calculation of the bioavailability (F) and fraction of an oral dose entering the central circulation (f) of a drug and its interconversion metabolite."	( Determination of bioavailability and systemically available fractions of drugs undergoing reversible metabolism: application to 4-amino-5-chloro-2-[2-(methylsulfinyl)ethoxy]-N-[2- (diethylamino)ethyl]benzamide and its sulfide and sulfone metabolites in ra Cheng, H; Hwang, KK; Kuo, BS; Poole, JC, 1994)	0.29
"The kinetics and bioavailability of a new formulation of metoclopramide (CAS 364-62-5) nasal spray (MTC NS) were assessed in two separate studies versus the same drug administered intravenously (MTC IV) according to a balanced-block design where each study subject served as his own control."	( Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients. Dimaiuta, M; Ferrari, P; Fraschini, F; Scaglione, F; Scanni, A; Tomirotti, M, 1993)	0.8
" The effect of metoclopramide, a drug which favors gastric emptying, was also investigated since gastric emptying could be a factor limiting the bioavailability of ingested glucose."	( Lack of effect of NaCl and/or metoclopramide on exogenous (13C)-glucose oxidation during exercise. Bronsard, E; Hillaire-Marcel, C; Massicotte, D; Péronnet, F; Tremblay, C, 1996)	0.94
"Previous studies have shown important inter- and intraindividual variations in bioavailability of 8-methoxypsoralen (8-MOP) under the influence of factors that are not yet known with certainty."	( Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997)	0.67
"The purpose of this study was to investigate a possible effect of metoclopramide on the bioavailability of 8-MOP since these drugs are frequently combined to prevent nausea, a common side effect of systemic 8-MOP."	( Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997)	0.9
"Concomitant administration of zolmitriptan and paracetamol resulted in a slight increase in bioavailability of zolmitriptan and a reduced rate and extent of paracetamol absorption."	( The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. Layton, G; Peck, RW; Posner, J; Ridout, G; Seaber, EJ, 1997)	0.5
" In contrast to MCA, declopramide has a rapid clearance from serum, a lower tissue concentration (about 15-fold lower than MCA) and a lower oral bioavailability (about 6-fold lower than MCA)."	( Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice. Hua, J; Kane, R; Pero, RW, 1999)	0.3
" HC did not change the pharmacokinetics of MCP: There were no statistically significant differences in MCP plasma concentrations, half-life, area under the curve (AUC), or rate of absorption between the two treatment groups."	( Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. Chao, ST; Cormier, M; Gupta, SK; Haak, R, 1999)	0.54
" Antiemetic effect of prochlorperazine (PCZ) is diminished by its low bioavailability owing to a significant gastric and hepatic first pass effect."	( Evaluation of prochlorperazine buccal tablets (Bukatel) and metoclopramide oral tablets in the treatment of acute emesis. Chaudhary, A; Sharma, DR; Singh, S, 1999)	0.55
" To examine bioavailability an in vivo study with rabbits was carried out."	( Controlled release of solid-reversed-micellar-solution (SRMS) suppositories containing metoclopramide-HCl. Müller-Goymann, CC; Schneeweis, A, 2000)	0.53
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
"To investigate the effect of two prokinetic drugs, cisapride and metoclopramide, on the bioavailability of drugs, a marker drug, ranitidine, was administered to healthy volunteers following pre-treatments with or without the prokinetic agents."	( Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats. Chung, SJ; Lee, HT; Lee, YJ; Shim, CK, )	0.63
"Assessment of the relative and absolute bioavailability of immediate release and sustained release formulations of metoclopramide."	( Analysis of formulation and food effect on the absorption of metoclopramide. Fisch, U; Mahr, G; Vergin, H; Winterhalter, B, 2002)	0.77
"The absolute bioavailability of the sustained release formulation (fasting state) was 58% and thus about 17% lower than the bioavailability of the immediate release formulation."	( Analysis of formulation and food effect on the absorption of metoclopramide. Fisch, U; Mahr, G; Vergin, H; Winterhalter, B, 2002)	0.56
" The data obtained showed that MCP was well absorbed nasally where almost 90% of the drug was absorbed after 60min from the rat nasal cavity."	( Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part I. Influence of formulation variables on drug absorption in anesthetized rats. Abd ElHady, SS; Awad, GA; Mortada, ND; Zaki, NM, 2006)	0.61
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" The objective of the present investigation was to develop a mucoadhesive in situ gel with reduced nasal mucociliary clearance in order to improve the bioavailability of the antiemetic drug, metoclopramide hydrochloride (MCP HCl)."	( Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Abd Elhady, SS; Awad, GA; Mortada, ND; Zaki, NM, 2007)	0.82
"The present investigation concerns the development of floating matrix tablets of metoclopramide hydrochloride (MHCl) for improving its bioavailability by prolonging gastric residence time."	( Gastroretentive drug delivery system of metoclopramide hydrochloride: formulation and in vitro evaluation. Balasubramaniam, J; Mishra, B; Muthu, MS; Singh, J; Singh, S, 2007)	0.83
" Finally, the bioavailability study in rabbits revealed that the absolute bioavailability of MET HCl was significantly increased from 40."	( In situ gels of Metoclopramide Hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits. Gattani, S; Mahajan, HS, 2010)	0.71
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" MTH is more effective to counteract gastric stasis associated with migraine, and it enhances the rate of absorption of non-steroidal anti-inflammatory drugs (NSAIDs)."	( Formulation and evaluation of bilayer tablets of metoclopramide hydrochloride and diclofenac sodium. Amrutkar, JR; Gattani, SG; Khabiya, SS; Kushare, SS, )	0.39
"Posaconazole has an important role in the prophylaxis and salvage treatment of invasive fungal infections (IFIs), although poor and variable bioavailability remains an important clinical concern."	( Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Chen, SC; Dolton, MJ; McLachlan, AJ; Ng, K; Pont, L; Ray, JE, 2012)	0.38
"To assess the effect of dimeticone and pepsin on the bioavailability of metoclopramide (CAS 7232-21-5) in healthy volunteers."	( Effect of dimeticone and pepsin on the bioavailability of metoclopramide in healthy volunteers. Bezerra, FA; Camarão, GC; de Moraes, ME; de Moraes, MO; de Moraes, RA; do Nascimento, DF; Silva Leite, AL, 2014)	0.88
" Thus, these results confirm the good bioavailability of metoclopramide in the new formulation and rule out any impaired absorption when the drugs are formulated in combination."	( Effect of dimeticone and pepsin on the bioavailability of metoclopramide in healthy volunteers. Bezerra, FA; Camarão, GC; de Moraes, ME; de Moraes, MO; de Moraes, RA; do Nascimento, DF; Silva Leite, AL, 2014)	0.89
" Posaconazole relative bioavailability was 55% lower in patients who received posaconazole than in healthy volunteers."	( Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Brüggemann, RJ; Burger, DM; Dolton, MJ; McLachlan, AJ, 2014)	0.4
" Compared to control IM, the bioavailability of oral tablets of MCP was 24."	( Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs. Fan, X; Li, W; Li, Y; Sun, J; Tang, D; Yang, P; Yin, X; Zhang, H; Zheng, A, 2018)	1.92
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" A minimal decrease in absorption rate (10%) was also observed."	( The effects of oral administration of Cola nitida on the pharmacokinetic profile of metoclopramide in rabbits. Amadi, CN; Nwachukwu, WI, 2020)	0.78
" Furthermore, in vitro release profiles and in human bioavailability were studied."	( Metoclopramide loaded buccal films for potential treatment of migraine symptoms: in vitro and in vivo study. Abdelkader, DH; El-Dahaby, E; Hussien, S; Mady, O, 2023)	2.35

Dosage Studied

Metoclopramide (Paspertin) was administered to 30 patients with duodenal ulcer at an average dosage of 2 tablets three times daily. Vomiting was a frequent side effect (about 20 per cent of cases) and was treated successfully with metocloprams.

Excerpt	Relevance	Reference
"01) 6 hours after dosing by metoclopramide 40 mg, and haloperidol 5 mg and 10 mg, when compared to placebo."	( Metoclopramide and haloperidol in tardive dyskinesia. Bateman, DN; Dutta, DK; McClelland, HA; Rawlins, MD, 1979)	2
" Part I of this paper is a review of the actions, clinical use, side effects, and dosage and administration of these new drugs."	( Some aspects of medical management of gastrointestinal disease. I. Badley, BW, 1975)	0.25
" It is suggested that when propantheline is selected as an anticholinergic for clinical use, there is need for greater awareness of the marked reduction in bioavailablity that results when the drug is administered at conventional therapeutic dosage by the oral as opposed to the intravenous route."	( Effects of intravenous and oral propantheline and metoclopramide on ethanol absorption. Gibbons, DO; Lant, AF, 1975)	0.51
" Peak levels occurred 30--210 min after dosage (mean 102 min)."	( Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism. Debono, A; Marsden, CD; Parkes, JD; Price, P; Rosenthaler, J, 1978)	0.26
" 5 It has not been possible to define a concentration-effect relationship for the action of metoclopramide on the stomach and comparison with previous results after intravenous dosing suggests that the route of administration is of major importance in determining the action of this drug."	( Concentration effect studies with oral metoclopramide. Bateman, DN; Davies, DS; Kahn, C, 1979)	0.75
" Similar plasma levels were observed after single oral dosing with capsules (5 X 11."	( [Preliminary pharmacokinetics of metoclopramide in humans. Plasma levels following a single oral and intravenous dose (author's transl)]. Heller, M; Schmidt, I; Schuppan, D, 1979)	0.54
" Complete dose-response curves to the oral compound showed greater absolute responsiveness in normals as compared to patients with LES incompetence."	( The effect of oral and intravenous metoclopramide on human lower esophageal sphincter pressure. Cohen, S; DiMarino, AJ; Morris, DW; Schoen, HJ, 1976)	0.53
"Metoclopramide (Paspertin) was administered to 30 patients with duodenal ulcer at an average dosage of 2 tablets three times daily (= 60 mg/day)."	( [Advances in the treatment of duodenal ulcer. Shortened healing time under high Paspertin dosage (author's transl)]. Schütz, E, 1976)	1.7
" Laboratories) were investigated following dosage with single tablets."	( Evaluation of an enteric coated aspirin preparation. Champion, GD; Day, RO; Graham, GG; Paull, PD, 1976)	0.26
" Patients received an intravenous dose of 16 mg dexamethasone with either 8 mg ondansetron or 60 mg metoclopramide before chemotherapy, followed by oral dosing with 8 mg ondansetron or 20 mg metoclopramide 3 times daily for 5 days."	( Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Cassidy, J; Coleman, R; Hunter, E; Kaye, S; Kerr, D; Khanna, S; McQuade, B; Smyth, J; Soukop, M; Stewart, A, 1992)	0.8
"The disposition of 4-amino-5-chloro-2-[2-(methylsulfinyl)ethoxy]-N- [2-(diethylamino)ethyl] benzamide hydrochloride (ML-1035) following intravenous (10 mg kg-1) and oral (200 mg kg-1) dosing was investigated in male and female New Zealand white rabbits."	( Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white r Hwang, KK; Otis, KW; Rao, N, 1992)	0.28
" Regimen B, employing a lower dosage of metoclopramide and steroids and using a more simple schedule of administration should be the preferred treatment."	( Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients. Basurto, C; Boschetti, E; Bracarda, S; Del Favero, A; Lupattelli, M; Picciafuoco, M; Roila, F; Sassi, M; Tonato, M, 1992)	0.79
" Dose-response studies were designed to determine the effects of these drugs on serum prolactin (PRL) concentrations."	( Effects of metoclopramide and quipazine on serum prolactin concentrations in steers. Lipham, LB; Stuedemann, JA; Thompson, FN, 1992)	0.67
" Routine MCP pharmacokinetic dosage adjustment is not indicated, but this therapeutic approach can be used to optimize antiemetic therapy in poor responder patients."	( Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. Brechot, JM; Chastang, C; Delattre, C; Dupeyron, JP; Laaban, JP; Rochemaure, J, 1991)	0.56
" We conducted a randomized, double-blinded, 7 arm clinical trial to: (1) identify the presence of a dose-response for complete protection from emesis, and (2) compare batanopride with a standard antiemetic, methylprednisolone if a dose-response was found not to exist."	( A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Findlay, B; Kaizer, L; Laberge, F; Latreille, J; Lofters, WS; Osoba, D; Pater, J; Rusthoven, J; Warr, D; Wilson, K, 1991)	0.28
" Overall, the evidence suggests that this dosing schedule for batanopride may be too toxic for clinical use."	( Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. Fleming, GF; Francher, D; Janisch, L; McEvilly, JM; Smaldone, L; Vokes, EE, 1991)	0.54
" Six steers were dosed orally with 15 mg of metoclopramide/kg of BW three times each week in gelatin capsules, and six steers received empty gelatin capsules."	( Effects of metoclopramide on steers fed Kochia scoparia hay. Hallford, DM; Rankins, DL; Smith, GS, 1991)	0.93
" Metoclopramide did not change baseline ERPF, GFR or FF over 2 h post dosing but it significantly reduced baseline UNaV, UKV, urine flow, urinary dopamine excretion, supine and erect diastolic blood pressure and supine systolic blood pressure."	( Metoclopramide, domperidone and dopamine in man: actions and interactions. MacDonald, TM, 1991)	2.63
"The pathophysiology, diagnosis, and treatment of diabetic gastroparesis are reviewed, and the mechanisms of action, pharmacokinetics, clinical efficacy, adverse effects, and dosage of metoclopramide, domperidone, and cisapride are described."	( Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis. Brown, CK; Khanderia, U, 1990)	0.93
" Baseline pH measurements were recorded for 60 min prior to dosing with 10 g of lactulose in three of the periods."	( New methods to detect the effect of alteration in gastric pH and intestinal transit by metoclopramide and propantheline using a continuous gastric pH probe and hydrogen breath analysis. Bays, M; Bohan, DF; Francom, SF; Hughes, GS; VanderLugt, JT, 1990)	0.5
" The dosing was either metoclopramide alone or combined with either neostigmine and pirenzepine or with neostigmine and atropine."	( The effect of neostigmine on metoclopramide-induced aldosterone secretion after the administration of muscarinic antagonists in man. Meyer, EC; Sommers, DK; van Wyk, M, 1990)	0.88
" Treatment with propantheline or metoclopramide was given 30 min before dosing with the antibiotic and the radioisotope."	( Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil. Batts, DH; Euler, AR; Heald, DL; Hughes, GS; Patel, R; Spillers, CR, 1990)	0.56
" Although zacopride potentiated the locomotor decrement to radiation, no clear dose-response relationship was evident."	( Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret. King, GL; Landauer, MR, 1990)	0.28
" Extrapyramidal symptoms occur rarely and only with high dosage or prolonged use."	( Metoclopramide: a dopamine receptor antagonist. DiPalma, JR, 1990)	1.72
" DA was less potent than VIP, and stimulated cyclase activity with a monophasic dose-response curve."	( Interactions between vasoactive intestinal peptide and dopamine in the rabbit retina: stimulation of a common adenylate cyclase. Lam, DM; Pachter, JA, 1986)	0.27
"In the present experiments, the dose-response effects of the dopamine (DA) receptor antagonists haloperidol, pimozide, clozapine, sulpiride, and metoclopramide, were assessed on patterns of copulatory behavior in intact, sexually active male rats with a high level of sexual experience and performance."	( Differential effects of dopamine receptor antagonists on the sexual behavior of male rats. Pfaus, JG; Phillips, AG, 1989)	0.48
" Dinnertime dosing of cimetidine appears to be a rational method of suppressing late-evening gastric acidity."	( Drug therapy of reflux oesophagitis: an update. Tytgat, GN, 1989)	0.28
" 12-hourly dosing of 60 mg long-acting metoclopramide in a typical oncology ward situation led to stable metoclopramide levels of approximately 100ng/ml in the observed 74 h in 18 patients, with the well-known wide plasma concentration variability."	( Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting. Schimke, J; Senn, HJ; Vergin, H; Wilder-Smith, C, 1989)	0.84
"The present trial with high oral doses of metoclopramide was undertaken to (a) determine a well-tolerated dosage of oral metoclopramide; (b) measure the blood levels achieved with these oral doses; (c) determine the side effects of high doses; and (d) observe for antiemetic efficacy."	( Dose-ranging antiemetic trial of high-dose oral metoclopramide. Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB; Young, CW, 1989)	0.8
" However, in the group of patients who received a high dosage of cisplatin (70-100 mg/m2), or ethylenediamine platinum II malonate (800-900 mg/m2), there was a significant difference in nausea and vomiting between patients who had and those who had not received prior chemotherapy, most probably due to anticipation."	( Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis. Gall, HE; Knobf, MK; Nauta, J; Pinedo, HM; Simons, KA; van Groeningen, CJ; van Loenen, AC; Vermorken, JB, 1989)	0.54
"A simple, reliable and selective high-performance liquid chromatographic method for the determination of metoclopramide hydrochloride in pharmaceutical dosage forms has been developed and evaluated."	( Stability-indicating high-performance liquid chromatographic assay for the determination of metoclopramide hydrochloride in pharmaceutical dosage forms. Badwan, A; el-Sayed, YM; Najib, NM; Suleiman, MS, 1989)	0.71
" Dosage adjustment was based on simple pharmacokinetics with determination of metoclopramide distribution and elimination values in each patient."	( [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. Brechot, JM; Delattre, C; Delfour, C; Dupeyron, JP; Guyon, F; Lebeau, B; Rochemaure, J, 1988)	0.82
" We suggest dose-response studies to solve the problem of equipotency of doses, when 2 drugs are compared."	( Methodological aspects of drug trials in migraine. Olesen, J; Tfelt-Hansen, P, 1985)	0.27
" The effects of intravenous metoclopramide on baseline values and dopamine dose-response curves for renal haemodynamics and natriuresis were investigated in healthy volunteers and patients with renal disease."	( Effect of metoclopramide on dopamine-induced changes in renal function in healthy controls and in patients with renal disease. Donker, AJ; Meijer, S; Reitsma, WD; Smit, AJ; Wesseling, H, 1988)	0.97
") from the oral dosage forms examined in this study."	( Linearity of metoclopramide kinetics at doses of 5-20 mg. Axelson, JE; McErlane, B; McMorland, GH; Ongley, RC; Price, JD; Rurak, DW; Tam, YK; Wright, MR, 1988)	0.64
"2 ng/ml within a 6-h dosing interval at steady state."	( Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. Butler, HL; Carchman, SH; Kearns, GL; Lane, JK; Wright, GJ, )	1.57
" With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis."	( A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. Carlini, P; Marolla, P; Nardi, M; Pollera, CF, 1987)	0.5
"Thirty-two patients with primary lung cancer receiving combination chemotherapy including cisplatin at a dosage of 80-120 mg/m2 were entered into an antiemetic randomized crossover trial."	( [Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial]. Fujii, M; Kamei, H; Kiura, K; Okabe, K; Toki, H, 1987)	0.54
" It is concluded that there is a dose-response relationship for the antiemetic effect of metoclopramide."	( High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. Grande, T; Moxnes, A; Onsrud, M; Solesvik, O; Sollien, A, 1988)	0.8
" The dosing was either metoclopramide alone or combined with ganglionic, muscarinic, beta-adrenergic or calcium-channel blockade."	( Aldosterone response to metoclopramide is mediated through the autonomic nervous system in man. de Villiers, LS; Meyer, EC; Sommers, DK; van Wyk, M, 1988)	0.89
"Continuous infusion of metoclopramide was compared with bolus dosing in a randomized, double-blind study in 27 patients receiving cisplatin therapy."	( Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis. Agostinucci, WA; Dinonno, EB; Gannon, RH; Golub, GR; Martin, RS; Schauer, PK, 1988)	0.83
" Bromopride induced a displacement to the right of the control dose-response curve constructed for apomorphine stereotypes."	( Dopaminergic supersensitivity after long-term bromopride treatment. Felicio, LF; Nasello, AG; Palermo-Neto, J, 1987)	0.27
" An increased index of suspicion for early diagnosis of this condition and adjustment of metoclopramide dosing in patients with renal failure are emphasized."	( Neuroleptic malignant-like syndrome induced by metoclopramide. Samie, MR, 1987)	0.75
" A further trial is necessary to determine the optimal dosage and scheduling of the available agents."	( [Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy]. Fujii, M; Kiura, K; Okabe, K; Tamai, M; Toki, H, 1986)	0.51
" The total dosage of metoclopramide was 20 mg."	( The effect of oral metoclopramide on the absorption of cyclosporine. First, MR; Myre, SA; O'Flaherty, E; Pesce, AJ; Schroeder, TJ; Wadhwa, NK, 1987)	0.92
" The total dosage of metoclopramide was 20 mg."	( The effect of oral metoclopramide on the absorption of cyclosporine. First, MR; Myre, SA; O'Flaherty, E; Pesce, AJ; Schroeder, TJ; Wadhwa, NK, 1987)	0.92
"To better define the dose-response relationship of moderate-dose (MD) metoclopramide (MCP), 42 patients receiving their first course of cisplatin (50 mg/m2) were randomly allocated to receive a short-course regimen of MCP, either at 1 mg/kg X 1 dose, 30 min before cisplatin (regimen A) or 1 mg/kg X 2 doses, 30 min before and 1 h after cisplatin (regimen B)."	( Randomized trial comparing two short courses of moderate-dose metoclopramide for moderate-dose cisplatin-induced emesis. Calabresi, F; Conti, EM; De Nigris, A; Pollera, CF, 1987)	0.75
" In nodose ganglia three 4-5 point dose-response (DR) curves were established, using bolus injections of 5-HT (5-80 nmol)."	( Further studies on the blockade of 5-HT depolarizations of rabbit vagal afferent and sympathetic ganglion cells by MDL 72222 and other antagonists. Round, A; Wallis, DI, 1987)	0.27
" The quantitative dose-response curves of the four doses of the emetic agonist cisplatin were shifted to the right by increasing doses of MCL."	( Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis. Hellenbrecht, D; Saller, R, 1986)	0.48
"Single dose studies were performed with three different dosage forms of metoclopramide (0."	( Absolute bioavailability of metoclopramide given orally or by enema in patients with normal liver function or with cirrhosis of the liver. Achtert, G; Brockmann, P; Gatzen, M; Hausleiter, HJ; Hellenbrecht, D; Hellstern, A; Leuschner, U; Manus, B; Saller, R, 1987)	0.8
" The dosage of CDDP was 80-100 mg/m2."	( [Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy]. Arai, R; Furuse, K; Hayashi, S; Kawahara, M; Kiyota, T; Kodama, N; Tsuruta, S, 1987)	0.57
" Its optimal dosage schedule, however, has not yet been completely defined."	( Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Ballatori, E; Basurto, C; Canaletti, R; Colombo, N; DiCostanzo, F; Donati, D; Morsia, D; Passalacqua, R; Roila, F; Tonato, M, 1985)	0.52
"Four consecutive trials were undertaken to study lorazepam at each of three dosage levels and diphenhydramine when used in combination with iv metoclopramide and dexamethasone in patients receiving cisplatin at 120 mg/m2."	( Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Clark, RA; Fiore, JJ; Gralla, RJ; Groshen, S; Kelsen, DP; Kris, MG; Tyson, LB, 1985)	0.7
" The results demonstrate that the dosage regimen originally suggested by Gralla for cytostatic drugs, with forced diuresis for high-dose metoclopramide therapy, may also be applied, with no dosage reduction, with to other cytostatic drugs which do not require forced diuresis."	( Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. Braun, J; Domschke, S; Domschke, W; Ell, C; König, HJ, 1985)	0.74
"The ergoline derivative, Metergoline, in a dosage of 4 to 24 mg/day, was administered for one to eight months to 42 patients with hyperprolactinemic amenorrhea."	( Treatment of hyperprolactinemic amenorrhea with Metergoline. Bohnet, HG; Kato, K; Wolf, AS, 1986)	0.27
" Compensatory dosage increases are probably unnecessary for most patients."	( Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Collins, CB; Crowe, JT; Heironimus, JD; Lehmann, CR; Melikian, AP; O'Neil, TJ; Pierson, WP; Wright, GJ, 1985)	1.71
" Regional catheterization before and after MCP dosing in one subject showed a considerable increase in adrenal epinephrine and norepinephrine concentrations 45 seconds after the MCP bolus dose."	( Effect of metoclopramide on plasma catecholamine release in essential hypertension. Buu, NT; Hamet, P; Kuchel, O; Larochelle, P, 1985)	0.67
" A 10 mg dose of MCP was given 15 min prior to dosing with CGZ and repeated 1 h after dosing."	( Bioavailability studies with ciglitazone in beagles. II. Effect of propantheline bromide and metoclopramide HCL on bioavailability of a tablet. Capponi, VJ; Cox, SR; Harrington, EL, )	0.35
" The following kinetics were derived from the metoclopramide steady-state plasma levels and the t1/2 of the elimination phase 26 to 38 hr after dosing (median value and range are listed): Steady-state plasma concentration in group A and group B was 750 (480 to 1520) and 360 (300 to 480) ng/ml plasma."	( Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis. Achtert, G; Briemann, L; Brockmann, P; Hausleiter, HJ; Hellenbrecht, D; Hellstern, A; Hess, H; Hodgson, M; Mitrou, P; Saller, R, 1985)	1.97
" IV prochlorperazine at 20-mg dosage is surprisingly effective."	( A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study. Bertrand, M; Browning, S; Carr, BI; Doroshow, JH; Hill, LR; Presant, C; Pulone, B, 1985)	0.51
" In the four higher dosed groups the averages were 8, 8, 5, and 6, respectively."	( High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study. Danneskiold-Samsøe, P; Hauksson, A; Tropé, C, 1985)	0.67
" Saline dosed control animals did not exhibit these changes."	( Lack of effect of metoclopramide on cisplatin-induced nephrotoxicity in rats. Buyan, RD; Perkins, WE; Schroeder, RL, 1985)	0.6
" This diabetes insipidus is reversible, non-progressive, unrelated to plasma level, and distinct in attack from lithium-induced hypothyroidism, which may occur at low dosage but is also usually of late onset and reversible or treatable with thyroxine while lithium is continued."	( Blood levels and management of lithium treatment. Crammer, JL; Crane, G; Rosser, RM, 1974)	0.25
" Each dopamine antagonist displaced the dose-response curve for dopamine-induced suppression of prolactin release to the right in a parallel manner."	( Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations. Besser, GM; Delitala, G; Grossman, A; Stubbs, WA; Yeo, T, 1980)	0.55
" administration of lisuride at the dosage known to be ineffective on the postsynaptic dopamine receptor."	( [Suppressive effects of lisuride on the synthesis, release and metabolism of dopamine in rat brain]. Azuma, H; Iwai, K; Kikuta, M; Liu, HJ; Oshino, N; Sato, K, 1982)	0.26
" The study indicated that the dosage level of 4 mg/kg is suitable for clinical use."	( [Phase I study of alizapride in cancer patients treated with cisplatin]. Bleiberg, H; Frisque, C; Nicaise, C; Ortmans, M; Rozencweig, M, 1983)	0.27
" Results of a 3-wk double-blind study indicate that metoclopramide at a dosage of one 10-mg tablet four times daily reduced nausea, vomiting, fullness, and early satiety and improved meal tolerance better than placebo."	( A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Behar, J; Deren, J; Falchuk, K; Ippoliti, A; McCallum, RW; Olsen, HW; Rakatansky, H; Rhodes, JB; Ricci, DA; Salen, G, )	0.63
" Metoclopramide reduced the time to reach peak concentration for both digoxin dosage forms."	( Effect of metoclopramide on digoxin absorption from tablets and capsules. Bustrack, JA; Hull, JH; Johnson, BF; Marwaha, R; Urbach, DR, 1984)	1.58
" Nine patients with non-Hodgkin's lymphoma entered the study, of whom six completed the study, receiving each of three dosage schedules of metoclopramide during three consecutive courses of chemotherapy."	( Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting. Bateman, DN; Proctor, SJ; Taylor, WB, 1984)	0.73
" The usual dosage of metoclopramide was 10 mg four times a day, before meals and at bedtime."	( Evaluation of the safety of metoclopramide in patients with gastroesophageal reflux disease. Taylor, DM, 1984)	0.88
" Increases in dosage for patients with low levels and poor responses improved control in four of five patients."	( Optimizing metoclopramide control of cisplatin-induced emesis. Drayer, DE; Lewin, M; Lonski, L; Meyer, BR; Pasmantier, M; Reidenberg, MM, 1984)	0.66
" At each dose tested, metoclopramide produced a larger rightward shift of the apomorphine dose-response curve in the control rats than in withdrawn rats."	( Kinetic analysis of central nervous system supersensitivity induced in rats by long-term haloperidol administration. I. pA2 determination. Bernardi, MM; Palermo-Neto, J; Saban, R, 1984)	0.58
" Metoclopramide and haloperidol are both excellent antiemetics when given in sufficient dosage by an effective route."	( Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. Cariffe, P; Gala, KV; Grunberg, SM; Jamin, D; Johnson, K; Krailo, M; Lampenfeld, M; Strych, D, 1984)	1.42
" Metoclopramide and methylprednisolone, at the dosage and schedule used, were well tolerated and moderately active in preventing nausea and vomiting induced by cis-platin; their use in combination could further improve these results."	( Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. Bertetto, O; Calciati, A; Ciuffreda, L; Clerico, M; Donadio, M; Ferrati, P; Giaccone, G; Musella, R, 1984)	1.45
"Twenty-four patients receiving combination chemotherapy including cisplatin at a dosage of 50 mg/m2 were entered on this antiemetic randomized open cross-over study."	( Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination. Caporali, C; Carlini, P; Cognetti, F; Pinnaro, P; Pollera, CF; Ruggeri, EM, 1984)	0.52
" Using the oral MCP dosage regimen presented in this study, high and relatively constant MCP plasma concentrations without undesired peak levels could be achieved."	( [Metoclopramide plasma levels following oral administration of high doses for prophylaxis of emesis in cytostatic therapy]. Köhler, M; Senn, HJ; Vergin, H, 1984)	1.18
" Patients were allocated at random to receive 2 tablets 3-times daily of either treatment for 6 weeks and were then crossed over to the alternative treatment at the same dosage for a further 6 weeks."	( Paracetamol plus metoclopramide ('Paramax') as an adjunct analgesic in the treatment of arthritis. Boston, PF; Matts, SG, 1983)	0.61
" In an additional, open single-dose study the pharmacokinetics of metoclopramide were investigated after administration of a newly developed sustained-release dosage form."	( [Pharmacokinetics and bioequivalence of various oral formulations of metoclopramide]. Bishop-Freudling, GB; Reeves, DS; Strobel, K; Vergin, H, 1983)	0.74
" Fifty patients received metoclopramide with one or more of three intravenous metoclopramide dosage schedules, based on whether they received their chemotherapy on an inpatient or outpatient basis."	( Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. McDermed, JE; Pileggi, J; Riech, LP; Strum, SB; Whitaker, H, 1984)	0.95
" Eighteen patients received a total of 20 courses of therapy with dosage schedules ranging from 5 mg tid to 10 mg qid."	( Prescribing of oral metoclopramide for nonapproved indications. Schwinghammer, TL, 1984)	0.59
" Divided dosage and a clear fluid diet were both beneficial, whereas oral metoclopramide was ineffective."	( Oral mannitol as a preparation for double contrast barium enema. Foord, KD, 1982)	0.5
" The importance of adequate dosage of metoclopramide and the role of IV metoclopramide are emphasized."	( Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. Cox, R; Leyland, MJ; Newman, CE, 1982)	1.98
" Patients given aspirin with oral metoclopramide tended to obtain better early pain relief than the other two treatment groups, though by one hour from dosage use of injected metoclopramide was also associated with better pain relief."	( Aspirin treatment of migraine attacks: plasma drug level data. Eadie, MJ; Heazlewood, V; Ross-Lee, L; Tyrer, JH, 1982)	0.54
" In the current study, we administered metoclopramide to rhesus monkeys and normal subjects and compared the time-course and dose-response characteristics of plasma aldosterone."	( The effect of metoclopramide and dopamine on plasma aldosterone concentration in normal man and rhesus monkeys (Macaca mulatta): a new model to study dopamine control of aldosterone secretion. Billman, GE; Brown, RD; Hegstad, RL; Jiang, NS; Kao, P; Kem, DC; Stone, HL, 1982)	0.89
" The toxicity of high dose metoclopramide was of concern mainly in patients younger than 30, and/or when dosage escalation have been attempted."	( [High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients]. Albin, H; Bui, NB; Durand, M; Hoerni, B; Marit, G; Mauriac, L, 1982)	0.95
" Further research is necessary to define proper dosage recommendations and to determine those patients who will be successfully treated."	( Metoclopramide in the treatment of an infant with gastroesophageal hypomotility. Ponte, CD, 1982)	1.71
"The pharmacokinetics of 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide (metoclopramide, Paspertin) after a single dose of the drug in five different dosage forms: ampoules, tablets, drops, dragées and suppositories, were studied."	( The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. Block, W; Khan, M; Kjellerup, P; Pingoud, A, 1981)	0.71
"The pharmacokinetics of metoclopramide have been studied after intravenous and oral dosing (10 mg) to 6 patients with chronic renal failure."	( The pharmacokinetics of single doses of metoclopramide in renal failure. Bateman, DN; Blain, PG; Dodd, TR; Gokal, R, 1981)	0.84
" The insults of this pilot study suggest that pretreatment with metoclopramide enables patients with rheumatoid arthritis who have non-ulcer dyspepsia to tolerate full dosage of NSAIDs."	( Metoclopramide. Management of gastrointestinal intolerance in rheumatoid arthritis patients. Alp, MH; Awerbuch, MS; Milazzo, SC; Reiner, RG, 1981)	1.94
" The average daily dosage ranged from a minimum of 20 mg to a maximum of 80 mg given in divided doses."	( Metoclopramide treatment of tardive dyskinesia. Hersh, T; Karp, JM; McKinney, AS; Perkel, MS, )	1.57
" 3 After oral dosing of 10 mg the mean half-life was 196."	( The pharmacokinetics of metoclopramide in man with observations in the dog. Bateman, DN; Davies, DS; Kahn, C, 1980)	0.57
") resulted in a 10-fold parallel displacement, to the right, of the RVR dose-response curve to dopamine."	( Antagonism of the renal vasodilator activity of dopamine by metoclopramide. Hahn, RA; Wardell, JR, 1980)	0.5
"An intermittent intake of low-dose droperidol with morphine given via a PCA delivery system in two treatment groups gave evidence for a dose-response relation between the amount of droperidol added and the proportion of patients needing a rescue antiemetic."	( Antiemetic efficacy of a droperidol-morphine combination in patient-controlled analgesia. Bach, T; Jackson, D; McKenzie, R; Riley, T; Tantisira, B, 1995)	0.29
"2 mg/kg, IP, 4 h before test) dose-dependently shifted the peak in the amphetamine dose-response function to the right, indicating an attenuation of conditioned reward."	( Dopamine D1 and D2 antagonists attenuate amphetamine-produced enhancement of responding for conditioned reward in rats. Beninger, RJ; Ranaldi, R, 1993)	0.29
" Busulfan was quantitated in plasma samples at 10 time points within the 6 h dosing interval using HPLC before and after dose numbers 1, 2, 5, 13 and 14."	( Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Blanz, J; Ehninger, G; Kühnle, A; Kumbier, I; Mewes, K; Proksch, B; Schroer, S; Schuler, U; Zeller, KP, 1994)	0.29
" Although carotid arterial pressure did not change significantly after administration of fenoldopam at the dosage of 3 mg/kg, administration of fenoldopam at the dosages of 6 and 9 mg/kg significantly reduced carotid arterial pressure from 113 +/- 10 to 88 +/- 3 and 81 +/- 5 mm of Hg, respectively."	( Antagonism of a specific dopaminergic receptor agonist with metoclopramide in horses. Eades, SC; Moore, JN, 1993)	0.53
" The pharmacokinetics of didanosine were not altered appreciably by dosing with metoclopramide."	( Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. Barbhaiya, RH; Knupp, CA; Milbrath, RL, 1993)	0.92
" Thus, an efficient anti-emetic drug with less frequent dosing, using a simplified dosage regimen and producing a reduction in anticipatory nausea and vomiting and in nursing time, may result in an overall reduction in cost."	( Clinical studies to assess the economic impact of new therapies: pragmatic approaches to measuring costs. Kirchner, V, 1993)	0.29
"kg-1 x min-1) until the end-point was reached and construction of the dose-response curve based on bolus injections of predetermined doses of thiopental (with the use of probit analysis)."	( Metoclopramide decreases thiopental hypnotic requirements. Bradley, EL; Kissin, I; Mehta, D, 1993)	1.73
" The frail elderly subjects reported more sedation after intravenous dosage than the other subjects, whilst only young subjects reported akathisia."	( The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Bateman, DN; Boddy, A; Cope, LH; Woodhouse, KW; Wynne, HA; Yelland, C, 1993)	0.51
" Metoclopramide kinetics after intravenous dosing were in good agreement with known data for the active substance, with no meaningful differences between healthy subjects and cancer patients."	( Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients. Dimaiuta, M; Ferrari, P; Fraschini, F; Scaglione, F; Scanni, A; Tomirotti, M, 1993)	1.46
" In addition it offered a simple and convenient dosing regimen and a safer side-effect profile."	( The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. , 1993)	0.52
" After dosing with enantiomers or with the racemate, the resulting plasma concentration-time curve of R was closely parallel to that of S in both intravenous and oral experiments, suggesting that the two enantiomers have approximately the same disposition kinetics."	( Disposition kinetics of ML-1035 sulfoxide enantiomers and the prochiral sulfide in rats. Hwang, KK; Kuo, BS; Mandagere, AK; Poole, JC, 1993)	0.29
" Patients received an intravenous dose of 16 mg dexamethasone with either 8 mg ondansetron or 60 mg metoclopramide intravenously before chemotherapy followed by oral dosing with 8 mg ondansetron or 20 mg metoclopramide 3 times daily for 5 days."	( Ondansetron: a cost-effective advance in anti-emetic therapy. Cox, F; Hirsch, J, )	0.35
"Twenty-four infants, 1 to 18 months-old, who were referred to four centers for suspected gastroesophageal reflux and whose esophageal pH after a standard formula meal given at 9 to 10 am (Ho-day 1) fulfilled the criterion of being < 4 for more than 5% of the time between H1 and H6, entered a double-blind placebo-controlled dose-response trial of metoclopramide (M)."	( Dose-response study of metoclopramide in gastroesophageal reflux in infancy. Bellissant, E; Bouglé, D; d'Athis, P; Duhamel, JF; Gouyon, JB; Guillot, M; Moran, C; Pons, G; Rey, E; Richard, MO, 1993)	0.77
" To improve the control of chemotherapy-induced emesis, further investigations on the additional tropisetron dosing at 8 h after cisplatin infusion or the combination use of tropisetron and other antiemetics by a continuous 4 h period of observation and comparison are mandatory."	( Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996)	0.55
" It was concluded that bethanechol and, less likely, neostigmine at the dosage used in this study may be suitable for medical treatment of cecal dilatation in cattle in which hypomotility of the cecum and proximal loop of the ascending colon has to be reversed."	( Effect of bethanechol, neostigmine, metoclopramide, and propranolol on myoelectric activity of the ileocecocolic area in cows. Martig, J; Roussel, AJ; Steiner, A, 1995)	0.57
" The pretreatment with 50 and 100 mg/kg zingicomb attenuated the LiCl-produced CPA, whereas a dosage of 10 mg/kg had no effect."	( Blockade of lithium chloride-induced conditioned place aversion as a test for antiemetic agents: comparison of metoclopramide with combined extracts of Zingiber officinale and Ginkgo biloba. Frisch, C; Häcker, R; Hasenöhrl, RU; Huston, JP; Mattern, CM, 1995)	0.5
" The appropriate use of prokinetic agents in these groups requires an understanding of the unique dosage considerations that may be necessary to ensure safe, effective therapy."	( Use of prokinetic agents in special populations. Horn, JR, 1996)	0.29
" A significant negative correlation was found between Cmin plasma concentration and gestational age as well as with postconceptional age, suggesting that the lower the gestational and postconceptional age, the lower the metoclopramide dosage should be."	( Metoclopramide plasma concentration in neonates. Badoual, J; D'Athis, P; Olive, G; Pons, G; Rey, E; Vauzelle-Kervroedan, F, 1997)	1.92
"To establish a dose-response relationship for ondansetron, and to evaluate any effects of oral premedication with metoclopramide in pediatric patients undergoing tonsillectomy and adenoidectomy and strabismus surgery."	( Ondansetron dose response curve in high-risk pediatric patients. Kymer, PJ; Lawhorn, CD; Shirey, R; Stewart, FC; Stoner, JM; Volpe, P, 1997)	0.51
" Successful treatment requires adequate dosing plus choosing the optimal route for drug delivery."	( Management of an acute primary headache. Ward, TN, 1998)	0.3
" These findings have significant implications in the design of a metformin modified release dosage form."	( Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Barbhaiya, RH; Greene, DS; Marathe, PH; Norton, J; Wen, Y; Wilding, IR, 2000)	0.31
" Therefore, it is quite possible that both drugs produce adverse immunological effects in vivo in cases of high dosage or obstruction of elimination."	( [Effect of migraine medications on monocyte chemotaxis] . Krumholz, W; Menges, T; Ogal, H; Szalay, G, 2000)	0.31
" Further studies with higher concentrations of these dopamine antagonists on dose-response relationships are needed before exact drug efficacy can be drawn."	( Effects of dopamine antagonists in human eye accommodation. Chiou, GC; Hung, PT; Lin, LL; Yang, CH; Yeung, L, 2001)	0.31
"A rapid, sensitive and selective spectrophotometric method has been developed for the quantitative determination of metoclopramide hydrochloride (MCP) and dapsone (DAP) in both pure and dosage forms."	( A spectrophotometric method for the determination of metoclopramide HCl and dapsone. Manju, B; Revanasiddappa, HD, 2001)	0.77
"We conclude that at the dosage level studied ondansetron is about twice as effective as metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting."	( Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002)	0.82
"Acetyl acetone is introduced as a new coupling agent for the spectrophotometric determination of some chemotherapeutic agents, such as metoclopramide, dapsone, p-aminobenzoic acid, and cisapride in both pure and dosage forms."	( Spectrophotometric determination of some chemotherapeutic agents using acetyl acetone. Manju, B; Revanasiddappa, HD, 2002)	0.52
" Clinicians should attempt to treat patients with the lowest effective dosage of medication for the briefest therapeutic period to minimize the risks of adverse reactions."	( Metoclopramide-induced supersensitivity psychosis. Lu, ML; Pan, JJ; Shen, WW; Su, KP; Teng, HW, 2002)	1.76
"In animal health care, current therapeutic regimens for gastrointestinal disorders require repeated oral or parenteral dosage forms of anti-emetic agents."	( Controlled delivery of metoclopramide using an injectable semi-solid poly(ortho ester) for veterinary application. Boisramć, B; Gurny, R; Moreau, M; Schneider, M; Schwach-Abdellaoui, K, 2002)	0.63
"To evaluate whether a dose-response curve exists for erythromycin, determine the lowest effective dose of erythromycin needed to improve gastric motility, and compare erythromycin's effectiveness with that of metoclopramide in improving gastric emptying."	( Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects. Boivin, MA; Carey, MC; Levy, H, 2003)	0.51
"Erythromycin increased gastric emptying in a dose-response manner."	( Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects. Boivin, MA; Carey, MC; Levy, H, 2003)	0.32
" Additionally, a 1 ml bolus dosage was administered at a 60-minute lockout interval employing a pump which contained 36 mg of morphine hydrochloride, 30 mg of metoclopramide hydrochloride in 62 ml of physiologic saline."	( Utilization of PCIA (patient-controlled intravenous analgesia) for postoperative analgesia of spine fusion. Hasegawa, J; Hirasawa, M; Nishiyama, J; Suzuki, T, 2003)	0.52
" Her tacrolimus dosage was increased from 7 to 28 mg twice/day, and ketoconazole therapy was added; however, her tacrolimus concentration remained undetectable."	( Tacrolimus toxicity associated with concomitant metoclopramide therapy. Callahan, BL; Park, JM; Prescott, WA, 2004)	0.58
"Although prokinetics are commonly used for management of POI in horses there is clearly a need for more controlled studies to define efficacious dosing and a need to develop new prokinetic drugs."	( Survey of prokinetic use in horses with gastrointestinal injury. Harmon, FA; Nieto, JE; Snyder, JR; Van Hoogmoed, LM, )	0.13
"When compared at 2 and 24 hours, aggressive (20 mg dosed up to four times) IV metoclopramide and 6 mg of subcutaneous sumatriptan relieved migraine headache pain comparably."	( A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Bijur, PE; Corbo, J; Esses, D; Friedman, BW; Gallagher, EJ; Lipton, RB; Solorzano, C, 2005)	0.95
"A simple, reliable and selective square wave anodic stripping (SWAS) voltammetric method at carbon paste electrode (CPE) of metoclopramide hydrochloride (MCP) in pharmaceutical dosage forms (tablet) and in biological fluids (spiked and real urine samples) has been developed and evaluated."	( Square wave anodic stripping voltammetric determination of metoclopramide in tablet and urine at carbon paste electrode. El-Sayed, AY; Farghaly, OA; Naggar, AH; Taher, MA, 2005)	0.78
"A rapid, sensitive and selective spectrophotometric method has been developed for the quantitative determination of dapsone (DAP) and metoclopramide hydrochloride (MCP) in both pure and dosage forms."	( Individual and simultaneous spectrophotometric determination of dapsone and metoclopramide HCl in pharmaceutical dosage forms and synthetic binary mixtures. Omran, AA, 2005)	0.76
"There is a need for nasal drug delivery of metoclopramide HCI (MTC) in specific patient populations where the use of commercially available intravenous and oral dosage forms may be inconvenient and/or unfeasible."	( Nasal absorption of metoclopramide from different Carbopol 981 based formulations: In vitro, ex vivo and in vivo evaluation. Altunay, H; Ozkan, CK; Ozkan, Y; Savaser, A; Tas, C; Tasdemir, U, 2006)	0.92
" To achieve dry polymer application, a new, experimental dosage form named Eutex (made of Eudragit L100-55 and latex) capsule has been developed."	( Comparative in vivo mucoadhesion studies of thiomer formulations using magnetic resonance imaging and fluorescence detection. Albrecht, K; Bernkop-Schnürch, A; Debbage, P; Greindl, M; Kremser, C; Wolf, C, 2006)	0.33
" Factorial design was a powerful tool, allowing simultaneous determination of dose-response relationships for three drugs and identifying a previously unreported negative interaction between OND and MET."	( A factorial study of ondansetron, metoclopramide, and dexamethasone for emesis prophylaxis after adenotonsillectomy in children. Beckman, EC; Gunter, JB; McAuliffe, JJ; Spaeth, JP; Varughese, AM; Wittkugel, EP, 2006)	0.61
"Floating dosage forms enable the sustained delivery of drugs in the gastro-intestinal tract."	( Sustained release of hydrophobic and hydrophilic drugs from a floating dosage form. Boey, FY; Tang, YD; Venkatraman, SS; Wang, LW, 2007)	0.34
" The dosage of anesthetic medications administered was also recorded for each patient."	( Metoclopramide does not influence the frequency of propofol-induced spontaneous movements. Ahmed, SA; Herazo, L; Iyer, C; Joshi, GP; Lenkovsky, F; Markin, V; Robertson, BD; Ross, L, 2007)	1.78
"Literature data are reviewed relevant to the decision for a biowaiver of immediate release (IR) solid oral dosage forms containing metoclopramide hydrochloride."	( Biowaiver monographs for immediate release solid oral dosage forms: metoclopramide hydrochloride. Barends, DM; Dressman, JB; Junginger, HE; Kopp, S; Midha, KK; Shah, VP; Stavchansky, S; Stosik, AG, 2008)	0.79
" We investigated whether N(2)O results in a dose-response increase in PONV."	( The dose-response of nitrous oxide in postoperative nausea in patients undergoing gynecologic laparoscopic surgery: a preliminary study. Gan, TJ; Mraovic, B; Simurina, T; Skitarelic, N; Sonicki, Z, 2008)	0.35
" Blood was collected for the dosage of prolactin and serum estrogen and progesterone using radioimmune assay."	( Effects of metoclopramide-induced hyperprolactinemia on the prolactin receptor of murine endometrium. Baracat, EC; de Jesus Simões, M; Dos Santos Simões, R; Oliveira, PB; Rossi, AG; Soares, JM; Teixeira Gomes, RC, 2010)	0.75
" Serial blood samples were collected before dosing and during 24 h post-treatment."	( Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Fass, R; Pieniaszek, HJ; Thompson, JR, 2009)	0.6
" In this perspective, nasal dosage forms (solution, gel, and lyophilized powder) of MTC were prepared by using a mucoadhesive polymer sodium carboxymethylcellulose (NaCMC)."	( Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation. Altunay, H; Ozkan, CK; Ozkan, Y; Savaser, A; Tas, C; Tasdemir, U, 2009)	0.66
" Cases were selected for inclusion if the exposure was an unintentional therapeutic error and if 10-fold dosing error was coded as one of the therapeutic-error scenarios."	( Tenfold therapeutic dosing errors in young children reported to U.S. poison control centers. Caravati, EM; Crouch, BI; Moltz, E, 2009)	0.35
"A total of 3894 10-fold dosing errors involving a single substance in children younger than six years of age were reported over a five-year period."	( Tenfold therapeutic dosing errors in young children reported to U.S. poison control centers. Caravati, EM; Crouch, BI; Moltz, E, 2009)	0.35
" Prior treatment with each dosage of metoclopramide significantly reduced the frequency of emetic episodes (P<0."	( Effects of metoclopramide on emesis in cats sedated with xylazine hydrochloride. Jarolmasjed, S; Kolahian, S, 2010)	1.02
"We enrolled 202 chemotherapy naïve patients treated with cisplatin at a dosage of ≥50 mg/m(2) as monotherapy or as combined chemotherapy."	( Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Baak-Pablo, RF; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Mustofa, M; Nortier, JW; Perwitasari, DA; van der Straaten, RJ; Wessels, JA, 2011)	0.59
" Using a Delphi study method, physicians were asked to rank preferences of drug and dosing schedule for first-line opioid, antiemetic, and laxative for the treatment of adults with chronic pain due to cancer and other life-threatening conditions."	( Strategic pain management: the identification and development of the IAHPC opioid essential prescription package. Bennett, MI; Bruera, E; De Lima, L; Nekolaichuk, C; Ripamonti, CI; Vignaroli, E; Wenk, R, 2012)	0.38
"The objective of this study is to develop sensitive and cost effective reverse phase high performance liquid chromatographic method for the estimation of Metoclopramide Hydrochloride in oral solid dosage formulations."	( Validation and application of RP-HPLC method for the quantification of metoclopramide hydrochloride in oral formulations prepared for IVIVC studies. Hanif, M; Khan, A; Khan, J; Madni, A; Naqvi, SB; Shoaib, MH; Yousaf, RI, 2012)	0.81
" Higher plasma concentrations of levodopa during the first 2 h after dosing were followed by lower plasma concentrations during the third and fourth hours."	( Plasma dopa concentrations after different preparations of levodopa in normal subjects. Groves, MJ; Morris, JG; Parsons, RL; Trounce, JR, 1976)	0.26
" Therefore, the proposed method is suitable for the routine control of these ingredients in multicomponent dosage forms."	( Capillary electrophoretic determination of antimigraine formulations containing caffeine, ergotamine, paracetamol and domperidone or metoclopramide. Alshehri, MM; Alzoman, NZ; Elshahed, MS; Maher, HM; Olah, IV; Rizk, MS; Sultan, MA, 2013)	0.59
"Compounds were dosed in conscious rats and mice."	( Pharmacological comparison of peristaltic effects in rats and mice. Larson, KJ; Martin, RL; Polakowski, JS; Shaughnessy, TK, )	0.13
" Prior to the revision of the European Medicines Agency (EMA, formerly EMEA) guideline in 2010, the "dose" in this ratio was consistently defined by the US FDA, the EMA, and the WHO biowaiver guidelines as the highest dosage strength."	( The impact of the EMA change in definition of "dose" on the BCS dose-solubility ratio: a review of the biowaiver monographs. Dressman, J; Kubbinga, M; Langguth, P; Sediq, A, 2014)	0.4
" Serial blood samples were collected before dosing and during 24 h post-treatment."	( Effect of dimeticone and pepsin on the bioavailability of metoclopramide in healthy volunteers. Bezerra, FA; Camarão, GC; de Moraes, ME; de Moraes, MO; de Moraes, RA; do Nascimento, DF; Silva Leite, AL, 2014)	0.65
" The suggested methods were successfully applied for the simultaneous analysis of the studied drugs in their co-formulated tablets as well as in their single dosage forms."	( Derivative spectrophotometric and liquid chromatographic methods for the simultaneous determination of metoclopramide hydrochloride and aspirin in pharmaceuticals. Belal, FF; Elmansi, H; Sharaf El-Din, MK; Tolba, MM, )	0.35
" We have reviewed the evidence for safety, effectiveness and dosing of metoclopramide in critically ill patients."	( Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients? Heyland, DK; van der Meer, YG; van Zanten, AR; Venhuizen, WA, 2014)	0.93
" However, as for all antiemetics, the maximum dosage and potential side effects need to be paid attention to."	( [Antiemetic therapy in preclinical emergency medicine - a literature review]. Luxen, J; Prückner, S; Trentzsch, H; Urban, B, 2015)	0.42
" A three-period crossover trial was then carried out in beagle dogs with three different MCP dosage forms: nasal sprays, oral tablets and intramuscular (IM) solution."	( Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs. Fan, X; Li, W; Li, Y; Sun, J; Tang, D; Yang, P; Yin, X; Zhang, H; Zheng, A, 2018)	1.92
"The present study involved segmental testing of hair in two clinical cases with known dosage histories."	( Segmental Hair Analysis-Interpretation of the Time of Drug Intake in Two Patients Undergoing Drug Treatment. Johansen, SS; Linnet, K; Nielsen, MKK; Wang, X, 2019)	0.51
" Designing the preparation procedures and selecting the age-appropriate dosage form should be based on a benefit-risk approach, taking into account safety, efficacy, ease of use and accessibility to the patient."	( Modern pediatric formulations of the soft candies in the form of a jelly: determination of metoclopramide content and dissolution. Karaiskou, SG; Kouskoura, MG; Markopoulou, CK, 2020)	0.78
" A set of core outcomes to standardise infant weight and milk volume measurement is also needed, as well as a strong basis for the dose and dosage form used."	( Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants. Foong, SC; Foong, WC; Ho, JJ; Marasco, LA; Ong, JH; Tan, ML, 2020)	0.56
" Most recommendations for drug usage and dosage are based on collective clinical experience."	( Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats. Fletcher, JM; Gaschen, FP; Gaschen, L; Husnik, R, 2020)	0.82
"The QbD-based approach was found successful in developing controlled release osmotic tablets of metoclopramide HCl, for reducing the dosage frequency, better emetic control, and improve patient compliance."	( Quality by Design (QbD)-Based Numerical and Graphical Optimization Technique for the Development of Osmotic Pump Controlled-Release Metoclopramide HCl Tablets. Ahmed, K; Ansar, S; Farooqi, S; Husain, T; Shoaib, MH; Yousuf, RI, 2020)	0.98

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
antiemetic	A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
dopaminergic antagonist	A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
gastrointestinal drug	A drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
tertiary amino compound	A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
substituted aniline
benzamides
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	22.4586	0.0025	41.7960	15,848.9004	AID1347395; AID1347398
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	35.4813	0.0112	12.4002	100.0000	AID1030
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	6.0070	0.0002	14.3764	60.0339	AID720691
cytochrome P450 2D6	Homo sapiens (human)	Potency	15.4871	0.0010	8.3798	61.1304	AID1645840
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	5.3233	0.0355	20.9770	89.1251	AID504332
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	11.0792	0.0020	7.5337	39.8107	AID891
D(1A) dopamine receptor	Homo sapiens (human)	Potency	7.7917	0.0224	5.9449	22.3872	AID488982; AID488983
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	0.0355	0.0010	6.0009	35.4813	AID943
lamin isoform A-delta10	Homo sapiens (human)	Potency	17.7442	0.8913	12.0676	28.1838	AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	94.8000	0.2100	5.5537	10.0000	AID386625
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	2.3830	0.0001	1.0076	8.7800	AID625218
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	Ki	1.2480	0.0000	0.8871	10.0000	AID625218
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	134.0000	0.1100	7.1903	10.0000	AID1443980; AID1473738
Myeloperoxidase	Homo sapiens (human)	IC50 (µMol)	2.6750	0.0200	1.8811	7.6800	AID1446226; AID1446231
5-hydroxytryptamine receptor 2C	Rattus norvegicus (Norway rat)	IC50 (µMol)	13.2000	0.0004	0.6298	10.0000	AID4828
Alpha-2A adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	2.7210	0.0000	1.4421	7.3470	AID625201
Alpha-2A adrenergic receptor	Homo sapiens (human)	Ki	1.0200	0.0001	0.8074	10.0000	AID625201
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	0.8000	0.0000	2.0151	10.0000	AID625249
Cytochrome P450 2D6	Homo sapiens (human)	Ki	0.9600	0.0001	1.1986	8.0000	AID589097
D(2) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	0.1270	0.0000	0.7472	8.0000	AID625253
D(2) dopamine receptor	Homo sapiens (human)	Ki	0.0420	0.0000	0.6518	10.0000	AID625253
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	13.2000	0.0004	0.9086	10.0000	AID4828
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	20.3000	0.0002	1.8742	10.0000	AID3672; AID36877
D	Rattus norvegicus (Norway rat)	Ki	0.2291	0.0001	0.6100	10.0000	AID6285
D(3) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.2291	0.0001	0.2567	5.8000	AID6285
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.8000	0.0003	1.3833	8.4000	AID3672
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.7000	0.0003	1.0914	7.7625	AID36926
D(2) dopamine receptor	Bos taurus (cattle)	Ki	0.0800	0.0000	0.5836	6.1000	AID62332
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.7000	0.0003	1.0914	7.7625	AID36926
Acetylcholinesterase	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0000	0.9332	10.0000	AID31967
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.7000	0.0003	1.0691	7.7625	AID36926
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	20.3000	0.0002	1.2704	10.0000	AID3672; AID36877
5-hydroxytryptamine receptor 3A	Mus musculus (house mouse)	Ki	0.2000	0.0013	0.2378	1.4300	AID6006
D(1B) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.2291	0.0002	0.2462	2.0000	AID6285
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	IC50 (µMol)	3.6750	0.0001	0.8801	8.8500	AID625192
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Ki	1.0500	0.0000	0.3855	10.0000	AID625192
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	IC50 (µMol)	2.3830	0.0001	1.0302	9.0000	AID625218
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	1.2480	0.0001	0.9549	10.0000	AID625218
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.8000	0.0005	1.4835	7.8000	AID3672
5-hydroxytryptamine receptor 1D	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.8000	0.0031	1.7360	7.8000	AID3672
D(4) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.2291	0.0002	0.1887	2.0000	AID6285
5-hydroxytryptamine receptor 1F	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.8000	0.0050	1.7962	7.8000	AID3672
5-hydroxytryptamine receptor 2B	Rattus norvegicus (Norway rat)	IC50 (µMol)	13.2000	0.0004	0.6156	10.0000	AID4828
D(3) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	0.2000	0.0001	1.0178	8.7960	AID625254
D(3) dopamine receptor	Homo sapiens (human)	Ki	0.0475	0.0000	0.6020	10.0000	AID625254; AID65133
5-hydroxytryptamine receptor 3A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8800	0.0002	1.1351	4.6000	AID6059; AID6063
5-hydroxytryptamine receptor 3A	Rattus norvegicus (Norway rat)	Ki	0.4224	0.0002	0.4841	10.0000	AID5886; AID5898; AID5903; AID6133; AID6284; AID6285; AID6298
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	IC50 (µMol)	0.6300	0.0001	1.1873	8.9125	AID625217
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	Ki	0.4010	0.0003	0.7693	10.0000	AID625217
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	20.3000	0.0000	1.8194	10.0000	AID3672; AID36877
5-hydroxytryptamine receptor 7	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	94.8000	2.0300	5.5313	9.9000	AID386625
6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)	Ki	2,111.3000	0.0100	2.7450	8.3000	AID1802944
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.6237	0.0001	0.5494	8.4000	AID61539; AID64290; AID64457; AID64596
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.1820	0.0000	0.4375	10.0000	AID6285; AID65098; AID65260
Lactoperoxidase	Bos taurus (cattle)	IC50 (µMol)	5.0000	0.4000	2.4250	6.1000	AID1446235
5-hydroxytryptamine receptor 4	Rattus norvegicus (Norway rat)	Ki	0.0800	0.0016	1.0253	5.0119	AID62332
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
5-hydroxytryptamine receptor 3B	Mus musculus (house mouse)	Ki	0.2000	0.0013	0.2635	1.4300	AID6006
5-hydroxytryptamine receptor 3B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8800	0.0004	1.1742	4.6000	AID6059; AID6063
5-hydroxytryptamine receptor 3B	Rattus norvegicus (Norway rat)	Ki	0.4224	0.0002	0.5023	10.0000	AID5886; AID5898; AID5903; AID6133; AID6284; AID6285; AID6298
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 3E	Homo sapiens (human)	Kd	0.0501	0.0000	0.0284	0.1060	AID6028
5-hydroxytryptamine receptor 3B	Homo sapiens (human)	Kd	0.0501	0.0000	0.0137	0.1060	AID6028
Albumin	Rattus norvegicus (Norway rat)	Kd	1,370.0000	1.4700	6.5317	9.3100	AID1215123
5-hydroxytryptamine receptor 3A	Homo sapiens (human)	Kd	0.0501	0.0000	0.0098	0.1060	AID6028
5-hydroxytryptamine receptor 3D	Homo sapiens (human)	Kd	0.0501	0.0000	0.0284	0.1060	AID6028
5-hydroxytryptamine receptor 3C	Homo sapiens (human)	Kd	0.0501	0.0000	0.0284	0.1060	AID6028
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 4	Rattus norvegicus (Norway rat)	ED50	24.1000	0.0230	0.0388	0.0547	AID6230
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
hydrogen peroxide catabolic process	Myeloperoxidase	Homo sapiens (human)
response to yeast	Myeloperoxidase	Homo sapiens (human)
hypochlorous acid biosynthetic process	Myeloperoxidase	Homo sapiens (human)
respiratory burst involved in defense response	Myeloperoxidase	Homo sapiens (human)
defense response	Myeloperoxidase	Homo sapiens (human)
response to oxidative stress	Myeloperoxidase	Homo sapiens (human)
response to mechanical stimulus	Myeloperoxidase	Homo sapiens (human)
removal of superoxide radicals	Myeloperoxidase	Homo sapiens (human)
response to food	Myeloperoxidase	Homo sapiens (human)
response to lipopolysaccharide	Myeloperoxidase	Homo sapiens (human)
low-density lipoprotein particle remodeling	Myeloperoxidase	Homo sapiens (human)
hydrogen peroxide catabolic process	Myeloperoxidase	Homo sapiens (human)
negative regulation of apoptotic process	Myeloperoxidase	Homo sapiens (human)
defense response to fungus	Myeloperoxidase	Homo sapiens (human)
response to gold nanoparticle	Myeloperoxidase	Homo sapiens (human)
defense response to bacterium	Myeloperoxidase	Homo sapiens (human)
positive regulation of cytokine production	Alpha-2A adrenergic receptor	Homo sapiens (human)
DNA replication	Alpha-2A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
Ras protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
Rho protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2A adrenergic receptor	Homo sapiens (human)
actin cytoskeleton organization	Alpha-2A adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell migration	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
cellular response to hormone stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2A adrenergic receptor	Homo sapiens (human)
vasodilation	Alpha-2A adrenergic receptor	Homo sapiens (human)
glucose homeostasis	Alpha-2A adrenergic receptor	Homo sapiens (human)
fear response	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of potassium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
intestinal absorption	Alpha-2A adrenergic receptor	Homo sapiens (human)
thermoception	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of lipid catabolic process	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of uterine smooth muscle contraction	Alpha-2A adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of wound healing	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transmembrane transporter activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
temperature homeostasis	D(2) dopamine receptor	Homo sapiens (human)
response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein phosphorylation	D(2) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(2) dopamine receptor	Homo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressure	D(2) dopamine receptor	Homo sapiens (human)
regulation of heart rate	D(2) dopamine receptor	Homo sapiens (human)
regulation of sodium ion transport	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
autophagy	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
neuron-neuron synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
axonogenesis	D(2) dopamine receptor	Homo sapiens (human)
synapse assembly	D(2) dopamine receptor	Homo sapiens (human)
sensory perception of smell	D(2) dopamine receptor	Homo sapiens (human)
long-term memory	D(2) dopamine receptor	Homo sapiens (human)
grooming behavior	D(2) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(2) dopamine receptor	Homo sapiens (human)
protein localization	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell population proliferation	D(2) dopamine receptor	Homo sapiens (human)
associative learning	D(2) dopamine receptor	Homo sapiens (human)
visual learning	D(2) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to light stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to toxic substance	D(2) dopamine receptor	Homo sapiens (human)
response to iron ion	D(2) dopamine receptor	Homo sapiens (human)
response to inactivity	D(2) dopamine receptor	Homo sapiens (human)
Wnt signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
striatum development	D(2) dopamine receptor	Homo sapiens (human)
orbitofrontal cortex development	D(2) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(2) dopamine receptor	Homo sapiens (human)
adenohypophysis development	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell migration	D(2) dopamine receptor	Homo sapiens (human)
peristalsis	D(2) dopamine receptor	Homo sapiens (human)
auditory behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(2) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
response to histamine	D(2) dopamine receptor	Homo sapiens (human)
response to nicotine	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of urine volume	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of renal sodium excretion	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of multicellular organism growth	D(2) dopamine receptor	Homo sapiens (human)
response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleep	D(2) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(2) dopamine receptor	Homo sapiens (human)
drinking behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(2) dopamine receptor	Homo sapiens (human)
response to morphine	D(2) dopamine receptor	Homo sapiens (human)
pigmentation	D(2) dopamine receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of innate immune response	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of insulin secretion	D(2) dopamine receptor	Homo sapiens (human)
acid secretion	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(2) dopamine receptor	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	D(2) dopamine receptor	Homo sapiens (human)
response to axon injury	D(2) dopamine receptor	Homo sapiens (human)
branching morphogenesis of a nerve	D(2) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(2) dopamine receptor	Homo sapiens (human)
epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(2) dopamine receptor	Homo sapiens (human)
release of sequestered calcium ion into cytosol	D(2) dopamine receptor	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of synapse structural plasticity	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(2) dopamine receptor	Homo sapiens (human)
excitatory postsynaptic potential	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of growth hormone secretion	D(2) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	D(2) dopamine receptor	Homo sapiens (human)
regulation of locomotion involved in locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cellular response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor production	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	D(2) dopamine receptor	Homo sapiens (human)
hyaloid vascular plexus regression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of neuron migration	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(2) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(2) dopamine receptor	Bos taurus (cattle)
negative regulation of prolactin secretion	D(2) dopamine receptor	Bos taurus (cattle)
negative regulation of lactation	D(2) dopamine receptor	Bos taurus (cattle)
positive regulation of mammary gland involution	D(2) dopamine receptor	Bos taurus (cattle)
hyaloid vascular plexus regression	D(2) dopamine receptor	Bos taurus (cattle)
acetylcholine catabolic process in synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
regulation of receptor recycling	Acetylcholinesterase	Homo sapiens (human)
osteoblast development	Acetylcholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Acetylcholinesterase	Homo sapiens (human)
cell adhesion	Acetylcholinesterase	Homo sapiens (human)
nervous system development	Acetylcholinesterase	Homo sapiens (human)
synapse assembly	Acetylcholinesterase	Homo sapiens (human)
receptor internalization	Acetylcholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission, cholinergic	Acetylcholinesterase	Homo sapiens (human)
amyloid precursor protein metabolic process	Acetylcholinesterase	Homo sapiens (human)
positive regulation of protein secretion	Acetylcholinesterase	Homo sapiens (human)
retina development in camera-type eye	Acetylcholinesterase	Homo sapiens (human)
acetylcholine receptor signaling pathway	Acetylcholinesterase	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Acetylcholinesterase	Homo sapiens (human)
temperature homeostasis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cytokine production involved in immune response	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glycolytic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
activation of phospholipase C activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
memory	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
response to xenobiotic stimulus	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
regulation of dopamine secretion	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
artery smooth muscle contraction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
urinary bladder smooth muscle contraction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of heat generation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
negative regulation of potassium ion transport	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of neuron apoptotic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein localization to cytoskeleton	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of glycolytic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of vasoconstriction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
symbiont entry into host cell	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
sensitization	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
behavioral response to cocaine	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of inflammatory response	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of execution phase of apoptosis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of platelet aggregation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of DNA biosynthetic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
locomotory behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
feeding behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of nervous system process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of appetite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of corticotropin-releasing hormone secretion	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of calcium-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
response to ethanol	D(3) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(3) dopamine receptor	Homo sapiens (human)
intracellular calcium ion homeostasis	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
learning or memory	D(3) dopamine receptor	Homo sapiens (human)
learning	D(3) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(3) dopamine receptor	Homo sapiens (human)
visual learning	D(3) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(3) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(3) dopamine receptor	Homo sapiens (human)
response to histamine	D(3) dopamine receptor	Homo sapiens (human)
social behavior	D(3) dopamine receptor	Homo sapiens (human)
response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(3) dopamine receptor	Homo sapiens (human)
response to morphine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of mitotic nuclear division	D(3) dopamine receptor	Homo sapiens (human)
acid secretion	D(3) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of oligodendrocyte differentiation	D(3) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(3) dopamine receptor	Homo sapiens (human)
musculoskeletal movement, spinal reflex action	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(3) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(3) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(3) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(3) dopamine receptor	Homo sapiens (human)
neural crest cell migration	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cytokine production	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of endothelial cell proliferation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor internalization	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
heart morphogenesis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cardiac muscle hypertrophy	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
activation of phospholipase C activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
response to xenobiotic stimulus	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neural crest cell differentiation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
intestine smooth muscle contraction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phosphorylation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
calcium-mediated signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
negative regulation of apoptotic process	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of MAP kinase activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
embryonic morphogenesis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cell division	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein kinase C signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cellular response to temperature stimulus	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
pentose-phosphate shunt	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
pentose-phosphate shunt, oxidative branch	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
pentose biosynthetic process	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
D-gluconate catabolic process	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
response to oxidative stress	Lactoperoxidase	Bos taurus (cattle)
thiocyanate metabolic process	Lactoperoxidase	Bos taurus (cattle)
antibacterial humoral response	Lactoperoxidase	Bos taurus (cattle)
hydrogen peroxide catabolic process	Lactoperoxidase	Bos taurus (cattle)
cellular oxidant detoxification	Lactoperoxidase	Bos taurus (cattle)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
chromatin binding	Myeloperoxidase	Homo sapiens (human)
peroxidase activity	Myeloperoxidase	Homo sapiens (human)
protein binding	Myeloperoxidase	Homo sapiens (human)
heparin binding	Myeloperoxidase	Homo sapiens (human)
heme binding	Myeloperoxidase	Homo sapiens (human)
metal ion binding	Myeloperoxidase	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein kinase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-1B adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-2C adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
thioesterase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
heterotrimeric G-protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(2) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(2) dopamine receptor	Homo sapiens (human)
protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(2) dopamine receptor	Homo sapiens (human)
dopamine binding	D(2) dopamine receptor	Homo sapiens (human)
ionotropic glutamate receptor binding	D(2) dopamine receptor	Homo sapiens (human)
identical protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterocyclic compound binding	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(2) dopamine receptor	Homo sapiens (human)
amyloid-beta binding	Acetylcholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
cholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
protein binding	Acetylcholinesterase	Homo sapiens (human)
collagen binding	Acetylcholinesterase	Homo sapiens (human)
hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
serine hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
acetylcholine binding	Acetylcholinesterase	Homo sapiens (human)
protein homodimerization activity	Acetylcholinesterase	Homo sapiens (human)
laminin binding	Acetylcholinesterase	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
virus receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein tyrosine kinase activator activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein-containing complex binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(3) dopamine receptor	Homo sapiens (human)
protein binding	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(3) dopamine receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G-protein alpha-subunit binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
GTPase activator activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
phosphogluconate dehydrogenase (decarboxylating) activity	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
NADP binding	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
peroxidase activity	Lactoperoxidase	Bos taurus (cattle)
calcium ion binding	Lactoperoxidase	Bos taurus (cattle)
heme binding	Lactoperoxidase	Bos taurus (cattle)
thiocyanate peroxidase activity	Lactoperoxidase	Bos taurus (cattle)
lactoperoxidase activity	Lactoperoxidase	Bos taurus (cattle)
protein binding	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
cell surface	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Myeloperoxidase	Homo sapiens (human)
extracellular space	Myeloperoxidase	Homo sapiens (human)
nucleus	Myeloperoxidase	Homo sapiens (human)
nucleoplasm	Myeloperoxidase	Homo sapiens (human)
lysosome	Myeloperoxidase	Homo sapiens (human)
secretory granule	Myeloperoxidase	Homo sapiens (human)
azurophil granule lumen	Myeloperoxidase	Homo sapiens (human)
azurophil granule	Myeloperoxidase	Homo sapiens (human)
intracellular membrane-bounded organelle	Myeloperoxidase	Homo sapiens (human)
extracellular exosome	Myeloperoxidase	Homo sapiens (human)
phagocytic vesicle lumen	Myeloperoxidase	Homo sapiens (human)
extracellular space	Myeloperoxidase	Homo sapiens (human)
cytoplasm	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
basolateral plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
neuronal cell body	Alpha-2A adrenergic receptor	Homo sapiens (human)
axon terminus	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic active zone membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopaminergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
postsynaptic density membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
glutamatergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
GABA-ergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor complex	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Homo sapiens (human)
acrosomal vesicle	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cilium	D(2) dopamine receptor	Homo sapiens (human)
lateral plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
endocytic vesicle	D(2) dopamine receptor	Homo sapiens (human)
axon	D(2) dopamine receptor	Homo sapiens (human)
dendrite	D(2) dopamine receptor	Homo sapiens (human)
synaptic vesicle membrane	D(2) dopamine receptor	Homo sapiens (human)
sperm flagellum	D(2) dopamine receptor	Homo sapiens (human)
dendritic spine	D(2) dopamine receptor	Homo sapiens (human)
perikaryon	D(2) dopamine receptor	Homo sapiens (human)
axon terminus	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(2) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(2) dopamine receptor	Homo sapiens (human)
dopaminergic synapse	D(2) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(2) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(2) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Bos taurus (cattle)
extracellular region	Acetylcholinesterase	Homo sapiens (human)
basement membrane	Acetylcholinesterase	Homo sapiens (human)
extracellular space	Acetylcholinesterase	Homo sapiens (human)
nucleus	Acetylcholinesterase	Homo sapiens (human)
Golgi apparatus	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Acetylcholinesterase	Homo sapiens (human)
cell surface	Acetylcholinesterase	Homo sapiens (human)
membrane	Acetylcholinesterase	Homo sapiens (human)
neuromuscular junction	Acetylcholinesterase	Homo sapiens (human)
synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Homo sapiens (human)
perinuclear region of cytoplasm	Acetylcholinesterase	Homo sapiens (human)
side of membrane	Acetylcholinesterase	Homo sapiens (human)
neurofilament	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
caveola	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
axon	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cytoplasmic vesicle	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neuronal cell body	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendritic shaft	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cell body fiber	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glutamatergic synapse	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
synapse	D(3) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
nucleoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
cleavage furrow	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
nucleus	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
cytosol	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
extracellular exosome	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
cytosol	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
extracellular space	Lactoperoxidase	Bos taurus (cattle)
cytoplasm	Lactoperoxidase	Bos taurus (cattle)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID395326	Fraction unbound in rat brain	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID29337	Ionisation constant (pKa)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1209385	AUC(0 to infinity) in Sprague-Dawley rat plasma at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID5903	Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1220558	Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1209417	AUC(0 to infinity) in Sprague-Dawley rat brain at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID63299	Compound was tested for anti-apomorphine effect in 3 dogs and the vomiting frequency expressed at a dose of 1.0 mg/kg perorally.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID1446236	Inhibition of MPO (unknown origin) assessed as apparent bi-molecular rate constant for PorFe(4)=O radical reduction by stopped-flow spectroscopic analysis	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29423	HPLC capacity factor (k')	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID62332	Compound was evaluated for the binding affinity at Dopamine receptor D2	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID1215126	Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID60832	Percent change from control in the functional refractory period (FRP) at 10 uM conc. on Canine ventricular muscle fibre.	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID179527	Evaluated for the effects on the gastric emptying rates of resin pellets solid meal through the stomach in rats, at a dose of 5.0 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID29813	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID781329	pKa (acid-base dissociation constant) as determined by other workers	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1209333	Ratio of drug level in brain to plasma in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID176969	In vivo antagonism activity against D2 receptor was measured as stereotypy in rat when administered subcutaneously	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID6172	Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID72071	In vivo antagonism of cisplatin-induced emesis in ferret measured as emetic episodes, twice the dose of 0.2 mg/kg in 4 ferrets	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID781330	pKa (acid-base dissociation constant) as determined by potentiometric titration	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID6011	Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID65133	Displacement of [125I]iodosulpiride from human Dopamine receptor D3 expressed in CHO cells	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach.
AID72058	Antiemetic activity (oral administration) against cisplatin-induced emesis in ferret, as the dose required to reduce emetic episodes to 50% of control value	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID64274	Concentration of compound required to inhibit the binding of radioligand [3H]spiperone to Dopamine receptor D2 in rat brain synaptic membrane	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID1220559	Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID60163	Tested in vivo for effective dose required for suppression of apomorphine-induced emesis in dog at oral dose of 1.0 mg/kg	1998	Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15	A novel series of 6-methoxy-1H-benzotriazole-5-carboxamide derivatives with dual antiemetic and gastroprokinetic activities.
AID1446228	Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in absence of H2O2 incubated for 5 mins followed by 100 fold enzyme dilution relative to control	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID72053	Antiemetic potency against cisplatin-induced emetic latency period in ferret after intravenous administration	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1446256	Selectivity ratio of IC50 for bovine milk LPO to IC50 for recombinant MPO (unknown origin)	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID65260	Compound was evaluated for binding affinity towards DA D-2 receptor using radioligand [3H]SPI	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	Conformational analysis of dopamine D-2 receptor antagonists of the benzamide series in relation to a recently proposed D-2 receptor-interaction model.
AID56089	Percent change from control in conduction time (CT) at 10 uM concentration tested on Canine ventricular muscle fibre.; M is minimal(<10% change in CT)	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID35976	Binding affinity was evaluated by Alpha-1 adrenergic receptor in calf cortex by displacing prazosin	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID1764400	Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID64290	In vitro antagonistic activity against Dopamine receptor D2 was evaluated for the inhibition of [3H]spiperone binding	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID6028	Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID1446262	Plasma concentration in po dosed human	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID61325	Binding affinity against dopamine D2 receptor in rat brain synaptic membrane using [3H]-spiperone as radioligand	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID72391	In vivo antagonism of cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 0.2 mg/kg in 4 ferrets	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID232561	Ratio of ED50 for inhibition of catalepsy induction to stereotypy induction	1981	Journal of medicinal chemistry, Oct, Volume: 24, Issue:10	Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
AID1209379	AUC(0 to 7 hrs) in Sprague-Dawley rat plasma at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID589097	Mechanism based inhibition of human cytochrome P450 2D6 measured by dextromethorphan O-demethylation	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID395324	Lipophilicity, log D at pH 7.4 by liquid chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID71931	Antiemetic activity (intravenous administration) against cisplatin-induced emesis in ferret, as the dose required to increase latency to first emetic bout by 100%	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID1215122	Percentage unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID117617	Motility of the Compound was tested against number of interrupted beams in 1 hour in naive mice by 10 determinations	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID63298	Compound was tested for anti-apomorphine effect in 3 dogs and the vomiting frequency expressed at a dose of 0.5 mg/kg perorally.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID72393	In vivo antagonism of cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 0.8 mg/kg in 5 ferrets	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60517	In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 0.2 mg/kg in 4 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID6142	5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors.
AID228899	Effective dose of the compound	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	Conformational analysis of dopamine D-2 receptor antagonists of the benzamide series in relation to a recently proposed D-2 receptor-interaction model.
AID1774079	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID131809	Evaluated for the effects on the gastric emptying rates of phenol red semisolid meal through the stomach in mouse, at a dose of 5 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID131804	Evaluated for the effects on the gastric emptying rates of phenol red semisolid meal through the stomach in mouse, at a dose of 1 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID5898	Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID180438	Compound was evaluated for the homovanillic acid levels of rats limbic system by 8 determinations	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID63300	Compound was tested for anti-apomorphine effect in 3 dogs and the vomiting frequency expressed at a dose of 2.0 mg/kg perorally.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID180915	The inhibitory effect on the continuous avoidance was expressed as the dose to increase the number of electroshocks by 60% of the rats	1981	Journal of medicinal chemistry, Oct, Volume: 24, Issue:10	Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID72056	Antiemetic activity (intravenous administration) against cisplatin-induced emesis in ferret, as the dose required to reduce emetic episodes to 50% of control value	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID1220560	Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID60749	Protection against cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 0.2 mg/kg	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID56858	Maximum percent change in repolarization at 100 uM concentration on Canine Purkinje fibers.	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID1764401	Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1446257	Permeability of the compound in human Caco2 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID6174	Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID1446233	Reversible inhibition of recombinant MPO (unknown origin) assessed as reduction in guaiacol peroxidation by measuring enzyme activity recovery at 5 uM incubated for 20 mins followed by 200 fold dilution measured for 10 mins	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID57689	Antiemetic activity was evaluated in vivo by the suppression of apomorphine-induced emesis in dogs at oral dose of 1.0 mg/kg	1998	Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15	A novel series of 6-methoxy-1H-benzotriazole-5-carboxamide derivatives with dual antiemetic and gastroprokinetic activities.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID131806	Evaluated for the effects on the gastric emptying rates of phenol red semisolid meal through the stomach in mouse, at a dose of 2 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID22791	Percent change from control in the rate of rise of phase 0 of the action potential at 10 uM concentration on Canine Purkinje fibers.	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1764399	Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID1446261	Acute toxicity in rat	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID72059	Antiemetic potency against cisplatin-induced emetic episodes in ferret after intravenous administration	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
AID222109	In vitro gastrointestinal motility enhancing activity was determined by potentiating action on electrically evoked contraction of the isolated guinea pig ileum	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis of 2-imidazolidinylidenepropanedinitrile derivatives as stimulators of gastrointestinal motility.
AID1774078	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID28235	Unbound fraction (plasma)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID6133	Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID179518	Evaluated for the effects on the gastric emptying rates of phenol red semisolid meal through the stomach in rats, at a dose of 2.0 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID180433	Compound was evaluated for the homovanillic acid levels of rats corpus striata by 7 determinations	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID5891	Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1764398	Substrate activity at P-gp (unknown origin) assessed as net efflux ratio	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID3672	Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID171714	Tested for antigenic challenge time, time measured was immediate when compound was administered before challenge in rat; immediate	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID176973	In vivo antagonistic activity against dopamine D2 receptor was measured as catalepsy in rat when administered subcutaneously	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID6156	5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors.
AID72397	In vivo antagonism of cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 2.5 mg/kg in 5 ferrets	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID1209409	AUC(0 to 7 hrs) in Sprague-Dawley rat brain at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID60520	In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 0.8 mg/kg in 3 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID1446226	Inhibition of recombinant MPO (unknown origin) assessed as reduction in taurine chloramine production preincubated with enzyme and taurine followed by H2O2 addition measured after 5 mins	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID59813	Effective dose required to inhibit 50% of apomorphine effect(95% confidence limits)	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID179515	Evaluated for the effects on the gastric emptying rates of phenol red semisolid meal through the stomach in rats, at a dose of 10.0 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1446252	Cytotoxicity against NHDF assessed as reduction in cell viability after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1774075	Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID72057	Antiemetic activity (oral administration) against cisplatin-induced emesis in ferret, as the dose required to increase latency to first emetic bout by 50%	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1215120	Binding affinity to Wistar rat brain lipid by TRANSIL assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID386625	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID60608	In vivo antagonism of cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 2.5 mg/kg in 4 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID72396	In vivo antagonism of cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 2.5 mg/kg in 5 ferrets	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID1215123	Binding affinity to Wistar rat serum albumin	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID36877	Inhibitory activity against Alpha-1 adrenergic receptor by 3H ligand binding experiments.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID117620	Motility of the Compound was tested against number of interrupted beams in 1 hr in reserpine & apomorphine treated mice by 12 determinations	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID60750	Protection against cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 0.8 mg/kg and in 3 dogs(1 protected)	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID1446260	Substrate activity at CYP2C9 (unknown origin)	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID6298	pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID22618	Maximum Percent change from control in the rate of rise of phase 0 of the action potential at 10 uM concentration on Canine Purkinje fibers.	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID72076	In vivo antagonism of cisplatin-induced emesis in ferret measured as emetic episodes, twice the dose of 2.5 mg/kg in 5 ferrets	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID395327	Dissociation constant, pKa by capillary electrophoresis	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1220556	Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID59667	Effective dose for inhibition of apomorphine (0.3 mg/kg) induced emesis in dogs when 1 mg/kg of compound administered perorally	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID1774076	Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1446235	Inhibition of bovine milk LPO assessed as reduction in NaOSCN production in presence of H2O2/NaSCN after 5 mins	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID75808	Concentration of compound which gives a 20% decrease in contractile force was tested on papillary muscle of guinea pig, activity was expressed as EC-20.	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID220680	Tested against rhythmic contractile activity in a Heidenhain pouch dog preparation	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants.
AID1209393	AUC(0 to 7 hrs) in Sprague-Dawley rat cerebrospinal fluid at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1209357	Ratio of unbound drug level in brain to plasma in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1446234	Reversible inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation at 5 uM in presence of NaCl and tyrosine incubated for 5 mins followed by H2O2 addition measured after 10 mins by spectrophotometric method	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID28236	Unbound fraction (tissues)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1220554	Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID28233	Fraction ionized (pH 7.4)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID176195	Effective dose to induce catalepsy in 50% of the rats	1981	Journal of medicinal chemistry, Oct, Volume: 24, Issue:10	Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID60751	Protection against cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 2.5 mg/kg and in 4 dogs(2 protected)	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60873	Percent inhibition of apomorphine (0.3 mg/kg) induced emesis in dogs when 1 mg/kg of compound administered perorally	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID467611	Dissociation constant, pKa of the compound	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID6284	Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID65098	Binding affinity to dopamine receptor D2	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype.
AID63468	Evaluated for the dopamine D2 receptor antagonistic activity (antagonism of apomorphine-induced emesis in dogs) at a dose of 3.0 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID59840	In vitro cisplatin-induced emesis in dog was measured for as stereotypy when administered iv twice daily	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID63200	Binding affinity was evaluated by Dopamine receptor D1 agonism in the calf striatum by displacing SCH 23390	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID3163	Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants.
AID64596	Inhibitory concentration required for displacing radioligand [3H]SPI from DA D-2 receptor	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	Conformational analysis of dopamine D-2 receptor antagonists of the benzamide series in relation to a recently proposed D-2 receptor-interaction model.
AID72073	In vivo antagonism of cisplatin-induced emesis in ferret measured as emetic episodes, twice the dose of 0.8 mg/kg in 5 ferrets	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1446258	Substrate activity at CYP2D6 (unknown origin)	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1215121	Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID64938	Affinity towards Dopamine receptor D2 in rat striatum using [3H]spiperone as radioligand	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID72054	Antiemetic potency was tested against cisplatin-induced emetic latency period in ferret after oral administration	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID72060	Antiemetic potency was tested against cisplatin-induced emetic episodes in ferret after oral administration	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID6239	Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors.
AID61539	Inhibition of [3H]- spiperone binding to rat brain Dopamine receptor D2	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis of N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)nicotinamides and their affinities for 5-HT3 and dopamine D2 receptors.
AID60516	In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 0.2 mg/kg in 4 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID60524	In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 2.5 mg/kg in 4 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID176655	Subcutaneous dose to inhibit apomorphine-induced stereotyped behavior in 50% of rats	1981	Journal of medicinal chemistry, Oct, Volume: 24, Issue:10	Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
AID6164	Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID179522	Evaluated for the effects on the gastric emptying rates of resin pellets solid meal through the stomach in rats, at a dose of 10 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID5886	Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.	1992	Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5	Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID60525	In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 2.5 mg/kg in 4 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID6230	Relaxation of carbachol induced contractions of rat tunica muscularis mucosae	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype.
AID186430	PCA activity of compound in rat at 100 mg/kg dose	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID395325	Lipophilicity, log P by microemulsion electrokinetic chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1764402	Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1215124	Binding affinity to Wistar rat brain lipid assessed as percentage unbound by TRANSIL assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1220555	Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1209401	AUC(0 to infinity) in Sprague-Dawley rat cerebrospinal fluid at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID132421	Evaluated for the antagonism of apomorphine-induced climbing behavior in mice (sc)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Substituted benzamides with conformationally restricted side chains. 2. Indolizidine derivatives as central dopamine receptor antagonists.
AID1220557	Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID59841	In vivo antagonism activity against dopamine D2 receptor was measured as emesis in dog when administered subcutaneously	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID1446237	Inhibition of MPO (unknown origin) assessed as apparent bi-molecular rate constant for PorFe(4)-OH reduction by stopped-flow spectroscopic analysis	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID184445	Evaluated for lowest active dose (LAD) for (gastric prokinetic activity) stimulation of intragastric pressure (IGP) in rats (sc)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Substituted benzamides with conformationally restricted side chains. 2. Indolizidine derivatives as central dopamine receptor antagonists.
AID1446229	Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in presence of H2O2 incubated for 5 mins followed by 100 fold enzyme dilution relative to control	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1446231	Inhibition of recombinant MPO (unknown origin) assessed as reduction in LDL oxidation in presence of H2O2 and HCl after 5 mins by ELISA	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID72062	In vitro antagonism of cisplatin-induced emesis in ferret measured as stereotypy when administered intravenously twice daily	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID60602	In vivo antagonism of cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 0.2 mg/kg in 4 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID63297	Compound was tested for anti-apomorphine effect in 3 dogs and the vomiting frequency expressed at a dose of 0.2 mg/kg perorally.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID3165	Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants.
AID65470	Concentration of compound required to inhibit the binding of radioligand [3H](R)-7-OH-DPAT to Dopamine receptor D3 in rat striatum	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID6006	Compound was evaluated for the binding affinity at 5- HT3 receptor subtype	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID179530	Gastric emptying of phenol red semisolid meal in rats at dose of 2.0 mg/kg, administered perorally.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1209349	Ratio of unbound brain concentration to drug level in cerebrospinal fluid in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID6285	Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID1446230	Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in presence of H2O2 and NaCl incubated for 5 mins followed by 100 fold enzyme dilution relative to control	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1446240	Reversible inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring recovery of enzyme activity at 0.05 to 20 uM preincubated for 15 mins followed 100 fold dilution with buffer containing H2O2 and TMB	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1129361	Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID5612	Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID6184	5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID29925	Volume of distribution in man (IV dose)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID186429	Tested for PCA activity of compound in rat at 10 mg/kg intravenous dose	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID176822	Tested for anti-apomorphine climbing activity in rat on sc administration	1985	Journal of medicinal chemistry, Dec, Volume: 28, Issue:12	Substituted benzamides with conformationally restricted side chains. 1. Quinolizidine derivatives as selective gastric prokinetic agents.
AID62628	Binding affinity was evaluated by Dopamine receptor D2 agonism in the calf striatum by displacing spiperone	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID179820	Tested for stimulation of intragastric pressure in rat on sc administration	1985	Journal of medicinal chemistry, Dec, Volume: 28, Issue:12	Substituted benzamides with conformationally restricted side chains. 1. Quinolizidine derivatives as selective gastric prokinetic agents.
AID3982	Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID60823	Maximum percent change in functional refractory period (FRP) at 100 uM on Canine ventricular muscle fibre.	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID179546	Compound was tested for its effect on the gastric emptying rate of phenol red semisolid meal through the stomach at oral dose of 3.0 mg/kg in rats.	1998	Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15	A novel series of 6-methoxy-1H-benzotriazole-5-carboxamide derivatives with dual antiemetic and gastroprokinetic activities.
AID56083	Maximum percent change in conduction time (CT) at 100 uM concentration tested on Canine ventricular muscle fibre	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID60605	In vivo antagonism of cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 0.8 mg/kg in 3 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID298031	Lipophilicity, log D at pH7.4	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID3166	Stimulatory activity of intragastric pressure was tested in the rat	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants.
AID31967	Inhibition of guinea pig acetylcholinesterase	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis of 2-imidazolidinylidenepropanedinitrile derivatives as stimulators of gastrointestinal motility.
AID60521	In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 0.8 mg/kg in 3 dogs	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID179520	Evaluated for the effects on the gastric emptying rates of phenol red semisolid meal through the stomach in rats, at a dose of 5.0 mg/kg administered perorally	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides.
AID56985	Percent change in repolarization at 10 Purkinje fibers.	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Heterocyclic analogues of benzamide antiarrhythmic agents.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID4828	Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID298032	Acid dissociation constant, pKa of the compound	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID6059	Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis of N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)nicotinamides and their affinities for 5-HT3 and dopamine D2 receptors.
AID19424	Partition coefficient (logD7.4)	2001	Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID171716	Antigenic challenge time in rat (measured when compound was administered before challenge)	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID6010	5-hydroxytryptamine 3 receptor agonism in mouse	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
AID36926	Inhibitory activity against alpha-2 adrenergic receptor by 3H ligand binding experiments.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID6063	Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1209341	Ratio of drug level in cerebrospinal fluid to unbound plasma concentration in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID64457	Inhibitory activity against dopamine receptor D2 by 3H ligand binding experiments.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID184263	The compound was evaluated for the percentage increase in gastric emptying for a dose of 10 mg/kg perorally in rat	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID6066	Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1345769	Mouse D2 receptor (Dopamine receptors)	1998	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 287, Issue:2	Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain.
AID1346938	Mouse 5-HT4 receptor (5-Hydroxytryptamine receptors)	1996	FEBS letters, Nov-25, Volume: 398, Issue:1	Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor.
AID624237	Agonists at Mouse 5-Hydroxytryptamine receptor 5-HT4	1996	FEBS letters, Nov-25, Volume: 398, Issue:1	Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor.
AID1802944	In Vitro Assay from Article 10.3109/14756360903257900: \\Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study.\\	2010	Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 25, Issue:4	Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2217 (47.95)	18.7374
1990's	1121 (24.24)	18.2507
2000's	591 (12.78)	29.6817
2010's	527 (11.40)	24.3611
2020's	168 (3.63)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,216 (24.11%)	5.53%
Reviews	425 (8.43%)	6.00%
Case Studies	557 (11.04%)	4.05%
Observational	14 (0.28%)	0.25%
Other	2,832 (56.15%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (133)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Olanzapine in Break-through Emesis After Prophylaxis With Dexamethasone, 5-HT3 Receptor Antagonists and Aprepitant Compared to Metoclopramide [NCT01148264]	Phase 2	23 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to poor enrolment)
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis- A Randomized Placebo Controlled Study [NCT02528760]		83 participants (Actual)	Interventional	2015-09-24	Completed
A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents Visiting the Emergency Department [NCT05102591]	Phase 3	40 participants (Anticipated)	Interventional	2022-02-22	Recruiting
Ondansetron Vs Metoclopramide in the Treatment of Vomiting in Gastroenteritis Patients: A Randomized Controlled Trial [NCT01165866]	Phase 4	170 participants (Actual)	Interventional	2008-06-30	Completed
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy [NCT03435003]	Phase 4	104 participants (Actual)	Interventional	2017-08-28	Completed
Can Opioid Induced Effects on Esophageal Motility and Lower Esophageal Sphincter be Counteracted by a Dopamine Receptor Antagonist? [NCT01191645]	Phase 4	14 participants (Actual)	Interventional	2010-10-31	Completed
The Effects of Combined Gum-chewing and Parenteral Metoclopramide on the Duration of Post-operative Ileus After Abdominal Surgery [NCT05669781]	Phase 4	105 participants (Actual)	Interventional	2018-10-01	Completed
Metoclopramide, Azithromycin, or Nondrug Pretreatment for Upper Gastrointestinal Bleeding to Reduce Second Endoscopy [NCT03840057]	Phase 2	435 participants (Anticipated)	Interventional	2020-07-01	Recruiting
Metoclopramide for Post-Traumatic Headache. A Pilot Study [NCT03056352]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2017-03-01	Completed
Metoclopramide Versus Hyoscine Butylbromide in Shortening Duration of the First Stage of Labor Among Nulliparous Women in Abakaliki [NCT05222646]	Phase 1	150 participants (Anticipated)	Interventional	2022-01-03	Recruiting
The Study of The Efficacy and Safety of Itopride For Feeding Intolerance in Critically-ill Patients Receiving Enteral Nutrition [NCT03698292]		60 participants (Anticipated)	Interventional	2018-10-31	Recruiting
Investigating the Efficacy of Using Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department: A Prospective Randomized Clinical Trial [NCT02972502]	Phase 4	66 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to PI lapsed institutional training)
Corticosteroids for Acute Migraine. An ED-based, Randomized, Comparative Effectiveness Trial [NCT02847494]	Phase 4	220 participants (Actual)	Interventional	2016-09-01	Completed
Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients: A Protocol for Double Blind Randomized Control Trial [NCT03934294]		28 participants (Actual)	Interventional	2019-05-15	Completed
MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial [NCT02135510]	Phase 3	249 participants (Actual)	Interventional	2013-06-30	Completed
Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo [NCT02253524]	Phase 4	200 participants (Actual)	Interventional	2012-11-30	Completed
Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine [NCT01289938]	Phase 1	49 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are completed (EM, IM and PM).)
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum [NCT02163434]	Phase 2	31 participants (Actual)	Interventional	2014-06-30	Completed
Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer [NCT02441894]	Phase 4	21 participants (Actual)	Interventional	2015-04-30	Completed
The Use of Propofol/Ketamine Anesthesia With Bispectral Monitoring (PKA-BIS) Versus Inhalational Anesthetics in Rhytidoplasty - A Prospective, Double-blinded, Randomized Comparison Study [NCT02410460]		30 participants (Actual)	Interventional	2013-09-30	Completed
The Effect of Metoclopramide on the Length of First Stage of Labor in Nulliparous Women, a Randomized Controlled Trial [NCT04969120]	Phase 4	80 participants (Actual)	Interventional	2022-03-01	Completed
Thiamine As An Adjuvant Therapy For Hyperlactatemia In Septic Shock Patients: A Prospective Randomized Study [NCT03649009]		72 participants (Anticipated)	Interventional	2018-01-01	Recruiting
Metoclopramide as Treatment of Clozapine-induced Hypersalivation [NCT02222220]	Phase 3	61 participants (Actual)	Interventional	2012-01-31	Completed
Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial [NCT03560583]		60 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
Intrathecal Atropine Versus Intravenous Metoclopramide for Prevention of Nausea and Vomiting During Caesarian Section Under Spinal Anesthesia [NCT03932578]	Phase 4	60 participants (Actual)	Interventional	2019-05-05	Completed
The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise [NCT02965963]		35 participants (Anticipated)	Interventional	2016-12-31	Active, not recruiting
A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance [NCT03477903]	Phase 2	1 participants (Actual)	Interventional	2018-08-25	Terminated(stopped due to Insufficient enrollment; No safety concerns)
Observation on the Efficacy of Three Antiemetics in Preventing Nausea and Vomiting Caused by Intravenous Tramadol Injection and Postoperative Nausea and Vomiting [NCT05533281]	Early Phase 1	200 participants (Anticipated)	Interventional	2022-09-15	Recruiting
A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastropares [NCT03268941]	Phase 2	51 participants (Actual)	Interventional	2017-09-26	Completed
An RCT of Metoclopramide/Diphenhydramine vs. Ketorolac Alone for Tension-type Headache [NCT01011673]	Phase 4	123 participants (Actual)	Interventional	2009-11-30	Completed
Oral v. Parenteral Medications for the Emergency Management of Acute Migraine: a Pilot Randomized Control Trial [NCT05983354]		55 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Ultrasound Assessment of the Effect of Metoclopramide Versus Granisetron on Gastric Volume in Patients Undergoing Caesarean Section [NCT04290026]	Early Phase 1	90 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Comparison of Efficacy of Ondansetron Versus Metoclopramide for Vomiting in Children With Acute Gastroenteritis: Randomized Controlled Clinical Trial [NCT02619201]	Phase 3	250 participants (Anticipated)	Interventional	2015-11-30	Not yet recruiting
Magnesium Sulfate vs Metoclopramide for Headache in Pregnant Women [NCT00632606]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2008-08-31	Withdrawn
[NCT01069536]		140 participants (Actual)	Interventional	2007-03-31	Completed
A Multi-center Randomised Controlled Trial to Explore the Ideal Initial Enteral Feeding Strategies in Patients With Severe Stroke at Acute Stage [NCT02982668]		306 participants (Actual)	Interventional	2017-01-31	Terminated(stopped due to Significantly higher mortality)
Comparison of Gastric Volumes by Gastric Ultrasound in Term Parturients Undergoing Scheduled Elective Cesarean Delivery With and Without Metoclopramide [NCT05033041]	Phase 4	72 participants (Anticipated)	Interventional	2021-10-20	Recruiting
The Use of Metoclopramide vs. Placebo in Infants With Gastroschisis. A Pilot Double Blind Randomized Controlled Trial [NCT02098915]	Phase 3	10 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to Decision to prematurely close the trial was made because of poor recruitment.)
Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block [NCT02441673]	Phase 2	130 participants (Anticipated)	Interventional	2018-10-12	Not yet recruiting
Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial [NCT02098499]	Phase 4	68 participants (Actual)	Interventional	2013-06-30	Completed
Metoclopramide and Diphenhydramine (MAD): A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective (MAD Headache Study) [NCT02295280]		70 participants (Actual)	Interventional	2012-01-31	Completed
Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women, Exploring a Potential Role of an Old Drug [NCT01937234]	Phase 4	250 participants (Actual)	Interventional	2013-07-31	Completed
A Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Intravenous Ulimorelin (LP101) in Patients With Enteral Feeding Intolerance (EFI) [NCT02784392]	Phase 2	120 participants (Actual)	Interventional	2016-10-31	Completed
A Randomized Controlled Trial Evaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia as Part of a Multimodal Antiemetic Strategy for Enhanced Recovery After Cesarean Delivery [NCT05731960]	Phase 4	192 participants (Anticipated)	Interventional	2023-03-06	Recruiting
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Clinical Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Subjects With Gastroparesis [NCT00845858]	Phase 2	287 participants (Actual)	Interventional	2009-04-30	Completed
A Prospective, Open Label, Non-comparative Trial to Determine the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients [NCT01298193]	Phase 4	212 participants (Actual)	Interventional	2011-05-31	Completed
Efficacy of Fixed-dose Combination of Bromopride and Simethicone Versus Isolated Bromopride in Participants With Functional Dyspepsia. [NCT02604576]	Phase 3	339 participants (Actual)	Interventional	2017-01-17	Completed
The Pathophysiology of Orthostatic Hypotension [NCT00748059]	Phase 1	10 participants (Actual)	Interventional	1996-12-31	Completed
National, Phase III, Multicenter, Randomized, Open, Parallel, to Evaluate the Efficacy, Safety and Superiority of Cefalium® Compared to the Tylenol® in the Treatment of Migraine Attacks [NCT02582996]	Phase 3	336 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Strategic reasons of the company)
Ondansetron 4 mg vs. 2 mg vs. Metoclopramide 10 mg for Nausea and Vomiting in the Emergency Department: A Randomized, Double-Blind Clinical Trial [NCT00778011]	Phase 4	137 participants (Actual)	Interventional	2005-11-30	Completed
The Efficacy of Metoclopramide for Gastric Visualization by Endoscopy in Patients With Acute Upper Gastrointestinal Bleeding: Double-blind Randomized Controlled Trial [NCT04771481]	Phase 4	68 participants (Actual)	Interventional	2021-04-10	Completed
Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial [NCT04252521]		150 participants (Actual)	Interventional	2019-07-03	Completed
Combined Spinal Epidural Anesthesia in Obese Patients Undergoing Cesarean Surgery: A Randomised Comparison of Lateral Decubitus and Sitting Positions [NCT04612998]		100 participants (Actual)	Interventional	2017-02-01	Completed
Rescue Emetic Therapy for Children Having Elective Therapy [NCT01067677]		0 participants (Actual)	Interventional	2010-02-28	Withdrawn(stopped due to We do not have the funding or resources to complete the study at this time)
A Phase III, Randomized, Open-label, Active-controlled, Two-arm, Parallel-design, Interventional Clinical Trial Evaluating the Efficacy and Safety of Ondansetron 8 mg IV/ IM Injection Compared to Metoclopramide 10 mg in the Management of Nausea and Vomiti [NCT05876585]	Phase 3	126 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC). Comparison vs Laxative Free CTC. [NCT02040285]	Phase 4	52 participants (Actual)	Interventional	2012-02-29	Completed
Electrogastrography (EGC) in Premature Infants With Feeding Intolerance: The Effect of Metoclopramide [NCT00008736]	Phase 2	0 participants	Interventional		Completed
The Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Interven Tion [NCT02913469]	Phase 4	128 participants (Anticipated)	Interventional	2014-12-12	Recruiting
Feasibility Study to Compare 2 Strategies of Treatment Algorithm for Treating Nausea and or Vomiting in the Palliative Phase of Cancer Care [NCT03017391]	Phase 4	20 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Efficacy of Metoclopramide for Gastric Visualization by Endoscopy in Patients With Active Upper Gastrointestinal Bleeding: Multicenter, Double-blind Randomized Controlled Trial [NCT06167837]	Phase 4	220 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room [NCT04726592]	Phase 3	420 participants (Anticipated)	Interventional	2021-07-08	Recruiting
Prochlorperazine Verus Metoclopramide for the Treatment of Acute Migraine in the Emergency Department Setting [NCT00364806]	Phase 4	76 participants	Interventional	2006-08-31	Completed
Cross-over Trial of Medical Treatment for GERD in Preterm Infants [NCT00131248]	Phase 3	18 participants (Actual)	Interventional	2004-04-30	Completed
[NCT00237705]		40 participants	Interventional	2004-05-31	Recruiting
Trimebutine Maleate (NEWBUTIN SR 300 mg Tab) as a Prophylactic Anti-emetic Drug for Patients Who Underwent Arthroscopic Rotator Cuff Repair: a Randomized Controlled Study [NCT01984931]	Phase 3	45 participants (Anticipated)	Interventional	2013-10-31	Recruiting
A Randomized, Placebo-Controlled, Double-Blind Study of the Effects of Magnesium Compared to Conventional Therapy on Acute Migraine [NCT05967442]	Phase 3	288 participants (Actual)	Interventional	2019-08-23	Completed
A Randomized Study of Dexamethasone as Adjuvant Therapy for Acute Post-traumatic Headache [NCT04799015]	Phase 4	162 participants (Anticipated)	Interventional	2021-02-24	Recruiting
Premedication With Metoclopramide in Upper Gastrointestinal Bleeds a Prospective Double Blinded Single Center Randomized Control Trial in a Small Community Hospital [NCT05746377]	Phase 4	60 participants (Anticipated)	Interventional	2023-05-20	Recruiting
Restoration of Hypoglycemia Awareness With Metoclopramide [NCT03970720]	Phase 2	36 participants (Anticipated)	Interventional	2019-05-28	Recruiting
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial [NCT00869310]	Phase 3	303 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to we terminated the study before enrolling 303/560 due to a slow accrual)
"Ultrasound Assessment of Metoclopramide Effect on Gastric Volume in Patients Undergoing Cesarean Section: A Randomized, Double-blind, Cross-sectional Study" [NCT04157998]		60 participants (Anticipated)	Interventional	2019-11-01	Recruiting
Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction [NCT02627950]	Phase 4	138 participants (Actual)	Interventional	2015-12-31	Completed
Randomized Controlled Trial on the Effectiveness of Metoclopramide Alone or in Combination With Ketoprofen in Acute Migraine of Child [NCT00557544]	Phase 3	0 participants (Actual)	Interventional	2009-06-30	Withdrawn
A Randomized, Facorial Design Study to Optimize the Dose of Parenteral Metoclopramide [NCT00475306]	Phase 4	289 participants (Actual)	Interventional	2007-05-31	Completed
Comparison of Intrathecal Levobupivacaine Combined With Sufentanil, Fentanyl, or Placebo for Elective Caesarean Section: A Prospective, Randomized, Double-blind, Controlled Study [NCT01858090]	Phase 3	93 participants (Actual)	Interventional	2009-01-31	Completed
Metoclopramide to Improve Lactogenesis II in Diabetic Women: a Randomized Controlled Trial [NCT00477776]	Phase 3	160 participants (Anticipated)	Interventional	2006-04-30	Completed
Assessment of Combined Bowel Preparation for Capsule Endoscopy Study [NCT01243736]	Phase 1	50 participants (Actual)	Interventional	2010-04-30	Completed
Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Metoclopramide or Morphine [NCT02939235]	Phase 4	32 participants (Actual)	Interventional	2016-07-31	Completed
Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age: A Randomized Controlled Trial [NCT02907632]	Phase 4	490 participants (Actual)	Interventional	2017-04-26	Completed
Comparison of the Effect of Metoclopramide Versus Erythromycin on Gastric Residual Volume [NCT04682691]	Early Phase 1	45 participants (Actual)	Interventional	2021-01-01	Enrolling by invitation
A Randomized Trial Comparing Auricular Acupuncture and Intravenous Migraine Medications in the Treatment of Status Migrainosus in the Pediatric Emergency Department [NCT02681211]		80 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS) [NCT00120653]	Phase 2	0 participants (Actual)	Interventional	2005-07-14	Withdrawn
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis [NCT00139893]		0 participants	Interventional	2005-06-30	Completed
Randomized Clinical Trial of Pregabalin for Opioid Withdrawal Syndrome [NCT03017430]	Phase 4	100 participants (Actual)	Interventional	2014-01-31	Completed
Metoclopramide for Acute Migraine: A Dose Finding Study [NCT00682734]	Phase 3	349 participants (Actual)	Interventional	2008-04-30	Completed
The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section [NCT01216410]		306 participants (Actual)	Interventional	2008-12-31	Completed
Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen [NCT01522326]		300 participants (Anticipated)	Interventional	2012-03-01	Completed
A Randomised Study of the Optimal Bowel Preparation for Routine Capsule Endoscopy Using Citramag and Senna or Metoclopramide [NCT00275184]	Phase 3	150 participants (Anticipated)	Interventional	2006-01-31	Recruiting
An Open-label, Randomised Study Comparing the Uptake of rIL-2 in HIV-1 Infected Individuals Receiving Different Combinations of Antiemetics and Analgesic Agents During rIL-2 Dosing in ESPRIT: Toxicity Substudy of ESPRIT: TOXIL-2 Substudy [NCT00147355]	Phase 3	28 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to 28 of 168 patients only were enrolled, numbers too low to be conclusive)
The Critical Illness Stress-induced Immune Suppression Prevention Trial [NCT00395161]	Phase 3	293 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to Terminated for futility on 11/30/09 based on the recommendation of the DSMB)
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance [NCT01953081]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2014-01-31	Completed
Metoclopramide vs Placebo for Prevention of Pneumonia in Acute Stroke Patients Fed Via Nasogastric Tubes [NCT04873297]	Phase 4	106 participants (Actual)	Interventional	2021-05-02	Completed
"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department" [NCT03081416]	Phase 3	80 participants (Actual)	Interventional	2016-05-31	Completed
Neostigmine Effect on Gastric Residual Volume on Mechanically Ventilated Patients in the Intensive Care Unit. A Comparative Controlled Study by Ondansetron [NCT05342818]	Phase 2	90 participants (Actual)	Interventional	2022-04-15	Completed
Treatment of Acute Migraine Headache in Children [NCT00355394]	Phase 2	31 participants (Actual)	Interventional	2006-08-31	Completed
The Effect of Metoclopramide on Feeding in Very Low Birthweight Newborns : a Randomized, Double Blind, Placebo Controlled Pilot Study and a Proposal for a Multicentre Trial [NCT00242450]	Phase 4	30 participants	Interventional	2002-03-31	Completed
Metoclopramide to Aid Establishment of Breastfeeding After Delivery: a Randomized Controlled Trial [NCT00264719]		160 participants (Anticipated)	Interventional	2006-01-31	Completed
A Prospective, Single Center, Randomized, Single Blinded Study to Evaluate the Efficacy of Oral Dissolving Metoclopramide Before Video Capsule Endoscopy. [NCT01631994]		6 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to No support to run the study)
Randomized Controlled Trial of Prophylactic Subhypnotic Propofol vs Metoclopramide and in Combination Therapy for the Prevention of Nausea and Vomiting During Subarachnoid Anesthesia for Cesarean Section. [NCT01781377]	Phase 4	112 participants (Anticipated)	Interventional	2008-02-29	Completed
A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP. [NCT01843868]		130 participants (Anticipated)	Interventional	2013-05-31	Not yet recruiting
COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure [NCT02481219]		122 participants (Actual)	Interventional	2015-05-31	Completed
Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis [NCT02025725]	Phase 3	205 participants (Actual)	Interventional	2014-03-27	Completed
Subcutaneous Route and Pharmacology of Metoclopramide [NCT02466984]	Phase 3	5 participants (Actual)	Interventional	2016-07-31	Completed
A Randomized Controlled Trial of Metoclopramide Versus Placebo During Gastrojejunostomy Tube Placement for Facilitating Guidewire Advancement Through the Pylorus [NCT03331965]	Phase 2	110 participants (Actual)	Interventional	2018-04-09	Completed
: Oral Midodrine for Prophylaxis Against Post Spinal Anaesthesia Hypotension During Hip Arthroplasty in Elderly Population: A Randomized Controlled Trial [NCT05548985]		58 participants (Actual)	Interventional	2022-10-17	Completed
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis [NCT02625181]		27,034 participants (Actual)	Interventional	2016-07-31	Completed
Is Intra-operative Acupuncture Point P6 Stimulation as Effective as Traditional Pharmacotherapy in Reducing Nausea and Vomiting During Cesarean Section With Regional Anesthesia? [NCT02959840]	Phase 4	180 participants (Actual)	Interventional	2015-07-31	Completed
Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial [NCT02314351]	Phase 4	148 participants (Actual)	Interventional	2014-12-31	Completed
Study to Evaluate the Anti-emetic Effect of Aprepitant as an add-on Therapy in Children and Adolescents Receiving AML Remission Induction Chemotherapy: An Investigator-initiated, Randomized, Open Label Trial [NCT02979548]	Phase 3	116 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches in the Emergency Department: A Prospective Randomized, Double-blinded Trial. [NCT01406860]		19 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to lack of enrollment/drug shortages)
Effects of Metoclopramide Administration on Gastric Emptying in Mechanically Ventilated Critically Ill Patients : A Prospective Randomized Controlled Trial [NCT05641051]	Phase 4	80 participants (Actual)	Interventional	2022-12-14	Completed
Role of Prophylactic Metoclopramide With Tramadol in Trauma Patients: A Randomised, Double Blind Placebo Controlled Trial [NCT03383315]	Phase 2	191 participants (Actual)	Interventional	2017-07-01	Completed
Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo. [NCT05586763]	Phase 3	90 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Trial of Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy: A Pilot Investigation [NCT05098067]	Phase 2	30 participants (Anticipated)	Interventional	2022-05-24	Recruiting
The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients [NCT05496179]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2022-03-07	Completed
Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department [NCT01596166]	Phase 4	56 participants (Actual)	Interventional	2012-02-29	Completed
Randomized, Placebo-controlled Trial of Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis in Patients Receiving High Dose Cisplatin in Routine Medical Practice [NCT01093690]		162 participants (Actual)	Interventional	2009-04-30	Completed
IV Valproate for Acute Migraine. A Randomized Comparison Versus IV Metoclopramide and IV Ketorolac [NCT01267864]	Phase 4	330 participants (Actual)	Interventional	2010-11-30	Completed
A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC R [NCT01636947]	Phase 4	494 participants (Actual)	Interventional	2012-12-12	Completed
A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis [NCT00003213]	Phase 3	267 participants (Actual)	Interventional	1996-05-31	Completed
A Randomized Trial of Greater Occipital Nerve Block With Bupivacaine Versus Intravenous Metoclopramide for Acute Migraine [NCT03269435]	Phase 4	99 participants (Actual)	Interventional	2017-11-01	Completed
PEP uP Protocol (Enhanced Protein-Energy Provision Via the Enteral roUte Feeding Protocol) in Surgical Patients [NCT02459275]	Phase 4	36 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Funding discontinued)
A Randomized Placebo Controlled Trial of IV Metoclopramide for Acute Post-traumatic Headache [NCT03220958]	Phase 3	160 participants (Actual)	Interventional	2017-08-01	Completed
Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery: a Randomized Clinical Trial [NCT05087615]	Phase 3	130 participants (Actual)	Interventional	2021-03-01	Completed
Ultrasound-guided Block of the Saphenous Nerve and Obturator Nerve, Posterior Branch, for Postoperative Pain Management After Ambulatory Knee Arthroscopy [NCT01837394]	Phase 4	60 participants (Actual)	Interventional	2012-08-31	Completed
Metoclopramide As An Adjunct To Small Bowel Capsule Endoscopy: Rate of Complete Evaluation And Affect on Transit Times [NCT01630109]	Phase 4	5 participants (Actual)	Interventional	2012-12-31	Completed
Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center [NCT04027348]	Phase 2	15 participants (Actual)	Interventional	2019-06-26	Terminated(stopped due to low accrual)
Study of Effects of Metoclopramide Versus Sumatriptan on Migraine Headache [NCT01791400]	Phase 2	124 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Double Blind, and Placebo-Controlled Trial Comparing Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult Emergency Department. [NCT00655642]		171 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to Conditional analysis showed observed differences were significantly less than power calculations)
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study [NCT01934192]	Phase 2	91 participants (Actual)	Interventional	2014-04-04	Terminated
Dopamine D-2 Antagonist Use in Poor Responders in IVF: a Randomized Controlled Trial [NCT02262923]		0 participants (Actual)	Interventional	2016-03-31	Withdrawn
Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial. [NCT01825941]	Phase 4	208 participants (Actual)	Interventional	2013-04-30	Completed
Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis [NCT02025751]	Phase 3	53 participants (Actual)	Interventional	2014-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00131248 (1) [back to overview]	Bradycardia Episodes/Day
NCT00355394 (6) [back to overview]	Change in Headache Intensity as Measured by the NRS Score From Baseline to the One Hour Assessment.
NCT00355394 (6) [back to overview]	Change in Headache Intensity as Measured by the NRS Score From Baseline to the Two Hour Assessment.
NCT00355394 (6) [back to overview]	The Number of Subjects With a NRS Score of Zero at 24 Hours.
NCT00355394 (6) [back to overview]	The Number of Subjects With a NRS Score of Zero at One Hour.
NCT00355394 (6) [back to overview]	The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours.
NCT00355394 (6) [back to overview]	Change in Headache Intensity as Measured by the NRS Score From Baseline to the 24 Hour Assessment.
NCT00395161 (5) [back to overview]	The Primary Endpoint of This Study is the Median Time Between Admission to the PICU and Occurrence of Nosocomial Infection or Clinical Sepsis in PICU Patients Who Have Endotracheal Tubes, Central Venous Catheters, or Urinary Catheters.
NCT00395161 (5) [back to overview]	All-cause 28-day Mortality Rate.
NCT00395161 (5) [back to overview]	Rate of Nosocomial Infection or Clinical Sepsis Per 100 Study Days
NCT00395161 (5) [back to overview]	Incidence of Prolonged Lymphopenia (Absolute Lymphocyte Count Less Than or Equal to 1,000/mm³ for > or Equal to 7 Days)
NCT00395161 (5) [back to overview]	Antibiotic-free Days
NCT00475306 (2) [back to overview]	Nausea Scale
NCT00475306 (2) [back to overview]	Number of Participants With Akathisia
NCT00655642 (1) [back to overview]	Change in Visual Analog Scale (VAS) Score for Nausea. This Was Calculated by Subtracting the Patient's Reported Score on the 30 Minute VAS From the Patient's Reported VAS Score on Their Baseline VAS.
NCT00682734 (1) [back to overview]	Pain Intensity Score
NCT00845858 (2) [back to overview]	The Pre-specified Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score by Gender.
NCT00845858 (2) [back to overview]	The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score.
NCT01011673 (2) [back to overview]	Satisfaction Scores
NCT01011673 (2) [back to overview]	Change in Pain Score
NCT01093690 (1) [back to overview]	Number of Patients Who Had Complete Response
NCT01216410 (5) [back to overview]	Pruritus
NCT01216410 (5) [back to overview]	Maternal Hemodynamics
NCT01216410 (5) [back to overview]	Intraoperative Nausea and Vomiting
NCT01216410 (5) [back to overview]	Postoperative Nausea and Vomiting (PONV)
NCT01216410 (5) [back to overview]	Satisfaction
NCT01267864 (4) [back to overview]	Participants Who Achieve Sustained Headache Freedom for 24 Hours
NCT01267864 (4) [back to overview]	Headache Pain Level on a 0-10 Verbal Scale
NCT01267864 (4) [back to overview]	Adverse Event
NCT01267864 (4) [back to overview]	Satisfaction With Medication
NCT01298193 (9) [back to overview]	Impact of Chemotherapy-Induced Nausea on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2
NCT01298193 (9) [back to overview]	Impact of Chemotherapy-Induced Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1
NCT01298193 (9) [back to overview]	Impact of Chemotherapy-Induced Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2
NCT01298193 (9) [back to overview]	Total Impact of Chemotherapy-Induced Nausea and Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1
NCT01298193 (9) [back to overview]	Total Impact of Chemotherapy-Induced Nausea and Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2
NCT01298193 (9) [back to overview]	Number of Participants With Complete Response (CR) in Cycle 2 for Patient Without Complete Response in Cycle 1
NCT01298193 (9) [back to overview]	Number of Participants With Complete Response (CR)
NCT01298193 (9) [back to overview]	Number of Participants With Treatment Related Adverse Events (AE) at Cycle 2
NCT01298193 (9) [back to overview]	Impact of Chemotherapy-Induced Nausea on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1
NCT01630109 (4) [back to overview]	Differences in Small Bowel Transit Time in Treatment vs. Placebo in Pill Capsule Studies
NCT01630109 (4) [back to overview]	Differences in Gastric Transit Time in Treatment vs. Placebo in Pill Capsule Studies
NCT01630109 (4) [back to overview]	Difference in Treatment vs. Placebo in Pill Capsule Completion Rates
NCT01630109 (4) [back to overview]	Difference in Pill Capsule Completion Rates in Diabetics vs. Non-diabetics
NCT01636947 (8) [back to overview]	Number of Emetic Events - Overall Stage
NCT01636947 (8) [back to overview]	Percentage of Participants With No Impact on Daily Life - Overall Stage
NCT01636947 (8) [back to overview]	Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage
NCT01636947 (8) [back to overview]	Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages
NCT01636947 (8) [back to overview]	Percentage of Participants With No Vomiting - Acute and Delayed Stages
NCT01636947 (8) [back to overview]	Percentage of Participants With One or More Clinical Adverse Event
NCT01636947 (8) [back to overview]	The Percentage of Participants With No Vomiting - Overall Stage
NCT01636947 (8) [back to overview]	Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages
NCT01825941 (1) [back to overview]	Number of Participants With Sustained Headache Relief Assessed by Self-evaluation
NCT01934192 (35) [back to overview]	GE Assessment as AUC (0-60) Within 24 Hrs of Developing Intolerance and Prior to Change of Treatment Using Acetaminophen
NCT01934192 (35) [back to overview]	GE Assessment as C60 Within 24 Hrs of Developing Intolerance and Prior to Change of Treatment Using 3-OMG
NCT01934192 (35) [back to overview]	GE Assessment as Cmax Within 24 Hrs of Developing Intolerance and Prior to Change of Treatment Using Acetaminophen
NCT01934192 (35) [back to overview]	Percentage of Participants That Became Intolerant
NCT01934192 (35) [back to overview]	Time to Delivery of 80 Percent Prescribed Calories Prior to Intolerance
NCT01934192 (35) [back to overview]	Time to Development of Feeding Intolerance
NCT01934192 (35) [back to overview]	Change From Baseline in Albumin and Total Protein Levels
NCT01934192 (35) [back to overview]	Change From Baseline in Alkaline Phosphatase (Alk. Phosph.), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma Glutamyl Transferase (GGT) Levels
NCT01934192 (35) [back to overview]	Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet and White Blood Cell (WBC) Levels
NCT01934192 (35) [back to overview]	Change From Baseline in Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN) Values
NCT01934192 (35) [back to overview]	Change From Baseline in Heart Rate (HR)
NCT01934192 (35) [back to overview]	Change From Baseline in Hematocrit Level
NCT01934192 (35) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Levels
NCT01934192 (35) [back to overview]	Change From Baseline in Mean Corpuscle Volume (MCV) Levels
NCT01934192 (35) [back to overview]	Change From Baseline in Red Blood Cell (RBC) and Reticulocyte Count
NCT01934192 (35) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT01934192 (35) [back to overview]	Change From Baseline in Total and Direct Bilirubin, Creatinine and Uric Acid Levels
NCT01934192 (35) [back to overview]	Derived AUC Over the Dosing Period [AUC(0-tau)] of GSK962040 Post Intolerance
NCT01934192 (35) [back to overview]	Derived Tmax of GSK962040 Post Intolerance
NCT01934192 (35) [back to overview]	GE Assessment as AUC (0-60) and AUC (0-240) Within 24 Hrs of Developing Intolerance and Prior to Change of Treatment Using 3-OMG
NCT01934192 (35) [back to overview]	Log Transformed AUC[0-60] of 3-O-methylglucose (3- OMG)
NCT01934192 (35) [back to overview]	Log Transformed AUC[0-60] of Acetaminophen
NCT01934192 (35) [back to overview]	Log Transformed C60 of 3-OMG
NCT01934192 (35) [back to overview]	Log Transformed Concentration at 60 Minutes (Min) (C60) and Maximum Observed Concentration (Cmax) of Acetaminophen (Prior to Intolerance)
NCT01934192 (35) [back to overview]	Log Transformed Derived Plasma Cmax of GSK962040 Post Intolerance
NCT01934192 (35) [back to overview]	Log Transformed Derived Plasma Cmax of GSK962040 Prior to Intolerance
NCT01934192 (35) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01934192 (35) [back to overview]	Number of Participants With Maximum Increase From Baseline in Electrocardiogram (ECG) Values
NCT01934192 (35) [back to overview]	Number of Participants With Occurrences of Vomiting, Regurgitation and Macroaspiration Episodes
NCT01934192 (35) [back to overview]	Total GRV for 24 hr Period
NCT01934192 (35) [back to overview]	Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Levels
NCT01934192 (35) [back to overview]	Average Percentage Goal Calories Delivered Prior to Development of Intolerance
NCT01934192 (35) [back to overview]	Average Percentage Goal Protein Delivered Prior to Development of Intolerance
NCT01934192 (35) [back to overview]	Average Percentage Goal Volume Delivered Prior to Development of Intolerance for ITT Population
NCT01934192 (35) [back to overview]	Average Percentage Goal Volume Delivered Prior to Development of Intolerance for PP Population
NCT01953081 (9) [back to overview]	Tmax
NCT01953081 (9) [back to overview]	Percentage of Gastric Retention by Scintigraphy at 240 Minutes Postdose
NCT01953081 (9) [back to overview]	Percentage Gastric Retention by Scintigraphy at 120 Minutes Postdose
NCT01953081 (9) [back to overview]	Gastric Emptying by Breath Test
NCT01953081 (9) [back to overview]	Cmax
NCT01953081 (9) [back to overview]	AUC
NCT01953081 (9) [back to overview]	Adverse Events
NCT01953081 (9) [back to overview]	Percentage Gastric Retention by Scintigraphy at 60 Minutes Postdose
NCT01953081 (9) [back to overview]	Gastric Retention by Scintigraphy
NCT02025725 (2) [back to overview]	Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure
NCT02025725 (2) [back to overview]	Gastroparesis Symptom Assessment (GSA)
NCT02025751 (1) [back to overview]	Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure
NCT02163434 (6) [back to overview]	Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7
NCT02163434 (6) [back to overview]	Baseline Adjusted Mean Daily Nausea Scores From the Motherisk-PUQE for Days 5-7.
NCT02163434 (6) [back to overview]	Baseline Adjusted Mean Daily Oral Nutrition Score for Days 5-7
NCT02163434 (6) [back to overview]	Global Satisfaction of Treatment at the Study Endpoint.
NCT02163434 (6) [back to overview]	Percent of Subjects Requiring Repeat iv Hydration or Hospital Admission for HG From the Outpatient Setting.
NCT02163434 (6) [back to overview]	Desire to Continue Therapy at Study Endpoint
NCT02295280 (1) [back to overview]	Number of Participants With Adequate Relief of Headache as a Measure of Efficacy
NCT02459275 (6) [back to overview]	Time to Initiation of Enteral Nutrition
NCT02459275 (6) [back to overview]	Hospital Length of Stay
NCT02459275 (6) [back to overview]	ICU Length of Stay
NCT02459275 (6) [back to overview]	Total Amount of Energy
NCT02459275 (6) [back to overview]	Total Amount of Protein Received
NCT02459275 (6) [back to overview]	Mortality
NCT02481219 (6) [back to overview]	Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]	Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]	Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)
NCT02481219 (6) [back to overview]	Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]	Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]	Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE
NCT02625181 (4) [back to overview]	PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]	Adherence to PONV Guidelines
NCT02625181 (4) [back to overview]	Time to Discharge From the Postanesthesia Care Unit (PACU)
NCT02625181 (4) [back to overview]	The Number of Prophylactic Interventions for PONV
NCT02847494 (3) [back to overview]	Headache Days as Self-reported by Participants
NCT02847494 (3) [back to overview]	Medication Preference as Assessed by Self-report
NCT02847494 (3) [back to overview]	Number of Participants With Sustained Headache Freedom
NCT02959840 (12) [back to overview]	Vomiting During Stage IV (the Rest of the Time Until Arrival at PACU)
NCT02959840 (12) [back to overview]	Overall Anesthetic Care Satisfaction
NCT02959840 (12) [back to overview]	Nausea
NCT02959840 (12) [back to overview]	Nausea During Stage I (After the Administration of CSE and Until Eversion of the Uterus)
NCT02959840 (12) [back to overview]	Nausea During Stage II (After Eversion of the Uterus and Until Replacement of the Uterus)
NCT02959840 (12) [back to overview]	Nausea During Stage III (After Replacement of the Uterus and to the Next 15 Minutes)
NCT02959840 (12) [back to overview]	Nausea During Stage IV (the Rest of the Time Until Arrival at PACU)
NCT02959840 (12) [back to overview]	Satisfaction of Anti-emetic Treatment
NCT02959840 (12) [back to overview]	Vomiting
NCT02959840 (12) [back to overview]	Vomiting During Stage I (After the Administration of CSE and Until Eversion of the Uterus)
NCT02959840 (12) [back to overview]	Vomiting During Stage II (After Eversion of the Uterus and Until Replacement of the Uterus)
NCT02959840 (12) [back to overview]	Vomiting During Stage III (After Replacement of the Uterus and to the Next 15 Minutes)
NCT02972502 (1) [back to overview]	Change in Pain Score According to the Numeric Pain Intensity Scale
NCT03056352 (3) [back to overview]	Post Concussion Symptoms Assessed by Post-concussive Symptom Scale
NCT03056352 (3) [back to overview]	Number of Participants Satisfied With Medication; Assessed by Self-evaluation
NCT03056352 (3) [back to overview]	Number of Participants With Sustained Headache Relief
NCT03220958 (3) [back to overview]	Headache Days
NCT03220958 (3) [back to overview]	0-10 Pain Scale on Which 0 = no Pain and 10= the Worst Pain Imaginable
NCT03220958 (3) [back to overview]	Sustained Headache Relief
NCT03268941 (12) [back to overview]	Number of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT03268941 (12) [back to overview]	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 in Part 1
NCT03268941 (12) [back to overview]	Number of Participants With Markedly Abnormal Vital Signs
NCT03268941 (12) [back to overview]	Number of Participants With Markedly Abnormal Laboratory Parameters Values
NCT03268941 (12) [back to overview]	Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Values
NCT03268941 (12) [back to overview]	Ctrough: Observed Concentration at the End of a Dosing Interval for TAK-906 in Part 1
NCT03268941 (12) [back to overview]	Cmax: Maximum Observed Plasma Concentration for TAK 906 in Part 1
NCT03268941 (12) [back to overview]	Change From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time Following Single Dose Administration of TAK-906 Maleate as Measured by the 13C Spirulina GEBT on Day 1
NCT03268941 (12) [back to overview]	Change From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time as Measured by the 13C Spirulina GEBT Following Multiple Dose Administration of TAK-906 Maleate on Day 7 for Part 1
NCT03268941 (12) [back to overview]	AUCτ: Area Under the Plasma Concentration-time Curve From 0 to Time (T) Over the Dosing Interval for TAK-906 in Part 1
NCT03268941 (12) [back to overview]	Percent Change From Baseline in Gastric Emptying (GE) Time as Measured by the SmartPill on Day 7 for Part 1
NCT03268941 (12) [back to overview]	Change From Baseline in Serum Prolactin Concentration on Day 1 at Tmax, Time of First Occurrence of Maximum Serum Concentration (Cmax) for TAK-906 Maleate for Part 1
NCT03269435 (3) [back to overview]	0-10 Pain Score
NCT03269435 (3) [back to overview]	Sustained Headache Freedom
NCT03269435 (3) [back to overview]	Sustained Headache Relief
NCT03331965 (5) [back to overview]	Total Procedure Time
NCT03331965 (5) [back to overview]	Total Procedure Fluoroscopy Time
NCT03331965 (5) [back to overview]	Time to Duodenal Intubation
NCT03331965 (5) [back to overview]	Number of Subjects Experiencing Adverse Effects in the Periprocedural Period
NCT03331965 (5) [back to overview]	Total Procedure Air Kerma
NCT04027348 (1) [back to overview]	Proportion of Patients With Obstruction Clearance

Bradycardia Episodes/Day

(NCT00131248)
Timeframe: 7 days

Intervention	episodes per day (Mean)
Medications	4.6
Placebo	3.6

Intervention	participants (Number)
Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide	15
Enteral Whey Protein, IV Saline	8

Intervention	units on a scale (Median)
Metoclopramide 20mg+Diphenhydramine	0
Metoclopramide 20+Placebo	0
Metoclopramide 10 + Placebo	0
Metoclopramide 10+Diphenhydramine	0

Intervention	millimeter (Median)
Ondansetron	-22.0
Metoclopramide	-30.0
Promethazine	-29.0
Placebo	-16.0

Intervention	scores on a scale (Mean)
Metoclopramide 10 mg Intravenous	4.7
Metoclopramide 20 mg	4.9
Metoclopramide 40 mg	5.3

Intervention	units on a scale (Mean)
Female-Metoclopramide Nasal Spray 10 mg	-1.2
Female-Metoclopramide Nasal Spray 14 mg	-1.3
Female-Placebo Nasal Spray	-0.8

Intervention	units on a scale (Mean)
Metoclopramide Nasal Spray 10 mg	-1.2
Metoclopramide Nasal Spray 14 mg	-1.2
Placebo Nasal Spray	-1.0

Intervention	participants (Number)
	0-2 hrs PONV	2-6 hrs PONV	6-24 hrs PONV
Combination Group	20	28	22
Metoclopramide	33	35	26
Phenylephrine Infusion	39	41	22

Intervention	score on a scale (Mean)
	Cycle 2 pre-chemotherapy NCR patients	Cycle 2 post-chemotherapy NCR patients	Cycle 2 pre-chemotherapy CR patients	Cycle 2 post-chemotherapy CR patients
Aprepitant NCR	17.71	36.16	19.57	24.30

Intervention	score on a scale (Mean)
	Cycle 1 pre-chemotherapy NCR patients	Cycle 1 post-chemotherapy NCR patients	Cycle 1 pre-chemotherapy CR patients	Cycle 1 post-chemotherapy CR patients
Aprepitant	23.86	27.46	23.53	24.15

Intervention	minutes (Mean)
Metoclopramide 5 mg	53
Metoclopramide 10 mg	218
Placebo Control	301

Intervention	Percentage of complete studies (Number)
Placebo Control (Diabetics)	100
Metoclopramide 5 mg (Non-diabetic)	100
Metoclopramide 10 mg (Non-diabetic)	0
Placebo (Non-diabetic)	100

Intervention	Percentage of Participants (Number)
	Overall Stage	Acute Stage	Delayed Stage
Aprepitant Regimen	73.4	95.8	74.3
Control Regimen	70.4	97.9	71.2

Intervention	Participants (Count of Participants)
Metoclopramide + Diphenhydramine	40
Metoclopramide + Placebo	38

Intervention	Gram per liter (g/L) (Mean)
	Albumin Day 2; n=1,1,0,0,0,0	Albumin; Day 3; n= 0,2,0,0,0,0	Albumin Day 4; n= 0,1,0,0,0,0	Albumin Day 5; n= 0,2,0,0,0,0	Albumin Day 6; n= 0,1,0,0,0,0	Albumin Day 7; n= 13,11,0,0,0,0	Albumin intolerance Day 2; n= 0,0,0,0,0,1	Albumin intolerance Day 3; n= 0,0,0,1,0,0	Albumin intolerance Day 4; n= 0,0,0,1,0,0	Albumin intolerance Day 6; n= 0,0,1,1,1,0	Albumin intolerance Day 7; n= 0,0,1,0,2,2	Albumin follow up; n= 18,17,3,3,4,2	Total protein Day 2; n= 0,1,0,0,0,0	Total protein Day 3; n= 0,1,0,0,0,0	Total protein Day 5; n= 0,2,0,0,0,0	Total protein Day 6; n= 0,1,0,0,0,0	Total protein Day 7; n= 10,11,0,0,0,0	Total protein intolerance Day 2; n= 0,0,0,0,0,1	Total protein intolerance Day 3; n= 0,0,0,1,0,0	Total protein intolerance Day 4; n= 0,0,0,1,0,0	Total protein intolerance Day 6; n= 0,0,1,1,1,0	Total protein intolerance Day 7; n= 0,0,1,0,1,2	Total protein follow up; n= 15,16,3,3,4,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	NA	NA	11.00	0.00	5.25	NA	NA	NA	NA	NA	NA	NA	NA	2.00	2.00	4.50
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	7.00	NA	NA	NA	1.20	2.30	NA	NA	NA	NA	NA	7.00	NA	NA	NA	10.75	18.60
Baseline EN Tolerant: Camicinal 50 mg	-1.00	-3.50	-3.00	0.50	-4.00	0.64	NA	NA	NA	NA	NA	4.59	-3.00	9.00	7.00	-2.00	3.21	NA	NA	NA	NA	NA	16.43
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	-3.00	7.00	-3.00	NA	8.33	NA	NA	NA	NA	NA	NA	6.00	14.00	8.00	NA	22.33
Baseline EN Tolerant: Placebo	4.00	NA	NA	NA	NA	0.98	NA	NA	NA	NA	NA	5.81	NA	NA	NA	NA	10.06	NA	NA	NA	NA	NA	16.27
Baseline EN Tolerant: Placebo/Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.00	-6.00	4.73	NA	NA	NA	NA	NA	NA	NA	NA	22.00	4.00	20.77

Intervention	International Unit per liter (IU/L) (Mean)
	Alk. phosp. Day 2; n= 32,34,2,2,0,0	ALk. phosp. Day 3; n= 28,28,1,1,0,0	Alk. phosp. Day 4; n= 25,25,0,0,0,0	Alk. phsp Day5; n= 22,23,0,0,0,0	Alk. phsp Day6; n= 18,19,0,0,0,0	Alk. phsp. Day7; n= 14,13,0,0,0,0	Alk. phosp. intolerance Day1; n= 1,0,2,3,0,0	Alk. phosp. intolerance Day2; n= 0,0,3,3,4,4	Alk. phosp. intolerance Day3; n= 0,0,2,3,3,4	Alk. phosp. intolerance Day4; n= 0,0,2,2,3,3	Alk. phosp. intolerance Day5; n= 0,0,2,1,3,3	Alk. phosp. intolerance Day6; n= 0,0,2,1,3,2	Alk. phosp. intolerance Day7; n= 0,0,1,0,3,2	Alk.phosp. follow up; n= 17,20,3,2,4,2	ALT Day 2; n= 32,35,2,2,0,0	ALT Day 3; n= 29,30,1,1,0,0	ALT Day 4; n= 25,25,0,0,0,0	ALT Day 5; n= 22,23,0,0,0,0	ALT Day 6; n= 18,19,0,0,0,0	ALT Day 7; n= 14,13,0,0,0,0	ALT intolerance Day 1; n= 1,0,2,3,0,0	ALT intolerance Day 2; n= 0,0,3,3,4,4	ALT intolerance Day 3; n= n= 0,0,2,3,3,4	ALT intolerance Day 4; n= 0,0,2,2,3,3	ALT intolerance Day 5; n= 0,0,2,1,3,3	ALT intolerance Day 6; n= 0,0,2,1,3,2	ALT intolerance Day 7; n= 0,0,1,0,3,2	ALT follow up; n= n= 18,20,3,3,4,2	AST Day 2; n= 31,34,2,1,0,0	AST Day3; n= 28,29,1,1,0,0	AST Day4; n= 23,23,0,0,0,0	AST Day5; n= 22,22,0,0,0,0	AST Day6; n= 18,18,0,0,0,0	AST Day7; n= 13,12,0,0,0,0	AST intolerance Day1; n= 1,0,2,1,0,0	AST intolerance Day2; n= 0,0,3,1,4,4	AST intolerance Day3; n= 0,0,2,2,3,4	AST intolerance Day4; n= 0,0,1,2,3,3	AST intolerance Day5; n= 0,0,1,1,3,2	AST intolerance Day6; n= 0,0,1,1,3,1	AST intolerance Day7; n= 0,0,1,0,3,1	AST follow up; n= 17,20,3,2,4,2	GGT Day2; n= 32,34,2,2,0,0	GGT Day3; n= 28,28,1,1,0,0	GGT Day4; n= 24,24,0,0,0,0	GGT Day5; n= 22,22,0,0,0,0	GGT Day6; n= 18,18,0,0,0,0	GGT Day7; n= 14,12,0,0,0,0	GGT intolerance Day1; n= 1,0,2,3,0,0	GGT intolerance Day2; n= 0,0,3,3,3,4	GGT intolerance Day3; n= 0,0,2,3,2,4	GGT intolerance Day4; n= 0,0,2,2,2,3	GGT intolerance Day5; n= 0,0,2,1,2,3	GGT intolerance Day6; n= 0,0,2,1,2,2	GGT intolerance Day7; n= 0,0,1,0,2,2	GGT follow up; n= 18,20,3,3,3,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	5.8	-5.0	2.3	35.5	29.7	25.0	77.5	NA	NA	NA	NA	NA	NA	NA	6.5	8.3	24.3	34.0	44.3	35.3	58.8	NA	NA	NA	NA	NA	NA	NA	8.500	0.333	22.000	19.000	18.667	-0.333	47.000	NA	NA	NA	NA	NA	NA	NA	21.0	28.5	45.5	82.5	116.5	118.5	224.0
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	18.0	39.3	56.0	81.3	53.5	65.5	110.5	NA	NA	NA	NA	NA	NA	NA	28.3	34.5	118.3	193.7	189.0	136.5	29.5	NA	NA	NA	NA	NA	NA	NA	6.000	20.250	126.333	281.000	374.000	171.000	-3.500	NA	NA	NA	NA	NA	NA	NA	25.3	65.5	196.7	269.3	399.5	590.0	216.0
Baseline EN Tolerant: Camicinal 50 mg	7.9	21.5	25.4	36.6	53.6	74.6	NA	NA	NA	NA	NA	NA	NA	76.0	2.0	7.2	7.0	6.7	8.5	14.8	NA	NA	NA	NA	NA	NA	NA	29.2	0.118	-4.828	-14.870	-14.318	-10.944	-11.417	NA	NA	NA	NA	NA	NA	NA	4.500	19.3	49.8	51.0	82.1	100.3	156.0	NA	NA	NA	NA	NA	NA	NA	84.9
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	-2.5	19.0	NA	NA	NA	NA	11.7	20.0	23.0	56.5	67.0	56.0	NA	71.5	-1.5	8.0	NA	NA	NA	NA	9.3	14.0	14.3	41.5	50.0	45.0	NA	50.7	-9.000	16.000	NA	NA	NA	NA	1.000	28.000	22.000	49.500	46.000	30.000	NA	8.500	8.5	74.0	NA	NA	NA	NA	41.7	59.0	89.0	216.0	223.0	218.0	NA	78.0
Baseline EN Tolerant: Placebo	2.7	-1.5	11.2	14.2	13.4	13.9	24.0	NA	NA	NA	NA	NA	NA	32.4	-1.9	-2.8	-4.0	0.4	0.1	-5.4	1.0	NA	NA	NA	NA	NA	NA	-4.6	-8.742	-11.500	-14.348	-11.518	-18.222	-29.538	-11.000	NA	NA	NA	NA	NA	NA	-33.412	7.4	13.4	54.8	81.7	100.1	85.6	43.0	NA	NA	NA	NA	NA	NA	84.6
Baseline EN Tolerant: Placebo/Camicinal 50 mg	2.5	43.0	NA	NA	NA	NA	38.0	37.7	22.0	47.0	46.5	51.5	76.0	274.0	-19.5	6.0	NA	NA	NA	NA	-2.0	-25.3	-68.0	-77.0	-81.0	-75.5	-20.0	-59.7	-36.500	-18.000	NA	NA	NA	NA	-50.000	-69.000	-96.000	-66.000	-63.000	-46.000	-64.000	-110.333	5.5	75.0	NA	NA	NA	NA	66.0	51.0	46.5	153.0	201.5	249.5	400.0	140.0

Intervention	Giga unit per liter (gI/L) (Mean)
	Basophils; Day2; n= 0,1,0,0,0,0	Basophils; Day3; n= 2,1,0,0,0,0	Basophils; Day5; n= 0,2,0,0,0,0	Basophils; Day6; n= 0,1,0,0,0,0	Basophils; Day7; n= 13,14,0,0,0,0	Basophils; intolerance Day2; n= 0,0,0,0,0,1	Basophils; intolerance Day3; n= 0,0,0,2,0,0	Basophils; intolerance Day4; n= 0,0,0,1,0,0	Basophils; intolerance Day6; n= 0,0,1,1,0,0	Basophils; intolerance Day7; n= 0,0,1,0,3,1	Basophils; follow up; n= 24,28,3,3,3,1	Eosinophils; Day2; n= 0,1,0,0,0,0	Eosinophils; Day3; n= 2,1,0,0,0,0	Eosinophils; Day5; n= 0,2,0,0,0,0	Eosinophils; Day6; n= 0,1,0,0,0,0	Eosinophils; Day7; n= 13,14,0,0,0,0	Eosinophils; intolerance Day2; n= 0,0,0,0,0,1	Eosinophils; intolerance Day3; n= 0,0,0,2,0,0	Eosinophils; intolerance Day4; n= 0,0,0,1,0,0	Eosinophils; intolerance Day6; n= 0,0,1,1,0,0	Eosinophils; intolerance Day7; n= 0,0,1,0,3,1	Eosinophils; follow up; n= 24,28,3,3,4,1	Lymphocytes; Day2; n= 0,1,0,0,0,0	Lymphocytes; Day3; n= 2,1,0,0,0,0	Lymphocytes; Day5; n= 0,2,0,0,0,0	Lymphocytes; Day6; n= 0,1,0,0,0,0	Lymphocytes; Day7; n= 13,15,0,0,0,0	Lymphocytes; intolerance Day2; n= 0,0,0,0,0,1	Lymphocytes; intolerance Day3; n= 0,0,0,2,0,0	Lymphocytes; intolerance Day4; n= 0,0,0,1,0,0	Lymphocytes; intolerance Day6; n= 0,0,1,1,1,0	Lymphocytes; intolerance Day7; n= 0,0,1,0,3,1	Lymphocytes; follow up; n= 24,28,3,3,4,2	Monocytes; Day2; n= 0,1,0,0,0,0	Monocytes; Day3; n= 2,1,0,0,0,0	Monocytes; Day5; n= 0,2,0,0,0,0	Monocytes; Day6; n= 0,1,0,0,0,0	Monocytes; Day7; n= 13,15,0,0,0,0	Monocytes; intolerance Day2; n= 0,0,0,0,0,1	Monocytes; intolerance Day3; n= 0,0,0,2,0,0	Monocytes; intolerance Day4; n= 0,0,0,1,0,0	Monocytes; intolerance Day6; n= 0,0,1,1,1,0	Monocytes; intolerance Day7; n= 0,0,1,0,3,1	Monocytes; follow up; n= 24,28,3,3,3,1	Neutrophils; Day2; n= 0,2,0,0,0,0	Neutrophils; Day3; n= 2,1,0,0,0,0	Neutrophils; Day5; n= 0,2,0,0,0,0	Neutrophils; Day6; n= 0,1,0,0,0,0	Neutrophils; Day7; n= 13,15,0,0,0,0	Neutrophils; intolerance Day2; n= 0,0,0,0,0,1	Neutrophils; intolerance Day3; n= 0,0,0,2,0,0	Neutrophils; intolerance Day4; n= 0,0,0,1,0,0	Neutrophils; intolerance Day6; n= 0,0,1,1,1,0	Neutrophils; intolerance Day7; n= 0,0,1,0,3,1	Neutrophils; follow up; n= 24,28,3,3,4,2	Platelet; Day2; n= 32,37,2,2,0,0	Platelet; Day3; n= 29,30,1,1,0,0	Platelet; Day4; n= 25,26,0,0,0,0	Platelet; Day5; n= 22,23,0,0,0,0	Platelet; Day6; n= 17,19,0,0,0,0	Platelet; Day7; n= 14,15,0,0,0,0	Platelet; intolerance Day1; n= 1,0,2,3,0,0	Platelet; intolerance Day2; n= 0,0,3,3,4,4	Platelet; intolerance Day3; n= 0,0,2,3,3,4	Platelet; intolerance Day4; n= 0,0,2,2,3,3	Platelet; intolerance Day5; n= 0,0,2,1,3,3	Platelet; intolerance day6; n= 0,0,2,1,3,2	Platelet; intolerance day7; n= 0,0,1,0,3,2	Platelet; follow up; n= 24,28,3,3,4,2	WBC; Day2; n= 32,37,2,2,0,0	WBC; Day3; n= 29,30,1,1,0,0	WBC; Day4; n= 25,26,0,0,0,0	WBC; Day5; n= 22,23,0,0,0,0	WBC; Day6; n= 17,19,0,0,0,0	WBC; Day7; n= 14,15,0,0,0,0	WBC; intolerance Day1; n= 1,0,2,3,0,0	WBC; intolerance Day2; n= 0,0,3,3,4,4	WBC; intolerance Day3; n= 0,0,2,3,3,4	WBC; intolerance Day4; n= 0,0,2,2,3,3	WBC; intolerance Day5; n= 0,0,2,1,3,3	WBC; intolerance Day6; n= 0,0,2,1,3,2	WBC; intolerance Day7; n= 0,0,1,0,3,2	WBC; follow up; n= 24,28,3,3,4,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.037	0.073	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.0000	0.0400	NA	NA	NA	NA	NA	NA	NA	NA	0.4000	0.1900	0.7100	NA	NA	NA	NA	NA	NA	NA	NA	0.5000	0.0600	-0.4900	NA	NA	NA	NA	NA	NA	NA	NA	7.5000	-1.7200	0.8250	NA	NA	NA	NA	NA	NA	NA	-8.8	0.7	11.0	14.7	26.0	49.7	66.8	NA	NA	NA	NA	NA	NA	NA	-1.050	-2.333	-1.300	-1.450	-0.367	-0.540	2.188
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	-0.030	NA	NA	NA	0.300	0.150	NA	NA	NA	NA	NA	-0.0200	NA	NA	NA	0.1000	-0.0200	NA	NA	NA	NA	NA	-0.7300	NA	NA	NA	1.5000	-0.1200	NA	NA	NA	NA	NA	0.0600	NA	NA	NA	1.3000	0.3600	NA	NA	NA	NA	NA	0.3100	NA	NA	NA	-6.6000	-6.7400	NA	NA	NA	NA	NA	NA	NA	16.3	29.0	86.3	158.0	271.0	429.0	891.0	NA	NA	NA	NA	NA	NA	NA	0.450	-2.925	-2.933	-1.800	-5.600	-3.650	-6.150
Baseline EN Tolerant: Camicinal 50 mg	0.000	-0.020	-0.050	0.000	0.013	NA	NA	NA	NA	NA	0.034	0.0000	-0.0400	0.0900	-0.2000	0.1079	NA	NA	NA	NA	NA	0.1886	0.2000	-1.0300	0.4400	-0.2000	0.2320	NA	NA	NA	NA	NA	0.6614	-0.4000	-0.0600	-0.0300	-0.2000	0.1647	NA	NA	NA	NA	NA	0.0611	-1.5000	0.7200	-0.3750	9.6000	1.1807	NA	NA	NA	NA	NA	-2.0968	4.2	22.1	48.7	82.7	113.6	133.3	NA	NA	NA	NA	NA	NA	NA	272.0	-0.199	0.398	0.489	1.320	2.314	1.913	NA	NA	NA	NA	NA	NA	NA	-0.813
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	0.000	0.000	0.020	NA	0.057	NA	NA	NA	NA	NA	NA	0.0300	0.0000	0.3300	NA	0.2267	NA	NA	NA	NA	NA	NA	-0.3550	-0.2000	0.4800	NA	0.7067	NA	NA	NA	NA	NA	NA	0.0900	0.1000	0.3600	NA	-0.0633	NA	NA	NA	NA	NA	NA	-2.1000	-2.9000	-0.8100	NA	-0.5233	14.0	10.0	NA	NA	NA	NA	21.0	13.7	31.7	42.5	-10.0	42.0	NA	272.0	-2.320	-4.400	NA	NA	NA	NA	-1.220	-1.713	-1.447	-2.125	-0.490	0.300	NA	0.230
Baseline EN Tolerant: Placebo	NA	0.000	NA	NA	0.022	NA	NA	NA	NA	NA	0.040	NA	0.3000	NA	NA	0.1615	NA	NA	NA	NA	NA	1.4454	NA	0.6500	NA	NA	0.3946	NA	NA	NA	NA	NA	0.6483	NA	0.5000	NA	NA	0.2100	NA	NA	NA	NA	NA	0.1475	NA	-5.3000	NA	NA	0.6708	NA	NA	NA	NA	NA	-2.0579	10.5	34.8	56.0	102.7	128.7	159.8	-24.0	NA	NA	NA	NA	NA	NA	258.9	-1.187	-1.033	-1.398	-0.015	0.881	0.690	-2.020	NA	NA	NA	NA	NA	NA	-1.223
Baseline EN Tolerant: Placebo/Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	NA	0.000	0.130	0.047	NA	NA	NA	NA	NA	NA	NA	NA	0.0000	0.7900	0.3367	NA	NA	NA	NA	NA	NA	NA	NA	0.1000	0.4600	0.3133	NA	NA	NA	NA	NA	NA	NA	NA	0.9000	-0.6900	-0.1067	NA	NA	NA	NA	NA	NA	NA	NA	1.1000	1.4600	-0.7133	8.5	-4.0	NA	NA	NA	NA	33.5	73.7	101.5	183.0	213.5	225.5	287.0	438.0	-2.490	0.300	NA	NA	NA	NA	0.300	-0.197	-1.910	1.150	1.850	0.750	4.000	-0.177

Intervention	millimol per liter (mmol/L) (Mean)
	Calcium; Day 2; n= 1,2,0,0,0,0	Calcium; Day 3; n= 1,2,0,0,0,0	Calcium; Day 4; n= 0,1,0,0,0,0	Calcium; Day 5; n= 0,2,0,0,0,0	Calcium; Day 6; n= 0,1,0,0,0,0	Calcium; Day 7; n= 12,12,0,0,0,0	Calcium; intolerance Day 2; n= 0,0,0,0,0,1	Calcium; intolerance Day 3; n= 0,0,0,1,0,0	Calcium; intolerance Day 4; n= 0,0,0,1,0,0	Calcium; intolerance Day 6; n= 0,0,1,1,1,0	Calcium; intolerance Day 7; n= 0,0,1,0,3,2	Calcium; follow up; n= 19,18,3,3,4,2	Chloride; Day 2; n= 33,37,2,2,0,0	Chloride; Day3; n= 28,31,1,1,0,0	Chloride; Day4 ; n= 25,26,0,0,0,0	Chloride; Day5; n= 22,23,0,0,0,0	Chloride; Day 6; n= 18,19,0,0,0,0	Chloride; Day7; n= 14,15,0,0,0,0	Chloride intolerance Day 1; n= 1,0,2,3,0,0	Chloride intolerance Day 2; n= 0,0,3,3,4,4	Chloride intolerance Day 3; n= 0,0,2,3,2,4	Chloride intolerance Day 4; n= 0,0,2,2,3,3	Chloride intolerance Day 5; n= 0,0,2,1,3,3	Chloride intolerance Day 6; n= 0,0,2,1,3,2	Chloride intolerance Day 7; n= 0,0,1,0,3,2	Chloride follow up; n= 22,23,3,3,3,2	Carbon dioxide; Day 2; n= 32,36,2,2,0,0	Carbon dioxide; Day 3; n= 27,31,1,1,0,0	Carbon dioxide; Day 4; n= 24,25,0,0,0,0	Carbon dioxide; Day 5; n= 20,22,0,0,0,0	Carbon dioxide; Day 6; n= 16,16,0,0,0,0	Carbon dioxide; Day 7; n= 12,13,0,0,0,0	Carbon dioxide; intolerance Day1; n= 1,0,2,3,0,0	Carbon dioxide; intolerance Day2; n= 0,0,3,3,3,4	Carbon dioxide; intolerance Day3; n= 0,0,2,3,2,3	Carbon dioxide; intolerance Day4; n= 0,0,2,2,2,2	Carbon dioxide; intolerance Day5; n= 0,0,2,1,2,2	Carbon dioxide; intolerance Day6; n= 0,0,2,1,2,2	Carbon dioxide; intolerance Day7; n= 0,0,1,0,2,2	Carbon dioxide; follow up; n= 15,20,3,3,3,2	Glucose; Day2; n= 31,35,2,2,0,0	Glucose; Day3; n= 29,29,1,1,0,0	Glucose; Day4; n= 25,24,0,0,0,0	Glucose; Day5; n= 22,21,0,0,0,0	Glucose; Day6; n= 18,18,0,0,0,0	Glucose; Day7; n= 14,13,0,0,0,0	Glucose; intolerance Day1; n= 1,0,2,3,0,0	Glucose; intolerance Day2; n= 0,0,3,3,4,3	Glucose; intolerance Day3; n= 0,0,2,3,3,4	Glucose; intolerance Day4; n= 0,0,2,2,3,3	Glucose; intolerance Day5; n= 0,0,2,1,3,3	Glucose; intolerance Day6; n= 0,0,2,1,3,2	Glucose; intolerance Day7; n= 0,0,1,0,2,2	Glucose; follow up; n= 18,17,3,3,4,2	Potassium; Day2; n= 33,37,2,2,0,0	Potassium; Day3; n= 29,31,1,1,0,0	Potassium; DAY4; n= 24,25,0,0,0,0	Potassium Day5; n= 22,23,0,0,0,0	Potassium; Day6; n= 18,19,0,0,0,0	Potassium; Day7; n= 14,15,0,0,0,0	Potassium; intolerance Day1; n= 1,0,2,3,0,0	Potassium; intolerance Day2; n= 0,0,3,3,4,4	Potassium; intolerance Day3; n= 0,0,2,3,3,4	Potassium; intolerance Day4; n= 0,0,2,2,3,3	Potassium; intolerance Day5; n= 0,0,2,1,3,3	Potassium; intolerance Day6; n= 0,0,2,1,3,2	Potassium; intolerance Day7; n= 0,0,1,0,3,2	Potassium; follow up; n= 25,28,3,3,4,2	Sodium; Day2; n= 33,37,2,2,0,0	Sodium; Day3; n= 29,31,1,1,0,0	Sodium; Day4; n= 25,26,0,0,0,0	Sodium; Day5; n= 22,23,0,0,0,0	Sodium; Day6; n= 18,19,0,0,0,0	Sodium; Day7; n= 14,15,0,0,0,0	Sodium; intolerance Day1; n= 1,0,2,3,0,0	Sodium; intolerance Day2; n= 0,0,3,3,4,4	Sodium; intolerance Day3; n= 0,0,2,3,3,4	Sodium; intolerance Day4; n= 0,0,2,2,3,3	Sodium; intolerance Day5; n= 0,0,2,1,3,3	Sodium; intolerance Day6; n= 0,0,2,1,3,2	Sodium; intolerance Day7; n= 0,0,1,0,3,2	Sodium; follow up; n= 25,28,3,3,4,2	BUN; Day2; n= 1,3,0,0,0,0	BUN; Day3; n= 1,2,0,0,0,0	BUN; Day4; n= 0,1,0,0,0,0	BUN; Day5; n= 0,2,0,0,0,0	BUN; Day6; n= 0,1,0,0,0,0	BUN; Day7; n= 13,14,0,0,0,0	BUN; intolerance Day3; n= 0,0,0,1,0,0	BUN; intolerance Day4; n= 0,0,0,1,0,0	BUN; intolerance Day6; n= 0,0,1,1,1,0	BUN; intolerance Day7; n= 0,0,1,0,3,2	BUN; follow up; n= 18,22,3,3,4,1
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4300	0.2000	0.2850	NA	NA	NA	NA	NA	NA	NA	0.5	0.0	2.3	4.3	5.7	4.3	-7.0	NA	NA	NA	NA	NA	NA	NA	-2.00	1.00	2.00	3.00	2.00	3.00	1.67	NA	NA	NA	NA	NA	NA	NA	-0.4500	0.7333	2.1000	1.2333	0.8000	2.5000	-1.1750	NA	NA	NA	NA	NA	NA	NA	0.40	0.30	0.63	0.67	0.83	0.87	0.38	NA	NA	NA	NA	NA	NA	NA	-0.5	3.7	3.7	6.3	7.3	6.3	-0.5	NA	NA	NA	NA	NA	NA	NA	NA	14.2000	16.4000	11.6500
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	-0.0400	NA	NA	NA	0.0200	0.2050	NA	NA	NA	NA	NA	NA	NA	-0.5	-2.3	-4.0	-4.7	-4.0	-6.5	-8.5	NA	NA	NA	NA	NA	NA	NA	0.93	2.80	4.40	4.75	4.15	2.65	1.45	NA	NA	NA	NA	NA	NA	NA	0.8000	0.6000	1.1667	0.9333	0.6500	0.1500	2.6000	NA	NA	NA	NA	NA	NA	NA	-0.18	-0.53	-0.10	-0.03	-0.55	-0.60	-0.10	NA	NA	NA	NA	NA	NA	NA	1.0	-0.5	0.0	0.0	-1.0	-2.5	-6.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.1500	2.8000
Baseline EN Tolerant: Camicinal 50 mg	0.0000	0.1300	0.0800	0.1500	-0.0100	0.0733	NA	NA	NA	NA	NA	0.2483	-0.6	-1.3	-1.8	-2.6	-4.8	-3.1	NA	NA	NA	NA	NA	NA	NA	-4.6	0.21	0.93	1.58	1.64	3.63	3.05	NA	NA	NA	NA	NA	NA	NA	-0.40	-0.2338	0.0655	-0.1458	0.1810	0.0889	0.8692	NA	NA	NA	NA	NA	NA	NA	-1.7176	0.02	0.01	0.06	0.07	0.09	0.05	NA	NA	NA	NA	NA	NA	NA	0.11	0.8	1.2	1.5	0.8	-0.2	0.1	NA	NA	NA	NA	NA	NA	NA	-2.5	2.3000	2.4000	1.5000	25.8500	29.2000	5.0143	NA	NA	NA	NA	1.7000
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	0.3400	0.2100	0.3600	NA	0.4767	-0.5	-7.0	NA	NA	NA	NA	-3.7	-4.3	-6.0	-11.0	-2.0	-4.0	NA	-11.0	1.50	3.00	NA	NA	NA	NA	0.33	0.33	1.67	2.50	4.00	5.00	NA	1.67	0.3000	-1.6000	NA	NA	NA	NA	-0.2000	-0.3000	0.1000	-0.3000	0.2000	-0.7000	NA	-0.3333	-0.20	-0.10	NA	NA	NA	NA	0.17	0.17	0.30	0.45	0.20	0.40	NA	0.47	-0.5	-5.0	NA	NA	NA	NA	-2.3	-3.3	-3.0	-8.0	1.0	-2.0	NA	-7.0	NA	NA	NA	NA	NA	NA	0.2000	0.3000	2.2000	NA	4.5667
Baseline EN Tolerant: Placebo	-0.0500	0.0200	NA	NA	NA	0.2208	NA	NA	NA	NA	NA	0.2821	-1.2	-1.5	-2.3	-3.4	-4.1	-4.3	-1.0	NA	NA	NA	NA	NA	NA	-6.1	3.31	1.64	0.43	-0.16	0.64	0.98	2.00	NA	NA	NA	NA	NA	NA	-1.26	0.2871	0.2414	0.7680	0.4636	0.8111	1.8857	-0.9000	NA	NA	NA	NA	NA	NA	-0.8889	-0.08	-0.12	0.08	0.10	0.33	0.49	0.40	NA	NA	NA	NA	NA	NA	0.37	0.3	0.4	-0.8	-1.4	-2.8	-2.7	-3.0	NA	NA	NA	NA	NA	NA	-3.8	1.0000	6.4000	NA	NA	NA	3.1231	NA	NA	NA	NA	2.1722
Baseline EN Tolerant: Placebo/Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.3400	-0.0700	0.2667	-2.0	-5.0	NA	NA	NA	NA	-6.0	-5.3	-6.5	-5.0	-1.5	0.0	1.0	-7.3	2.50	6.00	NA	NA	NA	NA	3.50	1.67	6.50	5.50	6.50	3.50	0.00	1.67	-0.8000	-2.9000	NA	NA	NA	NA	-1.6000	-0.5000	0.5000	0.8500	0.5500	1.1000	0.8000	-1.9667	-0.20	-0.40	NA	NA	NA	NA	0.00	0.00	-0.30	-0.15	-0.35	-0.05	-0.10	-0.07	1.5	0.0	NA	NA	NA	NA	-1.5	0.0	3.5	2.0	5.0	4.5	2.0	-3.0	NA	NA	NA	NA	NA	NA	NA	NA	7.4000	-1.0000	-0.3333

Intervention	beats per minute (bpm) (Mean)
	HR Day1; n= 23,33,1,3,0,0	HR Day2; n= 34,38,2,2,0,0	HR Day3; n= 29,31, 1,1,0,0	HR Day4; n= 25,27,0,0,0,0	HR Day5; n= 22,23,0,0,0,0	HR Day6; n= 18,19,0,0,0,0	HR Day7; n= 14,14,,0,0,0,0	HR intolerance Day1; n= 1,0,3,3,3,3	HR intolerance Day2; n= 0,0,2,3,4,4	HR intolerance Day3; n= 0,0,2,3,3,4	HR intolerance Day4; n= 0,0,2,2,3,3	HR intolerance Day5; n= 0,0,2,1,3,3	HR intolerance Day6; n= 0,0,2,1,3,3	HR intolerance Day7; n= 0,0,0,0,3,2	HR follow up; n= 27,28,3,3,4,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	1.3	9.0	6.3	14.0	19.0	19.7	16.3	16.8
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	2.3	7.5	13.5	5.3	17.3	17.0	16.0	27.0
Baseline EN Tolerant: Camicinal 50 mg	4.3	-0.5	1.6	2.1	0.2	1.4	0.6	NA	NA	NA	NA	NA	NA	NA	2.7
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	-0.7	5.0	-21.0	NA	NA	NA	NA	-2.0	-12.7	0.7	-2.0	-3.0	-1.0	NA	-2.0
Baseline EN Tolerant: Placebo	-4.0	-1.6	-0.0	-4.4	-3.0	-1.2	-1.9	6.0	NA	NA	NA	NA	NA	NA	0.8
Baseline EN Tolerant: Placebo/Camicinal 50 mg	-5.0	4.5	26.0	NA	NA	NA	NA	19.7	22.5	8.5	15.5	9.0	4.5	NA	11.0

Intervention	Fraction of 1 (Mean)
	Day2; n= 32,37,2,2,0,0	Day3; n= 29,30,1,1,0,0	Day4; n= 25,26,0,0,0,0	Day5; n= 22,23,0,0,0,0	Day6; n= 17,19,0,0,0,0	Day7; n= 14,15,0,0,0,0	Intolerance Day1; n= 1,0,2,3,0,0	Intolerance Day2; n= 0,0,3,3,4,4	Intolerance Day3; n= 0,0,2,3,3,4	Intolerance Day4; n= 0,0,2,2,3,3	Intolerance Day5; n= 0,0,2,1,3,3	Intolerance Day6; n= 0,0,2,1,3,2	Intolerance Day7; n= 0,0,1,0,3,2	Follow up; n= 24,28,3,3,4,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	-0.1385	-0.1917	-0.1803	-0.1963	-0.1617	-0.1673	-0.1180
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	-0.0113	-0.0065	0.0030	0.0213	-0.0030	-0.0120	0.0320
Baseline EN Tolerant: Camicinal 50 mg	-0.0048	-0.0046	-0.0107	-0.0064	-0.0088	-0.0145	NA	NA	NA	NA	NA	NA	NA	0.0179
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	-0.0195	-0.0300	NA	NA	NA	NA	-0.0150	-0.0287	-0.0373	-0.0350	-0.0200	-0.0200	NA	0.0607
Baseline EN Tolerant: Placebo	-0.0072	-0.0129	-0.0140	-0.0085	-0.0152	-0.0148	-0.0400	NA	NA	NA	NA	NA	NA	0.0183
Baseline EN Tolerant: Placebo/Camicinal 50 mg	-0.0310	-0.0090	NA	NA	NA	NA	0.0195	-0.0017	-0.0310	-0.0050	-0.0350	-0.0320	-0.0200	0.0650

Intervention	Picogram (PG) (Mean)
	Day2; n= 27,35,2,1,0,0	Day3; n= 24,28,1,0,0,0	Day4; n= 21,24,0,0,0,0	Day5; n= 19,21,0,0,0,0	Day6; n= 15,17,0,0,0,0	Day7; n= 12,14,0,0,0,0	Intolerance Day1; n= 1,0,2,2,0,0	Intolerance Day2; n= 0,0,3,2,3,3	Intolerance Day3; n= 0,0,2,2,2,3	Intolerance Day4; n= 0,0,2,1,2,2	Intolerance Day5; n= 0,0,2,1,2,2	Intolerance Day6; n= 0,0,2,1,2,1	Intolerance Day7; n= 0,0,1,0,2,1	Follow up; n= 21,26,3,2,3,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	-0.23	-0.65	-0.75	-1.00	-1.00	-0.75	-0.50
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	-0.10	-0.27	-0.50	-0.30	-0.70	0.40	-0.90
Baseline EN Tolerant: Camicinal 50 mg	0.02	-0.08	-0.24	-0.44	-0.41	-0.45	NA	NA	NA	NA	NA	NA	NA	-0.20
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	0.00	NA	NA	NA	NA	NA	-0.30	-0.10	-0.10	-0.60	-0.50	-1.10	NA	-2.15
Baseline EN Tolerant: Placebo	0.01	-0.10	-0.26	-0.23	-0.15	-0.02	0.20	NA	NA	NA	NA	NA	NA	-0.40
Baseline EN Tolerant: Placebo/Camicinal 50 mg	0.35	0.20	NA	NA	NA	NA	-0.65	-0.57	-0.10	-0.10	0.45	0.20	-0.50	-0.50

metoclopramide

Description

Cross-References

Synonyms (178)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (4)

Protein Targets (57)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (321)

Molecular Functions (94)

Ceullar Components (72)

Bioassays (367)

Research

Studies (4,624)

Market Indicators

Research Demand Index: 118.12

Study Types

Clinical Trials (133)

Trial Overview

Trial Outcomes

Bradycardia Episodes/Day

Change in Headache Intensity as Measured by the NRS Score From Baseline to the One Hour Assessment.

Change in Headache Intensity as Measured by the NRS Score From Baseline to the Two Hour Assessment.

The Number of Subjects With a NRS Score of Zero at 24 Hours.

The Number of Subjects With a NRS Score of Zero at One Hour.

The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours.

Change in Headache Intensity as Measured by the NRS Score From Baseline to the 24 Hour Assessment.

The Primary Endpoint of This Study is the Median Time Between Admission to the PICU and Occurrence of Nosocomial Infection or Clinical Sepsis in PICU Patients Who Have Endotracheal Tubes, Central Venous Catheters, or Urinary Catheters.

All-cause 28-day Mortality Rate.

Rate of Nosocomial Infection or Clinical Sepsis Per 100 Study Days

Incidence of Prolonged Lymphopenia (Absolute Lymphocyte Count Less Than or Equal to 1,000/mm³ for > or Equal to 7 Days)

Antibiotic-free Days

Nausea Scale

Number of Participants With Akathisia

Change in Visual Analog Scale (VAS) Score for Nausea. This Was Calculated by Subtracting the Patient's Reported Score on the 30 Minute VAS From the Patient's Reported VAS Score on Their Baseline VAS.

Pain Intensity Score

The Pre-specified Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score by Gender.

The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score.

Satisfaction Scores

Change in Pain Score

Number of Patients Who Had Complete Response

Pruritus

Maternal Hemodynamics

Intraoperative Nausea and Vomiting

Postoperative Nausea and Vomiting (PONV)

Satisfaction

Participants Who Achieve Sustained Headache Freedom for 24 Hours

Headache Pain Level on a 0-10 Verbal Scale

Adverse Event

Satisfaction With Medication

Impact of Chemotherapy-Induced Nausea on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2

Impact of Chemotherapy-Induced Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1

Impact of Chemotherapy-Induced Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2

Total Impact of Chemotherapy-Induced Nausea and Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1

Total Impact of Chemotherapy-Induced Nausea and Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2

Number of Participants With Complete Response (CR) in Cycle 2 for Patient Without Complete Response in Cycle 1

Number of Participants With Complete Response (CR)

Number of Participants With Treatment Related Adverse Events (AE) at Cycle 2

Impact of Chemotherapy-Induced Nausea on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1

Differences in Small Bowel Transit Time in Treatment vs. Placebo in Pill Capsule Studies

Differences in Gastric Transit Time in Treatment vs. Placebo in Pill Capsule Studies

Difference in Treatment vs. Placebo in Pill Capsule Completion Rates

Difference in Pill Capsule Completion Rates in Diabetics vs. Non-diabetics

Number of Emetic Events - Overall Stage

Percentage of Participants With No Impact on Daily Life - Overall Stage

Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage

Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages

Intervention	Femtoliter (fL) (Mean)
	Day2; n= 31,37,2,2,0,0	Day3; n= 28,30,1,1,0,0	Day4; n= 25,26,0,0,0,0	Day5; n= 22,23,0,0,0,0	Day6; n= 17,19,0,0,0,0	Day7; n= 14,15,0,0,0,0	Intolerance Day1; n= 1,0,2,3,0,0	Intolerance Day2; n= 0,0,3,3,4,4	Intolerance Day3; n= 0,0,2,3,3,4	Intolerance Day4; n= 0,0,2,2,3,3	Intolerance Day5; n= 0,0,2,1,3,3	Intolerance Day6; n= 0,0,2,1,3,2	Intolerance Day7; n= 0,01,0,3,2	Follow up; n= 23,27,3,3,4,2
Baseline EN Intolerant: Camicinal 50 mg	-0.60	-2.47	-2.53	-1.10	-2.20	-1.13	NA	NA	NA	NA	NA	NA	NA	-0.77
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	0.92	0.27	2.30	3.13	5.60	4.15	4.00
Baseline EN Tolerant: Camicinal 50 mg	0.14	0.40	0.79	0.40	0.53	-0.01	NA	NA	NA	NA	NA	NA	NA	1.46
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	-0.50	0.00	NA	NA	NA	NA	-1.10	0.00	-1.20	-1.10	0.10	-0.20	NA	-2.93
Baseline EN Tolerant: Placebo	0.36	0.13	-0.14	0.09	0.17	1.04	0.50	NA	NA	NA	NA	NA	NA	-0.24
Baseline EN Tolerant: Placebo/Camicinal 50 mg	1.70	3.90	NA	NA	NA	NA	3.10	3.43	1.30	3.05	2.90	3.95	5.10	4.57

Intervention	Tetra unit per liter (TI/L) (Mean)
	RBC; Day2; n= 32,37,2,2,0,0	RBC; Day3; n= 29,30,1,1,0,0	RBC; Day4; n= 25,26,0,0,0,0	RBC; Day5; n= 22,23,0,0,0,0	RBC; Day6; n= 17,19,0,0,0,0	RBC; Day7; n= 14,15,0,0,0,0	RBC; intolerance Day1; n= 1,0,2,3,0,0	RBC; intolerance Day2; n= 0,0,3,3,4,4	RBC; intolerance Day3; n= 0,0,2,3,3,4	RBC; intolerance Day4; n= 0,0,2,2,3,3	RBC; intolerance Day5; n= 0,0,2,1,3,3	RBC; intolerance Day6; n= 0,0,2,1,3,2	RBC; intolerance Day7; n= 0,0,1,0,3,2	RBC follow up; n= 24,28,3,3,4,2	Reticulocytes; Day5; n= 0,1,0,0,0,0	Reticulocytes; Day6; n= 0,1,0,0,0,0	Reticulocytes; Day7; n= 7,4,0,0,0,0	Reticulocytes; intolerance Day3; n= 0,0,0,1,0,0	Reticulocytes; intolerance Day4; n= 0,0,0,1,0,0	Reticulocytes; intolerance Day6; n= 0,0,0,0,1,0	Reticulocytes; intolerance Day7; n= 0,0,1,0,0,1	Reticulocytes; follow up; n= 11,11,2,2,3,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	0.018	-0.030	0.047	-0.157	0.267	0.150	0.188	NA	NA	NA	NA	NA	0.0340	NA	0.0870
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	-0.172	-0.105	-0.050	0.133	-0.170	-0.250	0.170	NA	NA	NA	NA	NA	NA	0.0822	0.0569
Baseline EN Tolerant: Camicinal 50 mg	-0.059	-0.067	-0.141	-0.085	-0.118	-0.149	NA	NA	NA	NA	NA	NA	NA	0.142	-0.0010	0.0810	0.0031	NA	NA	NA	NA	1.6622
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	-0.150	-0.200	NA	NA	NA	NA	-0.077	-0.293	-0.333	-0.270	-0.150	-0.130	NA	0.790	NA	NA	NA	0.0530	0.0080	NA	NA	0.0537
Baseline EN Tolerant: Placebo	-0.098	-0.163	-0.155	-0.099	-0.176	-0.202	-0.540	NA	NA	NA	NA	NA	NA	0.195	NA	NA	0.0074	NA	NA	NA	NA	4.1273
Baseline EN Tolerant: Placebo/Camicinal 50 mg	-0.375	-0.210	NA	NA	NA	NA	0.120	-0.113	-0.390	-0.165	-0.495	-0.505	-0.400	0.577	NA	NA	NA	NA	NA	NA	0.0170	0.0847

Intervention	millimeter of mercury (mmHg) (Mean)
	DBP Day1; n= 23,33,1,3,0,0	DBP Day2; n= 33,38,2,2,0,0	DBP Day3; n= 29,31,1,1,0,0	DBP Day4; n=25,27,0,0,0,0	DBP Day5; n= 22,23,0,0,0,0	DBP Day6; n= 18,19,0,0,0,0	DBP Day7; n= 14,14,0,0,0,0	DBP Intolerance Day1; n=1,0,3,3,3,3	DBP Intolerance Day2; n=0,0,2,3,4,4	DBP Intolerance Day3; n= 0,0,2,3,3,4	DBP Intolerance Day4; n= 0,0,2,2,3,3	DBP Intolerance Day5; n= 0,0,2,1,3,3	DBP Intolerance Day6; n= 0,0,2,1,3,3	DBP Intolerance Day7; n= 0,0,0,0,3,2	DBP Follow up; n= 27,28,3,3,4,2	SBP Day1; n= 23,33,1,3,0,0	SBP Day2; n= 33,38,2,2,0,0	SBP Day3; n= 29,31,1,1,0,0	SBP Day4; n= 25,27,0,0,0,0	SBP Day5; n= 22,23,0,0,0,0	SBP Day6; n= 18,19,0,0,0,0	SBP Day7; n= 14,14,0,0,0,0	SBP Intolerance Day1; n= 1,0,3,3,3,3	SBP Intolerance Day2; n= 0,0,2,3,4,4	SBP Intolerance Day3; n= 0,0,2,3,3,4	SBP Intolerance Day4; n= 0,0,2,2,3,3	SBP Intolerance Day5; n= 0,0,2,1,3,3	SBP Intolerance Day6; n= 0,0,2,1,3,3	SBP Intolerance Day7; n= 0,0,0,0,3,2	SBP follow up; n= 27,28,3,3,4,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	11.0	23.5	4.3	11.7	5.3	7.3	7.7	4.0	NA	NA	NA	NA	NA	NA	NA	1.0	32.8	30.7	43.0	19.7	20.3	22.0	11.8
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	0.0	-4.0	-0.5	-1.7	1.7	13.7	8.5	29.0	NA	NA	NA	NA	NA	NA	NA	-4.7	-4.0	13.0	-9.0	8.7	10.7	13.0	14.0
Baseline EN Tolerant: Camicinal 50 mg	-1.0	-0.2	1.7	3.2	-0.7	2.3	-2.4	NA	NA	NA	NA	NA	NA	NA	6.7	1.0	1.4	4.9	6.0	-0.6	-4.2	-5.4	NA	NA	NA	NA	NA	NA	NA	-1.4
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	-2.0	6.5	-16.0	NA	NA	NA	NA	-0.3	-12.0	6.3	15.5	2.0	-3.0	NA	18.0	3.0	16.0	-16.0	NA	NA	NA	NA	1.7	-9.3	16.3	22.0	15.0	5.0	NA	3.0
Baseline EN Tolerant: Placebo	-1.1	2.7	2.2	2.9	5.3	2.6	-4.6	7.0	NA	NA	NA	NA	NA	NA	9.1	-4.6	3.7	5.1	7.6	11.3	-1.6	-2.5	-2.0	NA	NA	NA	NA	NA	NA	-0.6
Baseline EN Tolerant: Placebo/Camicinal 50 mg	5.0	-1.5	5.0	NA	NA	NA	NA	9.3	4.5	10.5	9.0	-5.0	14.5	NA	23.0	1.0	12.5	6.0	NA	NA	NA	NA	16.3	4.5	11.0	19.5	17.0	46.5	NA	26.0

Intervention	micromoles per Liter (µmol/L) (Mean)
	Direct bilirubin; Day 2; n= 28,26,2,1,0,0	Direct bilirubin Day3; n= 25,23,1,1,0,0	Direct bilirubin; Day4; n= 19,18,0,0,0,0	Direct bilirubin; Day5; n= 17,15,0,0,0,0	Direct bilirubin; Day6; n= 13,12,0,0,0,0	Direct bilirubin; Day7; n= 10,7,0,0,0,0	Direct bilirubin; intolerance Day1; n= 1,0,2,2,0,0	Direct bilirubin; intolerance Day2; n= 0,0,2,1,2,2	Direct bilirubin; intolerance Day3; n= 0,0,1,2,1,3	Direct bilirubin; intolerance Day4; n= 0,0,1,1,2,2	Direct bilirubin; intolerance Day5; n= 0,0,1,1,2,2	Direct bilirubin; intolerance Day6; n=0,0,1,0,2,2	Direct bilirubin; intolerance Day7; n= 0,0,1,0,2,2	Direct bilirubin; follow up; n= 13,15,2,2,2,2	Total bilirubin; Day2; n= 32,35,2,2,0,0	Total bilirubin; Day3; n= 29,30,1,1,0,0	Total bilirubin; Day4; n= 25,25,0,0,0,0	Total bilirubin; Day5; n=22,22,0,0,0,0	Total bilirubin; Day6; n= 18,19,0,0,0,0	Total bilirubin; Day7; n= 14,12,0,0,0,0	Total bilirubin; intolerance Day1; n= 1,0,2,3,0,0	Total bilirubin; intolerance Day2; n= 0,0,3,3,4,4	Total bilirubin; intolerance Day3; n= 0,0,2,3,3,4	Total bilirubin; intolerance Day4; n= 0,0,2,2,3,3	Total bilirubin; intolerance Day5; n= 0,0,2,1,3,3	Total bilirubin; intolerance Day6; n= 0,0,2,1,3,2	Total bilirubin; intolerance Day7; n= 0,0,1,0,3,2	Total bilirubin; follow up; n= 19,20,3,2,4,2	Creatinine; Day2; n= 33,37,2,2,0,0	Creatinine; Day3; n= 29,31,1,1,0,0	Creatinine; Day4; n= 25,26,0,0,0,0	Creatinine; Day5; n= 22,22,0,0,0,0	Creatinine; Day6; n= 18,19,0,0,0,0	Creatinine; Day7; n= 14,15,0,0,0,0	Creatinine; intolerance Day1; n= 1,0,2,3,0,0	Creatinine; intolerance Day2; n= 0,0,3,3,4,4	Creatinine; intolerance Day3; n= 0,0,2,3,3,4	Creatinine; intolerance Day4; n= 0,0,2,2,3,3	Creatinine; intolerance Day5; n= 0,0,2,1,3,3	Creatinine; intolerance Day6; n= 0,0,2,1,3,2	Creatinine; intolerance Day7; n= 0,0,1,0,3,2	Creatinine; follow up; n= 25,28,3,3,4,2	Uric acid; Day3; n= 0,1,0,0,0,0	Uric acid; Day5; n= 0,2,0,0,0,0	Uric acid; Day6; n= 0,1,0,0,0,0	Uric acid; Day7; 11,11,0,0,0,0	Uric acid; intolerance Day2; n= 0,0,0,0,0,1	Uric acid; intolerance Day3; n= 0,0,0,1,0,0	Uric acid; intolerance Day4; n= 0,0,0,1,0,0	Uric acid; intolerance Day6; n= 0,0,0,1,1,0	Uric acid; intolerance Day7; n= 0,0,1,0,1,2	Uric acid follow up; n= 15,14,2,3,3,2
Baseline EN Intolerant: Camicinal 50 mg	NA	NA	NA	NA	NA	NA	NA	0.000	0.000	0.500	0.000	-0.500	0.500	16.000	NA	NA	NA	NA	NA	NA	NA	-0.075	0.167	0.833	0.633	0.000	-0.800	10.850	NA	NA	NA	NA	NA	NA	NA	5.7500	3.3333	-13.0000	-11.3333	-12.3333	-4.3333	-12.0000	NA	NA	NA	NA	NA	NA	NA	27.00	-100.00	72.33
Baseline EN Intolerant: Metoclopramide 10 mg	NA	NA	NA	NA	NA	NA	NA	1.700	12.167	4.800	-1.050	-7.100	-8.050	-15.000	NA	NA	NA	NA	NA	NA	NA	4.675	10.475	3.333	-1.100	-8.050	-9.250	-17.000	NA	NA	NA	NA	NA	NA	NA	-1.5000	-21.5000	-14.0000	-16.6667	-32.5000	-34.0000	-39.0000	NA	NA	NA	NA	-3640.00	NA	NA	NA	60.40	1076.90
Baseline EN Tolerant: Camicinal 50 mg	0.088	-0.126	0.172	-1.007	-0.583	-1.214	NA	NA	NA	NA	NA	NA	NA	-1.507	0.326	-0.660	-0.840	-1.055	-1.558	-3.133	NA	NA	NA	NA	NA	NA	NA	-1.805	-1.4281	-5.0323	-3.6923	1.5909	19.7895	6.4000	NA	NA	NA	NA	NA	NA	NA	11.6786	-70.00	-20.00	282.00	-15.36	NA	NA	NA	NA	NA	58.36
Baseline EN Tolerant: Camicinal 50 mg/ Metoclopramide 10 mg	1.000	0.000	NA	NA	NA	NA	0.000	1.000	0.500	0.000	0.000	NA	NA	-0.500	0.500	1.000	NA	NA	NA	NA	0.667	1.000	0.333	3.000	0.000	-1.000	NA	-2.000	-5.0000	-3.0000	NA	NA	NA	NA	-1.6667	-5.6667	-4.6667	-6.0000	-10.0000	-10.0000	NA	-4.0000	NA	NA	NA	NA	NA	-20.00	153.00	-20.00	NA	115.67
Baseline EN Tolerant: Placebo	-1.246	-1.512	0.700	1.482	1.031	3.240	0.000	NA	NA	NA	NA	NA	NA	-1.969	-1.172	-1.038	0.496	1.168	0.772	2.964	-1.000	NA	NA	NA	NA	NA	NA	-1.263	-2.1818	-4.2724	-6.2400	-7.0909	-7.5000	-7.5714	-11.0000	NA	NA	NA	NA	NA	NA	-5.8400	NA	NA	NA	-20.18	NA	NA	NA	NA	NA	60.47
Baseline EN Tolerant: Placebo/Camicinal 50 mg	0.800	25.300	NA	NA	NA	NA	7.100	7.100	1.000	5.000	4.000	-1.000	1.000	0.100	-1.350	25.700	NA	NA	NA	NA	6.700	7.100	5.000	5.500	7.500	7.500	1.000	-0.467	-13.5000	-3.0000	NA	NA	NA	NA	1.5000	-1.6667	-5.5000	-1.0000	-23.0000	-28.5000	-50.0000	-34.0000	NA	NA	NA	NA	NA	NA	NA	NA	-270.00	-25.50

Intervention	min*mmol/l (Geometric Mean)
	Intolerance Day 2	Intolerance Day 4
Camicinal 50 mg	792.8	2698.8

Intervention	Hr (Median)
	Intolerance Day 2; n= 2	Intolerance day 4; n= 1
Camicinal 50 mg	2.717	1.500

Intervention	min*mmol/l (Geometric Mean)
	AUC(0-60); n= 38, 34	AUC(0-240); n= 36, 33
Camicinal 50 mg	3.3709	31.4065
Placebo	3.8341	26.4060

Intervention	Log [Min. into mmol/L (min*mmol/l)] (Geometric Mean)
	Pre-dose; n=38,34	Post-dose; n= 32,27
Camicinal 50 mg	3.3709	7.2872
Placebo	3.8341	6.1047

Intervention	Log [min into ng/mL (min*ng/mL)] (Geometric Mean)
	Pre-dose; n=42,36	Post-dose; n= 33,27
Camicinal 50 mg	192321.7	234538.9
Placebo	222411.3	228473.7

Intervention	Log (mmol/L) (Geometric Mean)
	C60; Pre-dose	C60; post-dose
Camicinal 50 mg	0.12547	0.19960
Placebo	0.12856	0.18723